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Abstract

ROLE OF FDCs AND FDC ACTIVATED IN PROMOTING HUMORAL IMMUNITY
INCLUDING RESPONSES TO T-DEPENDENT ANTIGENS IN THE ABSENCE OF
T CELLS
By Rania M. El Sayed, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr. John G. Tew, Ph.D.
Professor, Department of Microbiology and Immunology

Follicular dendritic cells (FDCs) reside in primary B-cell follicles and in
the light zones of germinal centers (GCs) in secondary follicles, where their
dendrites interdigitate forming extensive networks intimately interacting with Bcells. In GCs, FDCs can be found at the edges attached to the supporting reticular
fibers. They trap and arrange immune complexes (ICs) in vivo and in vitro in a
periodic manner with 200–500Å spacing and provide both antigen-specific and
xv

non-specific accessory signals to B-cells. FDCs exist in resting and activated
states, with two characteristically different phenotypes. In their activated state,
FDCs upregulate the expression of accessory molecules and cytokines important
in the FDC-B cell interaction in GCs. We sought to determine the mechanisms
influencing the transition of FDCs from a resting to an activated state in GCs
and their impact on T-cell dependent (TD) and independent (TI)-GC reactions
(GCRs).
We

found

that

IC-FDC

interactions

via

FDC-FcγRIIB

induce

the

upregulation of FDC-FcγRIIB, -ICAM-1, and -VCAM-1, at both the protein and
mRNA levels. We also reported for the first time the expression of TLR-4 on
FDCs. Moreover, engagement of FDC-TLR4 with LPS activated NF-κB, upregulated expression of important FDC-accessory molecules, including FcγRIIB,
ICAM-1, and VCAM-1, and enhanced FDC accessory activity in promoting recall
IgG

responses.

Moreover,

IC-activated

FDCs

produced

IL-6

and

FDC-IL-6

promoted GCRs, somatic hypermutation (SHM) and IgG production.
Further, we reported that binding of FDCs to collagen coated surfaces
induced restoration of their dendritic processes and networks in vitro. In addition,
we

designed

assessment

an
of

FDC-supported
primary

human

in

vitro

antibody

model

capable

responses

to

of

induction

protein

and

antigens

characterized by class-switching and affinity maturation.
Uniquely, we generated TI immune responses to TD protein Ags in the complete
absence of T cell help in vivo and in vitro. In the presence of FDC-associated second
xvi

signals such as BAFF and C4BP, FDC- FcγRIIB-periodically trapped-ICs induced the
production of Ag-specific IgM, GC-development and plasmablast-differentiation in antiThy-1-pretreated nude mice. Purified murine and human B cells cultured in vitro with ICbearing FDCs also showed the production of antigen–specific IgM within just 48 h.

xvii

General Introduction

1

The secondary lymphoid tissues (the Theatre)
Secondary lymphoid tissues (e.g Lymph nodes and spleen), are the theatre where
players of the immune system meet to orchestrate the initiation of an immune (adaptive)
response.
Under steady-state conditions, peripheral tissues are patrolled by only low
numbers of lymphocytes that can potentially respond to invading microorganisms (1).
Secondary lymphoid tissues facilitate the efficient interaction between the immune
system and microorganisms. They possess a highly organized micro-architecture that
maximize the probability of antigen encounter with an antigen-specific lymphocyte and
are necessary for the compartmentalization of numerous cellular interactions, thus
providing the optimal environment for initiation of immune responses, including the
determination of cell fate (2). Moreover, they are remarkably well connected to the blood
and lymphatic systems, allowing them to continually sample and concentrate antigens
that are circulating throughout the body.
Secondary lymphoid tissues are characterized by their efficient role in reducing
pathogen spread throughout the host by capturing pathogens; via the action of the
strategically localized macrophages (3,4), and by the production of innate immune
mediators, such as type I interferons (IFNs) (5). These rapidly induced innate immune
mechanisms reduce the pathogen load in anticipation of an adaptive immune response to
be mounted. They also help bring antigen presenting cells (APCs) in contact with
infrequent antigen-specific lymphocytes for the induction of an efficient antigen specific
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immune response (6,7). In addition, they provide the necessary factors for the survival
and differentiation of lymphocytes (2,8).
Beneath the protective outer collagenous capsule of a lymph node (LN), distinct
regions with unique features have been described. Underneath the subcapsular sinus, the
LN cortex with the well organized aggregates of B-cells; known as follicles, can be
observed. The LN follicles are considered to contain the largest population of IgMmed
IgDhi CD21med CD23hi B cells in the body. They are also sites rich in radiation-resistant
follicular dendritic cells (FDCs). Adjacent to the follicles, the paracortex; which is the Tcell zone that is enriched in antigen presenting cells (APCs) and high endothelial venules
(HEVs), can be detected. The HEVs mediate the recruitment of APCs that have
encountered the antigen in the periphery. They are also specialized in the continuous
supply and drainage of lymphocytes to the LNs and the periphery, respectively. The
paracortex is also characterized by a network of collagenous conduit fibers, which permit
the passage of low molecular weight molecules of the lymphatic fluid, such as
lymphokines and small antigens (9). The medulla is the innermost area of the lymph node,
it contains B and T cells that are organized into medullary cords as well as antibody
forming cells (AFCs; plasmablasts and plasma cells) and is also rich in DCs and
macrophages (10).
Germinal centers (the Stage)
The germinal center (GC) was first described in 1884 by Walther Flemming, who
observed a site of large lymphocytes undergoing mitosis in the follicles of lymph nodes
and other secondary lymphoid organs and proposed this site to be a major source of all
3

lymphocytes in the body (11,12). Although this originally proposed function of the GC
was disproven, Flemming’s work motivated subsequent intense studies concerning GCs.
GCs are the sites where efficient antibody affinity maturation occurs through the
process of clonal proliferation, somatic hypermutation and selection (13-15). GCs are
known to be associated with T dependent antibody responses, and are identified as the
main sites where high-affinity antibody-secreting plasma cells and memory B cells are
generated.
A T cell dependent immune response is initiated when infrequent antigen-specific
T and B cells cognately interact at the boundary between B-cell follicles and T cell zones
(16-18). The activated B-cells can then move to extra-follicular areas where they
proliferate and differentiate into short-lived plasma cells or move into the B cell follicles
and proliferate within the FDC network, giving rise to GCs (19,20). As the GC matures,
two main compartments; termed dark and light zones, become evident. The light zone is
mainly occupied by FDCs with their complex network of processes intimately interacting
with B cells, whereas few processes extend into the dark zone, where actively
proliferating lymphocytes are densely packed (12).
Follicular Dendritic Cells (FDCs) and the FDC-B-T cell interaction (the players)
1. FDCs Morphology, Phylogeny and Development
Owing to their unique morphology and follicular location, the antigen retaining
cells residing in primary follicles, and light zones of germinal centers in secondary
follicles, were given the name “Follicular Dendritic Cells” (FDCs). In 1968, Szakal and
Hanna published the first electron micrographs and description of FDCs (21-23).
4

Follicular dendritic cells constitute a pleomorphic, non-phagocytic group of dendritic
type cells, which possess either filiform dendrites or “beaded” dendritic processes.
Filiform dendrites of FDCs, which have an average length and diameter of 15-20 and 0.10.3 μm, respectively, tend to branch and anastomose near the cell body forming a
radiating “sunburst”-like pattern (24). Studies of FDCs at the ultrastructural level
revealed that they have single, and sometimes double, lymphocyte-size cell bodies, with
an irregular, lobated euchromatic nucleus (sometimes there are multiple nuclei), Golgi
apparatus, numerous small vesicles, and some mitochondria which are not abundant in
the dendritic processes (24). The microspheres of the “beaded” dendrites range between
0.3 and 0.6 μm in diameter and are termed ICCOSOMES [immune complex-coated
bodies (some-s)] (25-28).
Information available on FDCs is based primarily on studies using humans and
rodents. However, FDCs are present and functional in birds and if FDCs are defined
broadly as cells with the ability to trap and retain ICs, they appear to exist in all jawed
vertebrates, including amphibians, reptiles and fish. The origin of FDCs remains unclear.
FDCs are radiation resistant making it difficult to study development using adoptive
transfer models. At present there are some data supporting a haematopoietic origin while
even more data support a stromal cell origin.
2. Immunoregulatory mechanisms involving FDCs
a. Capturing, retention and periodic arrangement of antigen-antibody complexes
(Immune complexes; ICs) by FDCs.

5

Follicular dendritic cells capture and retain antigens (Ags) in the form of immune
complexes (ICs), via their surface expressed FcγRIIB (CD32) and complement receptor
(CR2; CD21) (29-31). Antigens trapped on FDCs remain in their native conformation, a
phenomenon that was confirmed by their continued recognition by specific antibody (Ab)
and, on isolation, their co-migration with native Ag when applied to sizing columns (32)
Moreover, horse radish peroxidase (HRP) retained its activity and was chemically
detectable on the FDC cytoplasmic membranes indicating that the native structure was
conserved at the tertiary protein structure level; hence the enzymatic activity was
preserved. In mice, conventional soluble protein Ag-Ab ICs are retained on FDCs with a
t1/2 of ~2 months; nevertheless, Ags have been detected a full year after injection (33).
FDCs trap ICs in a periodic manner, a phenomenon that was discovered using
scanning EM with Ag trapped in vivo (24), revealing an orderly, spiraling, arrangement
of ICs made up of alternating light and dark bands. The same periodicity was observed in
recent in vitro studies (34) where ICs were arranged on FDCs with a 200Å to 500Å
spacing between epitopes. This spacing correlates with the 95-675 Å spacing originally
described by Dintzis as optimal for B cell receptor for Ag (BCR) cross-linking and
activation in thymic independent (TI) responses.
IC trapping by FDCs in primary (35) and secondary (36-38) immune responses is
critical for induction of GC reactions, class switching, somatic hypermutation, affinity
maturation, and regulation of IgG and IgE serum levels (35,38-53). In primary responses
to thymic dependent (TD) Ags, ICs form as soon as Ab is produced and, by four days
after Ag challenge, ICs may be found on splenic FDCs. The kinetics of recall responses is
6

dramatic. Ags are almost instantaneously converted into ICs by Ab persisting from prior
immunization and by 1 min after challenge labelled Ags can be detected on cells in a
chain transporting ICs to FDCs deeper in the lymph node cortex. IC retention is localized
and Ag injection into a single limb of an immune mouse will be restricted to the draining
lymph nodes and to a lesser extent in the spleen. With time, FDC-Ag becomes more and
more focused to lymph nodes nearest the site of Ag injection and by 1 year, persisting Ag
and specific Ab-forming cells are almost exclusively confined to the most proximal
lymph node (51,54).
b. Molecular FDC-T-B-cell interactions.
FDC promote B-cell proliferation and survival by providing both Ag-dependent
and independent signals. The ability of FDC to prolong B cell viability relates to both
Ag-specific and non-specific signaling, and the FDC-mediated co-stimulatory signals are
not species-restricted, as evidenced by the ability of murine FDC to provide costimulation to human B and T cells and vice versa (55,56). The Ag–Ab complexes
trapped by FDCs provide intact Ag for interaction with BCRs on GC B cells and this Ag–
BCR interaction provides a positive signal for B cell activation and differentiation
(36,44). FDC-FcγRIIB binds the Fc regions of Igs, thereby inhibiting the SHIP signaling
pathway and thus minimizes ITIM activation in B cells by reducing co-cross-linking of
BCR and B cell-FcγRIIB (30,57,58). FDC–CD21L binds complement receptor 2 (CR2 or
CD21) on the B cell via CD21 in the B cell co-receptor complex consisting of
CD19/CD21/TAPA-1. Engagement of CD21 in the B cell co-receptor complex by
complement-derived FDC–CD21L delivers a critical co-signal. Co-ligation of BCR and
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CD21 facilitates association of the two receptors, and the cytoplasmic tail of CD19 is
phosphorylated by a tyrosine kinase associated with the B cell receptor complex. This cosignal dramatically augments stimulation delivered by engagement of BCR by Ag, and
blockade of FDC–CD21L reduces the immune responses considerably (typically 10- to
1000-fold (29).
In addition to the accessory signals delivered by the complement derived CD21L
interacting with the CD21/CD19/TAPA-1 complex, activated forms of both C3 (C3b) and
C4 (C4b) can bind C4 binding protein (C4BP), which in humans and likely in rodents,
co-localizes with ICs on FDCs as well as CD40 in secondary B cell follicles. C4BP is a
novel CD40 ligand capable of activating B cells through CD40. C4BP in immune
complexes (ICs) trapped on FDCs has been shown to signal B cells via intact CD40 in
short-lived antigen-specific TI GCs independent of the T-cell derived CD40L (CD154)
expression (59). Several other FDC-associated molecules are also involved in and are
critical for B-cell activation, FDC- B-cell-activating factor of the TNF family (BAFF)
(60-62), engaging B cell-BAFF-R (60,63), has been reported to be involved in several
immunological phenomena, such as T independent B cell responses and antibody isotype
switching, CD21 & CD23 expression, peripheral B-cell and plasma cell survival, MZ B
cell integrity and GC maintenance (64). FDC-8D6 and CD44 engaging their ligands on B
cells are also involved as co-stimulatory signal-providing molecules in FDC-B cell
interactions (65). Further, FDC-CXCL-13, which attracts B cells and helps organize
follicles (66,67), IL-6 that promotes terminal B cell differentiation (68), and membrane-
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bound molecules necessary for FDC-B cell synapse formation, ICAM-1 and VCAM-1
(69) are also critical in B cell activation.
c. FDC-phenotypes and major FDC-molecules (receptors, cytokines, chemokines,
etc.) with known functions
FDC-phenotypes in primary and secondary follicles are very different. In
secondary follicles (i.e. germinal centres), FDCs bear high levels of FcγRIIB, ICAM-1,
and VCAM-1, which are involved in converting poorly immunogenic ICs into a highly
immunogenic form as well as facilitating FDC-B cell interactions. In contrast, FDCFcγRIIB, -ICAM-1, and -VCAM-1 levels are low and difficult to detect in primary
follicles.
Expression of FDC accessory molecules is subject to regulation; and as reported
here in projects 1-3 (70-72), engagement of ICs, TLR ligands, or collagen type 1 induces
FDC activation and upregulation of these molecules. Similarly, FDC-FCγRIIB mediated
trapping of ICs in vitro, induces the secretion of BAFF and IL-6 (projects 4 and 5 in the
present work [(73) & in press]). FDC-activation by TLR agonists was generally done
using lipopolysaccharide (LPS). However, FDCs express mRNA for TLR2, 3, 4 & 9 and
injection of poly I:C increases FDC-FcγRIIB in draining lymph nodes similar to results
for LPS (project 3 (71)). FDCs also express CD44 and CD29 and FDC binding to
collagen type I in vitro induces regeneration of FDC processes and networks with
features in common with networks in vivo (project 2 (72)). A major consequence of
activation is a marked increase in accessory activity. For example, the number of FDCs
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needed for IgG responses in vitro could be reduced four-fold and somatic hypermuation
could be increased if FDCs were activated (project 3 (71) & (35)).
FDCs express and secrete various molecules with important immunoregulatory
functions as listed below in table 1 (Reviewed in (74)).
FDC-molecules

Immunoregulatory role
1- Conversion of poorly immunogenic ICs into a highly
immunogenic form: FDCs express high levels of FcγRs relative to
GC B cells and these receptors bind immunoglobulin-Fc in ICs and
minimize binding to B cell FcγRIIB. Thus, cross-linking of BCR and
B cell-FcγRIIB via ICs is minimized, ITIM signalling is reduced, and
B cells are productively signalled.
2- FDC activation: Both wild-type (WT) and FcγRIIB–/– mice trap ICs
but only WT mice respond to ICs by up-regulating FcγRIIB, ICAM1, and VCAM-1. Similarly, blockade of FDC-FcγRIIB results in
inhibition of IC-induced FDC-IL-6 and FDC–BAFF production
indicating the importance of FDC-FcγRIIB in FDC activation and
cytokine production.

FcγRIIB
(CD32)

3- IC periodicity: In the absence of complement, ICs are trapped by
FDC-FcRs and are periodically arranged on FDC dendrites. ICs
trapped via complement receptors do not induce the B cell activation
characteristic of periodically arranged Ags.
4- Long term IC retention: Complement-mediated IC trapping in the
draining lymph nodes of FcγRIIB-/- mice is normal. However, longterm retention of ICs is reduced in FcγRIIB-/- mice suggesting the
importance of this receptor in the long-term retention of ICs.
5- Regulation of serum IgG levels: High IgG levels feedback on Ag
retained on FDC dendrites and “zip” them together thus hiding the
ICs within "ball-of-yarn"-like dendritic convolutions. When Ab
levels decline, Ab dissociates from Ag-epitopes, the dendrites
unravel and the persisting Ag is exposed to memory B cells. This
exposure initiates a rebound in Ab and memory B cell production,
thereby maintaining humoral immunity.

FcεRII (CD23)

Immune complex retention and regulation of IgE levels: Serum IgE
is suppressed in CD23 transgenic (Tg) mice where FDC-CD23 and B
cell-CD23 are elevated. Adoptive transfer studies indicated that IgE
production is suppressed when normal lymphocytes are used to
reconstitute Tg mice with high levels of FDC-CD23. Furthermore,
isolated Tg-FDCs augment IgG production normally but IgE
10

Fcα/μR
CR1/2
(CD21/35)

CD21L (iC3b,
C3d or C3dg)

FDC-M1
(Mfge8)
FDC-M2
(C4b eptiope)
ICAM-1
(CD54)
VCAM-1
(CD106)
MadCAM-1

CXCL13

IL-6

production is reduced suggesting that a high level of FDC-CD23
selectively suppresses IgE.
Immune complex retention: In humans FDCs are the predominant
cell type expressing Fcα/μR. This Fc receptor can bind Abs of both
IgM and IgA isotypes and may function in Ag presentation and B cell
selection in the GC response in systemic and mucosal immunity.
Immune complex retention especially in the spleen: Splenic IC
retention does not occur without Complement
B cell co-stimulation via CD21: Engagement of CD21 in the B cell coreceptor complex by complement derived FDC-CD21L delivers a
critical co-signal. Co-ligation of BCR and CD21 facilitates association
of the two receptors and the phosphorylation of the cytoplasmic tail of
CD19 by a BCR-complex-associated tyrosine kinase. This co-signal
augments stimulation delivered by Ag and blockade of FDC-CD21L
reduces B cell proliferation, activation induced cytidine deaminase, and
Ab production 10 to 1,000 fold.
Clearance of apoptotic bodies: Fat globule epidermal growth factor 8
(Mfge8) “licenses” tingible body macrophages to engulf apoptotic
bodies in GCs and helps minimize autoimmunity
Binds C4b localized with FDC-ICs: C4b binding protein (C4BP) binds
C4b and co-localizes with ICs on FDCs. FDC-C4BP has been shown to
signal B cells via CD40, independent of T-cell CD40L (CD154).
Injection of mice with FDC-M2 inhibits C4BP localisation and TI-GC
development.
Stability of the FDC-B cell synapse: Abs reactive with murine ICAM1 and/or leukocyte functional Ag-I (LFA-I) interfere with FDC-B cell
clustering resulting in reduced B cell proliferation. In addition, VLA-4
and VCAM-1 have been observed in GCs and likely also play a role in
FDC-B cell interactions. These adhesion molecules are thought to
stabilize the FDC-B cell synapse and promote interaction of FDC-Ag
and FDC-costimulatory molecules with B cells.
B cell homing to lymphoid follicles via CXCR5: CXCL13 is secreted
by FDCs and acts as a chemoattractant for B cells via the CXCR5
chemokine receptor. FDC development and expression of this
chemokine depend on LTα1β2, TNF-α and related molecules. A
persistent LTa1β2 stimulus is important for both the induction and the
maintenance of FDC networks. Further studies suggest that the
maintenance of the primary lymphoid follicle structure is mediated by a
positive feedback loop: CXCL13 stimulates B cells to express high
levels of LTα1β2 and in turn LTα1β2 stimulates FDCs to produce
CXCL13.
GC development and terminal B cell differentiation: FDCs are the
source of IL-6 in GCs. Engaging FDC-FcγRIIB by ICs activates FDCs
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IL-15

8D6 (CD320)

BAFF

CD40

Toll-like
receptors
(TLRs) (2, 3,
and 4)

CD44

CD29

TNF-α
IL-7

and enhances FDC-IL-6 production. FDC-IL-6 promotes GC
development, IgG production, and somatic hypermutation.
Enhancement of GC B cell proliferation: IL-15 is produced by FDCs
and is captured by IL-15Rα on the surface of FDCs. Surface IL-15 is
active and promotes GC-B cell proliferation. GC-B cells have the
signal-transducing components (IL-2/15Rβγ), but not a receptor for
binding of soluble IL-15 (IL-15Rα) and the IL-15 signal may be
delivered by trans-presentation from FDCs to GC-B cells via cell-cell
contact.
B cell anti-apoptosis: The 8D6 molecule inhibits apoptosis and
influences both proliferation and Ab secretion by GC B cells. Moreover,
GC B cells that are induced to differentiate into pre-plasma cells are the
most sensitive to the neutralizing effects of anti-8D6.
Enhancement of T independent B cell proliferation: FDC-BAFF has
the ability to support TI B cell activation. The outcome of BAFF
signalling is multifaceted and different receptors mediate different
functions. Peripheral B cell survival, plasma cell survival, MZ B cell
integrity, GC maintenance, CD21 & CD23 expression, T independent B
cell responses, and Ig class switching may be influenced by BAFF.
Regulation of FDC-CD23: FDCs express CD40 and when incubated
with either CD40L trimer or agonistic anti-CD40 Ab, the expression of
FDC-CD23 is increased both at the mRNA and protein levels. As
explained above, FDC-CD23 helps regulate IgE levels.
Engagement of Pathogen-associated molecular patterns (PAMPs)
and FDC activation: Dramatic upregulation of FDC-ICAM-1, VCAM1, and FcγRIIB is observed after injecting LPS into animals expressing
wild-type TLR4 but not in animals with mutated TLR4. Incubation of
FDCs with LPS in vitro upregulates FcγRIIB, ICAM-1, and VCAM-1.
FDC activation by TLR agonists has been largely studied with LPS.
However, FDCs express mRNA for TLR2, 3, 4 & 9 as well, and
injection of poly I:C increases FDC-FcγRIIB to levels comparable with
LPS.
Interaction with ECM proteins, regeneration of FDC dendrites and
B cell anti-apoptosis: FDCs express CD44 and CD29 and FDC binding
to collagen type I in vitro induces the regeneration of FDC processes
and networks. CD44 also enhances B-cell adherence to FDCs allowing
delivery of the FDC-derived B cell survival signals including 8D6 and
BAFF.
T cell stimulation: FDCs produced soluble tumor necrosis factor alpha
(TNFα) that increases transcription and production of HIV in GC T
cells.
Interleukin 7 has been found in isolated tonsilar FDCs using RT-PCR
and intracellular staining. IL-7 signalling coupled with crosslinking of
12

surface immunoglobulin receptors results in B cell proliferation.
LT-R (and
TNFα)

FDC development and maturation

d. T-dependant and independent-immune responses and FDCs
By the 1950s, the lymphopoietic function of the thymus had been well established,
but no one believed that it had any immunological role. It was a common principle that
thymus was a useless organ that had become unnecessary during evolution; a conclusion
that was based on a number of observed phenomena (75).
First, efficient immune responses were documented in mice thymectomized in
adult life (76). Moreover, thymus lymphocytes were inefficient in initiating immune
reactions after adoptive transfer to appropriate recipients if compared to lymphocytes
from the spleen, lymph nodes and blood. Again, thoracic duct lymphocytes homed
efficiently from blood into lymphoid tissues, with the thymus as ‘the only exception’,
where only very few lymphocytes lodged (75). In addition, antibody-forming plasma
cells and germinal centers were absent from thymus tissue, although so prominent in
spleen and lymph nodes. However, in 1961, Miller published in The Lancet the first data
supporting an immunological function for the thymus (77) and in 1962 Martinez et al.
and Miller (78,79) provided data further supporting the direct or indirect involvement of
the thymus in immunological reactions and its role as a supply of lymphocytes to other
lymphoid tissues.
Inspite of the general assumption, by that time, that all the immune responses of
neonatally thymectomized animals to all types of antigenic stimuli are impaired (80-82),
Humphrey and Parrott in 1964 (83) showed that mice thymectomized at birth can, in
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certain circumstances (e.g. in response to pneumococcal polysaccharides), produce as
much or even more antibody than intact controls.
The term Thymus-dependent was first assigned to histologically delineated areas
of lymphocyte depletion in secondary lymphoid tissue of neonatally thymectomized mice
(immediately surrounding the central arterioles in the spleen, and constitute the mid and
deep cortical zones of the lymph nodes) (84-87). The remaining areas in the peripheral
lymphoid organs were all designated 'thymus-independent' (88). In 1966 Micklem et al.
(89) demonstrated the presence of cells from two distinct origins in the peripheral
lymphoid tissues and in 1969 Davies and co-workers (90,91) demonstrated the bone
marrow origin of thymus-independent areas of the secondary lymphoid organs. This
concept was further supported by proceeding studies, and the term T-cells and B-cells (i.e
of bone marrow origin) was assigned to cells in thymus-dependant and thymusindependent areas of the secondary lymphoid organs, respectively (92,93). Subsequent
studies showed a clear distinction between thymus-dependent and independent
populations based on functional and phenotypic analysis (94).
T cell-independent antigens represent two major groups. TI type 2 (TI-2) antigens
are characterized by their large molecular weight, possession of repeating immunogenic
epitopes, ability to activate the complement cascade, poor in vivo degradability, and
inability to stimulate MHC class II-dependent T cell help. TI type 1 (TI-1) antigens, on
the other hand, are characterized by being mitogenic for B cells. In contrast to TI antigens,
T cell-dependent antigens (TD), which comprise soluble proteins or peptides are
characterized by their ability to associate with MHC molecules on an antigen presenting
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cell (APC), which subsequently interact with and activate T cells, in part, through ligation
of their T cell antigen receptor complex (TCR), as well as through binding of accessory
and adhesion molecules (reviewed in (95-104)).
TI-2 antigens express repetitive epitopes on a stable backbone with an extended
length of 460 nm. This backbone carries 48 epitopes that can engage 10-50 mIg receptors
forming a small number of highly cross-linked clusters with 14-fold reduction in the
diffusion coefficient of the bound mIg receptors. This conformation is critical for
delivering the BCR-mediated signal in TI-2 responses and is achieved by minimizing the
extent of modulation and disappearance of Ig from the surface of antigen-specific B cells
thus allowing for prolonged contact of the antigen with mIg and therefore persistent Bcell signaling with relatively low antigen concentrations. In addition to the spatial density
and affinity of antigens, BCR signaling in TI responses is also influenced by important
regulatory molecules such as complement and Fc-receptors (97-99). In addition, Ig
secretion is enhanced by additional immunostimulatory signals (second signals) such as
complement fragments, C4-binding protein (C4BP), B-cell-activating factor of the TNF
family (BAFF), pathogen-associated molecular patterns (PAMPs), DC-, macrophage-,αβ, γ-δ, and NK T-cell- derived factors (95-97,105-107). Antibody responses to TI
antigens are characterized by the absence of a typical immunological memory, failure to
induce classic GC formation, and the involvement of mIgD, Bruton’s tyrosine kinase
(Btk), B-1 and MZ B cells.
Studies showed that virus-specific IgM responses are mounted in athymic nude,
TCRα- TCRβ- TCRαβ- and TCRαβγδ-knockout mice infected with Coxsackie,
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influenza, vesicular stomatitis virus and many other viral models. Moreover, all of the
antiviral TI antibody responses reported so far are directed to viral antigens repetitively
displayed in the virions (108). Besides, antibodies bound to strictly ordered, but not to
irregularly arranged, viral antigens dramatically enhanced the induction of anti-antibodies
after a single immunization and without using adjuvants (109).
In addition to the well known role of FDCs in GC reactions of the classic TD
responses, our studies revealed an important role of FDCs in augmenting and enhancing
B-cell proliferation and Ab responses, respectively, in in vitro B cell cultures stimulated
with slg-dependent (anti-δ) or -independent (LPS) polyclonal activators (40).
Subsequently, molecules involved in FDC-mediated enhancement of Ab responses by B
cells in Ag-driven or LPS-stimulated systems were characterized and revealed an
important interaction between a complement-derived CD21 ligand on follicular dendritic
cells and CD21 on B cells in the initiation of IgG responses (29,39,44). The fact that
blockade of CD21 receptors on B-cells co-cultured with FDCs results in the reduction of
Ab responses to the TD antigen tetanus toxoid (TT), and to the TI type 1 pokeweed
mitogen (PWM), further supports the importance of FDC-associated molecules (CD21
ligand) in the enhancement of Ab responses by B-cells (56).
FDC-FcγRIIB is another important molecule that influences B-cell Ab responses.
FDC- FcγRIIB binds the Fc regions of Igs thereby inhibiting the SHIP signaling pathway
and thus minimizes ITIM activation in B cells by reducing co-cross-linking of BCR and
B cell-FcγRIIB (57,58). The role of FDC-FcγRIIB in B cell activation has been
investigated under Ag-specific and anti-BCR ligation conditions. The addition of ICs to
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cultures of Ag-specific T and B cells elicited pronounced Ab responses only in the
presence of FDCs. In addition, Ag-specific responses in cultures containing FDCs
derived from FcγRIIB-/- mice or FcγRIIB-/- mice transplanted with wild-type Ag-specific
T and B cells and challenged with specific Ag were significantly depressed compared
with those of controls with wild-type FDC in vitro and in vivo (30). In another study, the
addition of normal FDCs, but not FDCs lacking FcγRIIB from FcγRIIB-/- mice, reduced
and reversed the anti-BCR-induced SHIP phosphorylation in A20 cells supporting the
concept that binding Ig Fc regions by FDC-FcγRIIB could inhibit the SHIP signaling
pathway and thus minimize ITIM activation in B cells by reducing co-cross-linking of
BCR and B cell-FcγRIIB (57). Again, the immune response to the immunodominant Ag
of Actinobacillus actinomyctemocomitans, which is a 150 kD polymer of disaccharide
repeating units capable of maintaining immune responses for long periods of time in the
absence of continuous source of the Ag, increased 3-40-fold after the addition of Agspecific IC-bearing FDCs in in vitro cultures(110).
TI polysaccharide antigens activate the alternative complement pathway directly
and the classical pathway indirectly by making ICs with specific IgM produced early in
the immune response. In addition to the accessory signals delivered by the complement
derived CD21L interacting with the CD21/CD19/TAPA-1 complex, activated forms of
both C3 (C3b) and C4 (C4b) can bind C4 binding protein (C4BP), which in humans and
likely in rodents, co-localizes with ICs on FDCs as well as CD40 in secondary B cell
follicles. C4BP is a novel CD40 ligand capable of activating B cells through CD40.
C4BP in immune complexes (ICs) trapped on FDCs has been shown to signal B cells via
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intact CD40 in short-lived antigen-specific TI GCs independent of the T-cell derived
CD40L (CD154) expression. Consistent with the hypothesis that ICs on FDCs can
provide antigen-specific, complement-derived, and CD40-mediated signals to B cells
initiating B cell proliferation in TI GCs (59).
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CHAPTER 1
Follicular dendritic cell (FDC)-FcγRIIB engagement via immune
complexes induces the activated FDC phenotype associated with
secondary follicle development
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Introduction
Follicular dendritic cells (FDC) are localized to the light zones of
germinal centers (GC), where their dendritic processes interdigitate and form
three-dimensional networks or FDC-reticula that help these non-circulating cells
to remain localized (37,42). FDC functions include the capture and retention of
immune complexes (IC) (30), promotion of B cell survival (111-115), and the
production of high-affinity Ab (39,116). The ability to stimulate B cells depends
in large measure on the ability of FDC to trap and present Ag to specific B cells.
FDC capture and retain Ag in the form of IC, and starting in the early 1970s, a
number of studies elegantly documented that complement and complement
receptors (CR) were necessary for optimal IC trapping and retention (117-121).
Although, Fc receptors may not be as important as complement and CR in IC
trapping, they do appear to enhance long-term retention of IC by FDC (30).
Both FDC and B cells express FcγRIIB (57,58), but B cell activation
may be inhibited by immunoreceptor tyrosine-based inhibition motif (ITIM)
signaling mediated by IC coligating the B cell receptor for Ag (BCR) and B cellFcγRIIB (reviewed in (122,123)). Engagement of BCR in the absence of such
coligation induces rapid activation of tyrosine kinases, generation of inositol
phosphates, elevation of cytoplasmic Ca2+ concentrations, and activation of
mitogen-activated

protein

kinases

(reviewed

in

(122,123)).

These

events

promote B cell activation and lead to proliferation, differentiation, and Ab
secretion (reviewed in (124)). In marked contrast, coligation of BCR and
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FcγRIIB by IC leads to inhibition of the extracellular Ca2+ influx, reduction of
cell proliferation, blockage of blastogenesis, and inhibition of Ig synthesis
(reviewed in (122-124)). Nevertheless, on FDC, IC provide potent activation
signals for B cells that result in induction of GC dark zones where B cells are
proliferating and differentiating rapidly (reviewed in (125)). However, FDC
lacking FcγRIIB or expressing only low levels of FcγRIIB are unable to convert
poorly immunogenic IC into a highly immunogenic form for B cells, although
they can trap IC using CR (30). In active GC, FDC express high levels of FcR
relative to B cells, and it appears that these receptors bind Fc portions of Ab in
IC and minimize their binding to FcR on B cells (30,44,57). Thus, cross-linking
of BCR and FcγRIIB via IC is minimized, ITIM signaling is reduced, and B cell
proliferation and differentiation is promoted.
In follicles lacking GC, FDC exhibit a resting phenotype with significant
CR1/2 levels, but with low levels of FcγRIIB, ICAM-1, and VCAM-1, raising
the issue of mechanisms involved in activating FDC adequately to productively
present IC to B cells. Remarkably, challenge of actively immunized mice with
Ag induces a dramatic increase in FDC-FcγRIIB expression. Up-regulation of
FDC-FcγRIIB is apparent within 24 h, reaches a peak by day 3, and remains
high for at least 10 days (57,58). The rapidity of this response suggested that
memory T and B cells were not involved and prompted the hypothesis that
interaction of IC with FcγRIIB on FDC up-regulated the expression of FcγRIIB
as well as of other surface molecules that participate in the immune response,
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including ICAM-1 and VCAM-1 (69,126,127). A recent paper by Victoratos et
al. (128) provides support for the concept that IC binding of FcR on FDC can
lead to up-regulation of FDC-ICAM-1 and -VCAM-1.
To test this hypothesis, mice were passively immunized with anti-OVA
Ab, and the levels of FcγRIIB, ICAM-1, and VCAM-1 on FDC-reticula and
purified FDC were determined 3 days after challenging wild-type (WT) and
FcγRIIB-/- mice with OVA. Both WT and FcγRIIB-/- mice trapped OVA-antiOVA Ab IC, but only the WT mice responded with dramatic up-regulation of
FcγRIIB, ICAM-1 and VCAM-1. Furthermore, addition of IC to purified FDC
from WT mice, but not FcγRIIB-/- mice, in vitro prompted the production of
mRNA for FcγRIIB, ICAM-1, and VCAM-1 within 3 h, indicating that this Fc
receptor promoted activation rather than inhibition as it is known to occur in
other cells including T cell-associated dendritic cells (122,123,129). In short, the
data support the concept that direct interaction of IC with FDC-FcγRIIB upregulates

FcγRIIB,

as

well

as

ICAM-1

and

VCAM-1,

indicating

that

engagement of FcγRIIB is important in initiating pathways leading to FDC
activation, as indicated by the expression of molecules on FDC needed for
accessory function.
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Materials and methods
Animals
BALB/c mice 6-8 wk old were purchased from the National Cancer
Institute, and FcγRIIB KO mice (C57BL/6; 129-Fcγr2tm1) were obtained from
Taconic Farms (Hudson, NY). Mice were housed in shoebox cages and food and
water were given ad libitum. Animals were handled in compliance with
guidelines established by VCU's institutional animal care and use committee.
Ab and other reagents
The rat anti-mouse CD16/32 (clone2.4G2), CD106 (mVCAM-1), FDCM1, biotin labeled anti-rat kappa Ab and the DAB substrate kit were from BD
PharMingen (San Diego, CA). Rat anti-mouse CD54 Ab (ICAM-1), HRPconjugated goat anti-rat IgG, and HRP-conjugated goat anti-rabbit IgG were
from Southern Biotech (Birmingham, AL). Rabbit anti-OVA Ab was purchased
from Biodesign International (Saco, ME) and normal rabbit serum from Gibco
(Grand Islands, NY). Anti-biotin microbeads and MACS LS columns were
purchased from Miltenyi Biotec GmbH (Auburn, CA).
FDC isolation
FDC were isolated by positive selection from LN (axillary, lateral
axillary, inguinal, popliteal, and mesenteric) of adult mice as described (130).
Before

isolation,

mice

were

irradiated

with

1000 rad

to

eliminate

most

lymphocytes. On the day of isolation, mice were killed, LN were collected,
opened and treated with 1.5 mL collagenase D (22 mg/mL, C-1088882; Roche),
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0.5 mL of DNase I (5000 U/mL, D-4527; Sigma), and 2 mL DMEM with
20 mM HEPES. After 45 min at 37°C in a CO2 incubator, released cells were
washed in 5 mL DMEM with 10% FCS. Cells were then sequentially incubated
with FDC-specific Ab (FDC-M1) for 45 min, 1 µg of biotinylated anti-rat

light

chain for 45 min, and with 20 µL anti-biotin microbeads (Miltenyi Biotec) for
15-20 min on ice. The cells were layered on a MACS LS column and washed
with

10 mL

ice-cold

MACS

buffer.

The

column

was

removed

from the

VarioMACS and the bound FDC were released with 5 mL MACS buffer.
Isolation of peritoneal macrophages
DMEM (20 mL) was injected i.p. and the cells were recovered by
peritoneal lavage. The cells were washed by centrifugation and resuspended in
complete DMEM with 10% FCS.
Isolation of lymphocytes
Lymphocytes were suspended by grinding LN from non-irradiated mice
between the frosted ends of two sterile slides in complete DMEM with 10%
FCS. The suspension, containing 30-45% B cells, was washed and resuspended
in complete medium.
IC preparation and cell cultures
FDC isolated from murine LN were cultured at 1 × 106 cells/mL in 5-mL
polypropylene tubes containing 1 mL complete medium supplemented with 10%
FCS. OVA and rabbit anti-OVA Ab IC were made at a final ratio of 1 ng/mL
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OVA to 6 ng/mL anti-OVA Ab. The cultures were maintained for 12 h at 37°C
in a CO2 incubator unless otherwise indicated.
Analysis of FcγRIIB, ICAM-1, and VCAM-1 mRNA levels by qRT-PCR
Total cellular RNA was extracted by using TRIzol reagent (Invitrogen
Life Technologies, Carlsbad, CA) according to the manufacturer's instructions.
Then, the one-step RT-PCR reaction was achieved by using an iCycler (BioRad, Hercules, CA). The TaqMan one-step RT-PCR master mix reagent kit
(ABI, Foster City, CA) was used for RT-PCR. The amplification of various
mRNA and 18S RNA were run in separate wells using the same amount of total
RNA

retrieved

from

the

same

sample.

The

sequences

for

the

various

oligonucleotides starting with the forward primer, followed by reverse primer,
then probe and going from 5′ to 3′ are indicated in Table 1. Amplifications were
performed under the following conditions: 48°C for 30 min (cDNA synthesis),
initial denaturation at 95°C for 10 min followed by 40 cycles of denaturation at
95°C for 15 s and a combined annealing/extension step at 60°C for 1 min.
Finally, fold differences in mRNA expression levels were calculated using the
ΔΔCT method (131). The PCR efficiency was first ascertained to be close to
100% by performing multiple standard curves using serial mRNA dilutions. An
amplification cycle threshold value (CT value), defined as the PCR cycle number
at which the fluorescence signal crosses an arbitrary threshold, was calculated
for each reaction. The fold change between mRNA expression levels was
determined as follows: Fold change = 2-ΔΔCT, where ΔΔCT = (CT-GoI - CT-Hk)
25

Sample - (CT-GoI - CT-Hk) Control, where CT: cycle threshold, GoI: gene of
interest, Hk: house keeping gene.

Table 1. Primer and probe sequences used in real-time qRT-PCR analysis
Sense primer
TCCTAGTATCCTTGGTCTATCTC
FcγRIIB
Anti-sense primer GTGAGTAGGTGATCGTATTCTC
Probe 50-FAMAAGCAGGTTCCAGACAATCCTCCT-30-BHQ-2a)
Sense primer
TTGAGAACTGTGGCACCGTG
Anti-sense
primer
CAGCTCCACACTCTCCGGAA
mICAM1
CGCTTCCGCTACCATCACCGTGTATTCG-30Probe 50-FAMBHQ-1a)
Sense primer
GTGACCTGTCTGCAAAGGAC
Anti-sense
primer
AAAGGGATACACATTAGGGACTG
mVCAM1
AAGAGAACCCAGGTGGAGGTCTACTCATTCProbe 50-FAM30-BHQ-1a)
Sense primer
AAAATTAGAGTGTTCAAAGCAGGC
18S rRNA Anti-sense primer CCTCAGTTCCGAAAACCAACAA
Probe 50-Cy5CGAGCCGCCTGGATACCGCAGC-30-BHQ-2a)
a)
Black hole quencher.

Immunizations and immunohistochemistry
Three mice were subcutaneously injected in the front legs with an initial
dose of 100 µL rabbit anti-OVA Ab (10 mg/mL) followed 1 h later by 100 µL
OVA (1 mg/mL) (Sigma, St. Louis, MO). A final dose of 100 µL rabbit antiOVA Ab (10 mg/mL) was injected 1 h later. Controls were injected with OVA +
NSS or with rabbit anti-OVA Ab alone. At 3 days post immunization, axillary
LN were collected and frozen in CryoForm embedding medium (IEC, Needham
Heights, MA) and frozen sections of 10 µm thickness were cut on a Leitz (1720
Digital) cryostat and air-dried. Five representative midsagittal sections were
collected and processed together for the quantitative analysis. Following acetone
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fixation, the sections were rehydrated and the endogenous peroxidase activity
was quenched with PBS containing 0.1% phenylhydrazine-HCl (Sigma). The
sections were washed and saturated with 10% BSA, then incubated with: mouse
adsorbed

HRP-conjugated

CD16/CD32

(FcγRIIB),

goat
CD106

anti-rabbit

IgG,

(VCAM-1),

or

unlabeled
CD54

Ab

rat

anti-mouse

(ICAM-1).

The

sections with rat Ab were washed and then incubated with mouse adsorbed
HRP-conjugated goat anti-rat IgG. The sections were developed with a DAB
substrate kit (BD PharMingen) and images were captured using an optronics
digital camera and analyzed using Bioquant Nova software.
The rat mAb 2.4G2 recognizes murine FcγRIIB and FcγRIII. However,
FDC-reticula in GC of FcγRIIB-/- mice do not label with 2.4G2, indicating that
activated FDC have little if any FcγRIII (30). Accordingly, we attribute the
histochemical labeling of FDC-reticula in WT mice with 2.4G2 to FDCFcγRIIB.
Analyses of immunohistochemistry results
BIOQUANT

NOVA

Advanced

Image

Analysis

software

(R&M

Biometrics, Nashville, TN) was used to analyze the immunohistochemistry as
described (58). This system allowed us to determine number, position, area, and
density of the labeling after setting an arbitrary threshold that was the best for
the FDC-reticula. This predefined threshold was used throughout to enable
reliable comparisons.
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Flow cytometry
FDC

were

isolated

from

WT

and

FcγRIIB-/-

mice

3 days

after

subcutaneous injection of Ag and Ab to form IC. Control mice were injected
with saline. Except for CD32/CD16-FITC labeling, FDC were first incubated
with mouse Fc-Block (BD PharMingen) for 15 min on ice, followed by antiCD54/ICAM-1-FITC Ab, anti-CD106/VCAM-1-FITC Ab or isotype control for
60 min in the dark at 4°C. After washing, the cells were analyzed using an
FC500 flow cytometer and Cytomics RXP analysis software. Histograms were
gated for FDC based on their forward and side scatter properties established
with FDC phenotypic markers including FDC-M1, CD21/35, and CD32 (130).
The figures were plotted using WinMDI software (Scripps Research Institute).
Statistical analysis
For analysis of results including qRT-PCR data, a t-test (two-tailed distribution)
was used. To account for multiple comparisons, a p value of less than 0.01 was
required to conclude significance.
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Results
FDC-mediated IC trapping
Increases in FDC-FcγRIIB are apparent 1-3 days after challenge of immune
mice

with

Ag,

prompting

the

postulate

that

FDC

may

be

activated

by

encountering IC. If IC directly initiated up-regulation, then memory T and B
cells would not be important and IC in normal mice should activate FDC. To
test this, we passively immunized WT and FcγRIIB-/- mice with rabbit anti-OVA
IgG and challenged with OVA to form IC. Localization of the IC on FDCreticula

after

3 days

was

determined

with

immunohistochemistry

and

morphometrically analyzed (Fig. 1A1-A5). Complement and CR are known to
facilitate trapping of IC on FDC (117-121); thus, IC strongly labeled FDCreticula in both passively immunized WT and FcγRIIB-/- mice. In contrast,
neither anti-OVA Ab nor OVA in the presence of nonspecific rabbit serum
(NSS) were retained on the FDC-reticula, confirming the importance of the IC.
The number of FDC-reticula ranged between five and six in IC-immunized WT
and FcγRIIB-/- mice compared to a total lack of labeling in Ag- or Ab-aloneinjected animals (Fig. 1A4). The average reticular size was approximately
250 000 µm2 (Fig. 1A5) whereas the average density per reticulum, which
reflects the amount of IC staining, ranged between 110 and 120 pixels and did
not differ between WT and knockout (KO) mice.
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IC-mediated up-regulation of FDC-FcγRIIB expression
We hypothesized that direct interaction between IC and FDC-FcγRIIB
up-regulates FcγRIIB expression in an auto-regulated or self-induced manner.
To begin testing, we analyzed FcγRIIB labeling in FDC-reticula of 3 days
passively immunized animals (Fig. 1B1-B5). Whereas the number of FcγRIIB
labeling FDC-reticula in passively immunized WT animals ranged between five
and six, the number in control non-immune mice with Ag in NSS or Ab alone
averaged <1 per midsagittal draining axillary LN section (p <0.001). No labeling
was detected on sections from FcγRIIB-/- mice (Fig. 1B3). The reticular size in
passively immunized WT animals measured 144 200 µm2 compared to 8200,
6153 and 6131 µm2 in the non-immunized WT, Ag-alone- and Ab-aloneinjected controls, respectively (p <0.001). The average density per reticulum,
which indicates the intensity of FcγRIIB labeling, was highly variable in the
control groups which include reticula induced by environmental Ag that were in
various

stages

of

decline.

Moreover, the

density

of

labeling

was

almost

homogenous in the 3-day reticula in passively immunized animals, and this
contrasted with the variability in the controls where the initial time of
stimulation could not be determined.
IC increase FcγRIIB mRNA levels in FDC but not in B lymphocytes or
macrophages
The immunohistochemical results support the concept that FcγRIIB is
important in up-regulating FDC-FcγRIIB. However, many other cells, including
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Figure 1: Analysis of light micrographs illustrating trapping of IgG-OVA IC (A1-A5)
and labeling with anti-FcγRIIB Ab (B1-B5) in the FDC-reticula of draining axillary
LN. Mice were passively immunized with rabbit anti-OVA Ab, followed by OVA to
produce IC. After 3 days, draining axillary LN were harvested, sectioned, and midsagittal
sections were labeled. IC-retaining reticula were labeled in (A1-A5) using anti-rabbit IgG.
(A1) Representative passively immunized and OVA-challenged WT mouse ×50;
(A2) representative no-IC (Ab alone or NSS + Ag) WT mouse ×80; (A3) representative
passively immunized and challenged FcγRIIB-/- mouse ×50. (A4) Number and (A5) size
of FDC-reticula per midsagittal axillary LN section. FDC-reticula were labeled for
FcγRIIB in (B1-B5). (B1) Representative passively immunized and challenged WT
mouse ×50; (B2) no-IC WT mouse with a GC ×50; (B3) representative passively
immunized and challenged FcγRIIB-/- mouse ×50. (B4) Number and (B5) size of FDCreticula per draining midsagittal axillary LN section. The averages were calculated using
data

from

three

mice,

and

results

[Normal View 59K | Magnified View 95K]
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illustrate

the

means

± SEM.
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mast cells and macrophages, can interact with IC in vivo and could play a role in
regulating expression of FDC-FcγRIIB. However, if direct interaction between
IC and FcγRIIB induces FDC-FcγRIIB, then addition of complement-free IC to
purified FDC should result in increased FcγRIIB mRNA. To examine this, we
determined the effect of IC on FcγRIIB mRNA levels in purified FDC using
quantitative reverse transcriptase PCR (qRT-PCR). The fold change in FcγRIIB
mRNA in IC-treated FDC, as compared to untreated FDC, was calculated. IC
treatment resulted in an approximately 2000-fold increase in FcγRIIB mRNA in
12 h, whereas treatment with Ab alone or Ag alone was without effect (Fig. 2A).
This response appeared to be FDC specific because B cells, which bear
FcγRIIB, and macrophages treated with the IC for the same period of time did
not show any change in FcγRIIB expression (Fig. 2B). This result minimizes the
probability that contaminating B cells or macrophages in the FDC preparations
contribute to the dramatic increase in FcγRIIB mRNA levels. Furthermore, this
result is consistent with histochemistry where the increase in FcγRIIB on FDC
was dramatic, but was not apparent on adjacent B cells (Fig. 1B1).
Anti-FcγRIIB Ab blocks the IC-mediated increase in FcγRIIB mRNA levels
WT FDC treated with rat anti-mouse CD16/32 Ab (clone 2.4G2) for
30 min prior to IC addition showed no change in FcγRIIB mRNA levels (Fig.
2C). Since 2.4G2 blocks FcγRIIB, this result further supported a crucial role of
FcγRIIB in mediating the IC-induced FcγRIIB expression on FDC.
Kinetics of IC-induced increases in FcγRIIB mRNA
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The IC-induced increase in FDC-FcγRIIB mRNA levels was determined
at 1, 3, 12 and 24 h. Increased FcγRIIB mRNA levels were apparent within 3 h
and increased over the entire 24-h period (Fig. 2D).
IC-mediated up-regulation of FDC-ICAM-1 and -VCAM-1 expression
Murine ICAM-1 and VCAM-1 are inducible on FDC and high levels
coincide with GC formation (132,133). Furthermore, these adhesion molecules
are critical to the ability of FDC to stimulate B cells (69). In the present study,
we sought to determine the impact of IC on FDC-ICAM-1 and -VCAM-1
expression. Three days after passive immunization and Ag challenge, FDCICAM-1 and -VCAM-1 were analyzed with immunohistochemistry (Fig. 3). The
number

of

ICAM-1-

and

VCAM-1-labeled

FDC-reticula

3 days

after

IC

formation in passively immunized WT animals ranged between five and six per
midsagittal draining axillary LN section and corresponded with IC trapping and
FcγRIIB expression. In contrast, the number in non-immune WT, Ag-alone-,
Ab-alone-, and passively immunized FcγRIIB KO mice was approximately one
per midsagittal draining axillary LN section (p <0.01). The same difference
between IC vs. Ag or Ab alone existed with cumulative reticular size for FDCICAM-1 and -VCAM-1 in passively immunized WT animals. In contrast,
neither ICAM-1 nor VCAM-1 labeling in FDC-reticula of passively immunized
FcγRIIB-/- mice was significantly changed after IC treatment (Fig. 3).
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Figure 2: RT-PCR quantification of IC-mediated FcγRIIB mRNA induction in FDC.
(A) FDC (1 × 106) were isolated from LN and cultured for 12 h in the presence of
50 ng/mL OVA (Ag), 300 ng/mL anti-OVA Ab (Ab) or the combination of OVA + antiOVA Ab to form IC. (B) IC-mediated FcγRIIB mRNA induction was not observed in B
cells or macrophages. FDC, B cells, and peritoneal macrophages (1 × 106) were cultured
in the presence of 50 ng/mL OVA (Ag), 300 ng/mL anti-OVA Ab (Ab) for 12 h.
(C) Induction of FcγRIIB mRNA production in FDC by IC was blocked by anti-FcR Ab
(2.4G2). FDC (1 × 106) were cultured for 12 h in the presence of 50 ng/mL OVA (Ag),
300 ng/mL anti-OVA Ab (Ab), directly or after being treated with 2.4G2 (2 µg in a final
volume of 200 µL) for 30 min on ice. (D) Kinetics of IC-induced FcγRIIB mRNA
production in FDC. FDC were cultured in the presence of 50 ng/mL OVA (Ag),
300 ng/mL anti-OVA Ab (Ab), and maintained for 1, 3, 12 and 24 h at 37°C in a CO2
incubator. Data are expressed as fold increase in mRNA. These results are representative
of three separate experiments of this type, and results are depicted as the means ± SEM
for replicate cultures. [Normal View 26K | Magnified View 39K]
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Figure 3: Analysis of light micrographs of draining axillary LN illustrating
immunohistochemical labeling of FDC-reticula with anti-VCAM-1 (A1-A5) and antiICAM-1 Ab (B1-B5). LNs were harvested 3 days after passive immunization and
challenge with OVA to form ICs. VCAM-1 labeling of FDC-reticula is analyzed in (A1A5). (A1) Representative, passively immunized and challenged WT mouse ×50; (A2) noIC WT mouse with a GC ×50; (A3) a passively immunized and challenged FcγRIIB-/mouse with a labeled GC ×80. (A4) Number and (A5) size of FDC-reticula per draining
midsagittal axillary LN section. ICAM-1 labeling of FDC-reticula is shown in (B1-B5).
(B1) Representative passively immunized and challenged WT mouse ×50; (B2) no-IC
WT mouse with a labeled GC ×50, (B3) passively immunized and challenged FcγRIIB-/mouse with a labeled GC ×80. (B4) Number and (B5) size of FDC-reticula per draining
midsagittal axillary LN section. The averages were calculated using data from three mice,
and results illustrate the means ± SEM. [Normal View 61K | Magnified View 96K]
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Up-regulation of surface expression of FcγRIIB, ICAM-1 and VCAM-1 on ICstimulated FDC confirmed by flow cytometry
Flow cytometric analysis of FcγRIIB, ICAM-1 and VCAM-1 on FDC purified
from

WT

mice

showed

significantly

increased

labeling

3 days

after

IC

stimulation (Fig. 4A-C). Whereas 39% of FDC were FcγRIIB positive from
unstimulated WT mice, 70% were FcγRIIB positive after IC activation (Fig.
4A). Labeling with anti-ICAM-1 Ab indicated that 30% of unstimulated WT
FDCs

were

CD54/ICAM-1

positive,

whereas

65%

were

positive

after

IC

stimulation (Fig. 4B). Similarly, CD106/VCAM-1 was expressed on 6% of
unstimulated WT FDC, rising up to 38% in IC-activated FDC (Fig. 4C). In
contrast,

FcγRIIB-/-

FDC

showed

no

change

in

surface

expression

of

CD54/ICAM-1 (Fig. 4D), or CD106/VCAM-1 (Fig. 4E) after binding IC.
IC-mediated induction of FDC-ICAM-1 and -VCAM-1 mRNA in vitro
If engagement of FDC-FcγRIIB with IC initiates pathways leading to upregulation of surface molecules that participate in interactions with GC B cells,
then RNA messages for these molecules should be apparent after IC stimulation.
Using qRT-PCR, mRNA levels for ICAM-1 and VCAM-1 in FDC from WT
and FcγRIIB-/- mice were determined after culture with IC for 3, 12 and 24 h,
and the fold change was calculated using mRNA levels in untreated FDC as the
baseline. In WT FDC, mRNA levels for FcγRIIB, ICAM-1, and VCAM-1 were
significantly elevated within 3 h and dramatically increased after 24 h (Fig. 5).
In contrast, FDC from FcγRIIB KO mice did not display any changes in ICAM39

1 or VCAM-1 mRNA levels (Fig. 5). Controls included IC made in the presence
of fresh complement to enhance IC binding to FDC from FcγRIIB KO and WT
mice. The presence of complement fragments in the IC did not up-regulate
ICAM-1 or VCAM-1 mRNA levels in KO mice or enhanced the IC-mediated
up-regulation of these molecules in WT mice (data not shown).
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Figure 4: Effect of IC stimulation on FDC-CD32/CD16, CD54/ICAM-1 and
CD106/VCAM-1 surface expression. FDC were from WT (A-C) or FcγRIIB-/- (D, E)
mice. Three days after subcutaneous injection of IC or saline, FDC were isolated and
labeled for CD32/CD16, CD54/ICAM-1 or CD106/VCAM-1, and analyzed by flow
cytometry. WT FDC exhibited increased surface expression of CD32/CD16 (A),
CD54/ICAM-1 (B) and CD106/VCAM-1 (C) when stimulated with IC, whereas FcγRIIB/-

FDC showed no change in the surface expression of CD54/ICAM-1 (D) or

CD106/VCAM-1 (E) upon IC treatment. These data are representative of three separate
experiments

of

this

type.

[Normal

View

41

41K

|

Magnified

View

63K]
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Figure 5: Effect of IC stimulation on mRNA for markers indicative of the activated
FDC phenotype. FDC were cultured in the presence of 50 ng/mL OVA (Ag) and
300 ng/mL anti-OVA Ab (Ab) for 3, 12 and 24 h. Total RNA was isolated and FcγRIIB,
VCAM-1, and ICAM-1 mRNA were quantified using qRT-PCR. Data are expressed as
fold increase in mRNA of IC-activated FDC above the basal level expressed in untreated
FDC. These results are representative of three separate experiments of this type, and
results

are

depicted

as

the

means

[Normal View 17K | Magnified View 25K]
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± SEM

of

replicate

cultures.
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Discussion
The phenotype of FDC in primary and secondary follicles is very
different. In secondary follicles, FDC bear high levels of FcγRIIB, ICAM-1 and
VCAM-1, and these molecules are involved in converting poorly immunogenic
IC into a highly immunogenic form for B cells and in facilitating FDC-B cell
interactions required for optimal FDC accessory activity (30,57,69,132). In
contrast, in primary follicles, FDC-reticula can be found by labeling with antiCR1/2 Ab, but FcγRIIB, ICAM-1, and VCAM-1 levels are low and difficult to
detect (30,132,134). These relationships prompted questions about how FDC are
activated and what molecules participate in the activation process. Disruption of
lymphotoxin (LT)/TNF, or their cognate receptors, disrupts LN organogenesis
and interferes with FDC development (135-138). Furthermore, these molecules
are important to maintain FDC with a functional phenotype, as indicated by the
loss of IC and the activated phenotype when these interactions are blocked
(136,139). Activated B cells are known to provide LT and TNF, suggesting that
B cell activation might lead to FDC activation and that could explain why FDC
associated with resting B cells exhibit a resting phenotype while those in active
GC express an active phenotype (138-141). However, in recall responses, FDC
activation is evident before B cell activation is apparent, suggesting that the IC
itself might play a role in activating FDC (57,58). The data presented here
support this concept. Encounter of FDC-FcγRIIB with Ag-Ab complexes in the
absence of complement in vitro leads to increased mRNA for FcγRIIB in
45

purified FDC in 3 h. Increased levels of FDC-FcγRIIB could be detected by 24 h
in passively immunized mice, and by 3 days not only was the labeling intense,
but the area occupied by FcγRIIB-positive FDC-reticula on a single midsagittal
draining axillary LN section had increased between 10- and 15-fold (10 000 µm2
to nearly 150 000 µm2). Results for ICAM-1 and VCAM-1 were similar, with
mRNA being clearly elevated in isolated cells within 3 h and 10-15-fold
increases in the area of FDC-reticula being occupied by labeled FDC.
The importance of FcγRIIB in initiating the signaling pathway for these
molecules is supported by results indicating that IC could be trapped on FDCreticula by FcγRIIB-/- mice, but there was no increase in mRNA or protein for
ICAM-1, or VCAM-1. Furthermore, blocking FcγRIIB on WT FDC with antiFcR Ab (clone 2.4G2) also blocked the mRNA response. FcγRIIB-/- mice
exhibited ICAM-1 and VCAM-1 labeling at a frequency of approximately one
FDC-reticulum per LN section, indicating that FDC in these animals could
express these molecules. However, the presence of five to six IC-retaining
reticula per LN section did not correspond with any increase in ICAM-1 or
VCAM-1. The complement receptors are capable of trapping IC on FDC in
these KO animals (30), but CR engagement did not mediate the IC-induced upregulation of VCAM-1 or ICAM-1. Thus, the signaling pathways involved in
converting resting FDC in primary follicles into activated FDC that emerge as
the

secondary

follicles

develop

appears

engaging IC.
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to

be

initiated

by

FDC-FcγRIIB

The molecules used to characterize FDC activation are known to be
important in FDC-B cell interactions. The FcγRIIB binds the Ig-Fc in IC and
thus minimizes ITIM activation as a consequence of coligation of B cellFcγRIIB and BCR (57,58). The adhesion molecules, ICAM-1 and VCAM-1, are
important in stabilizing FDC-B cell interactions leading to FDC-B cell clusters,
and FDC accessory activity is most apparent in the clustered cells (69).
Engaging FDC-FcγRIIB with IC induced a significant rise in ICAM-1 and
VCAM-1 mRNA within 3 h and showed a dramatic increase after 24 h. In some
experiments, we also examined mRNA for FDC-CD40 which has no known role
in interactions between FDC and B cells. In this case, no increase in mRNA was
found after engaging FDC-FcγRIIB with IC (data not shown). These results
indicate

that

stimulation

through

FDC-FcγRIIB

does

not

induce

mRNA

production generally, but does promote messages for proteins involved in B cellFDC interactions.
In

the

present

study,

the

initial

trapping

in

FcγRIIB-/-

mice

was

indistinguishable from WT after 3 days. These data are consistent with the wellestablished role of complement and CR in IC trapping by FDC and suggest that
CR on resting FDC in primary follicles would trap IC very well. The trapped IC
could engage the low level of FDC-FcγRIIB and auto-up-regulate this receptor
as well as up-regulate other molecules important in FDC-B cell interactions. We
reason that IC formation and binding to FDC-FcγRIIB would occur as soon as
the first Ab appears in a primary response and within minutes after injecting Ag
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into an immune animal for a recall response. This rapid up-regulation would
facilitate GC formation, leading to class switching, somatic hypermutation, and
the selection of B cells with high-affinity receptors needed to facilitate affinity
maturation (39).
Phenotypic changes in FDC-reticula appear to be closely associated with
the dynamics of the GC reaction. Typical GC have a lifespan of approximately
3 wk (137) and their termination begins around day 14. This corresponds with
alterations in FDC morphology including termination of iccosome production,
and persisting Ag becomes buried within a labyrinth of membrane, thus
minimizing BCR stimulation (28). While primary FDC-reticula can be labeled
with CR1/2, FDC with the activated phenotype are associated with active peanut
agglutinin (PNA)+ GC (30). The lack of activated FDC-reticula in the absence of
PNA labeling strongly suggests that the activated FDC phenotype is lost as the
GC reaction is terminated.
FcγRIIB is generally considered to be an inhibitory receptor and is known to
reduce the functionality of B cells, mast cells, and conventional dendritic cells (reviewed
in (122,142)). However, in FDC, this receptor appears to promote a phenotype associated
with FDC accessory activity. Clearly, engaging the same FcγRIIB receptor on B cells
with the same IC did not lead to an apparent up-regulation of FcγRIIB on GC B cells or
an increase in mRNA on isolated B cells. Thus, the FcγRIIB signaling pathway leading to
the change in FDC phenotype is likely very different in FDC vs. other FcγRIIB-bearing
cells. A recent report by Victoratos et al. (128) indicates that IκB kinase (IKK)248

dependent signals are critical for IC-driven induction of VCAM-1 and ICAM-1
expression in FDC through the canonical NF-κB pathway, whereas, p55TNFR is
essential for FDC network formation and maintenance, which is independent of IKK2.
The data reported here are in complete harmony with these results (128).
Critical ligand-receptor reactions involved in FDC-B cell interactions include AgBCR, CD21L-CD21 and FcγRIIB-Fc. These receptor-ligand interactions are not MHC
restricted and murine as well as human FDC work across MHC and even species barriers
(56). FcγR genes are derived from a common ancestral gene, and the FcγRII genes in
humans and mice are structurally related with a single FcgRIIB gene coding for a single
protein chain characterized by an extracellular ligand-binding domain together with an
intracellular cytoplasmic tail (143,144). The present data support the concept that
engagement of murine FDC-FcγRIIB with IC induces the activated phenotype, and we
reason that ICs likely activate human FDC as well.
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CHAPTER 2
Toll-like Receptor-4 on Follicular Dendritic Cells:
An Activation Pathway that Promotes Accessory Activity
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Introduction
Accessory cells of the immune system tend to remain quiescent until
they

encounter

upregulation

alarm

of

signals

molecules,

that

promote

including

activation.

co-stimulatory

Activation

molecules,

involves

needed

for

optimal presentation of Ag to specific lymphocytes and the initiation of adaptive
immune responses.

Infectious agents are a major source of alarm signals that

are recognized by pattern recognition receptors (PRRs) that engage conserved
pathogen-associated

molecular

patterns

(PAMPs)

(145-147).

The

range

of

molecular patterns recognized by PRRs includes signals from injured or stressed
host cells and tissues (148,149).

Prominent PRRs include the evolutionarily

conserved membrane bound Toll-like receptors (TLRs) that recognize PAMPs
and initiate responses in organisms as diverse as flies and mammals (150-154).
TLR4 is an especially clear example of a receptor that is known to engage LPS,
an amphiphilic molecule in the outer leaflet of the outer membrane of Gramnegative bacteria, and activate accessory cells (149,155,156).
Follicular dendritic cells (FDCs) are localized to the light zones of
germinal centers (GCs), where their dendritic processes interdigitate and form
three-dimensional FDC-networks or -reticula (44,46,157) that help these noncirculating cells remain fixed while attracting specific lymphocytes (47,67).
FDC functions include the capture and retention of ICs (22,30,158), promotion
of B cell survival (111-115,115) and promotion of high affinity Ab production
(39,116).

The phenotype of FDCs in primary and secondary follicles is very
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different. In secondary follicles, FDCs bear high levels of FcγRIIB, ICAM-1,
and

VCAM-1

and

these

molecules

are

involved

in

converting

poorly

immunogenic ICs into a highly immunogenic form for B cells and in facilitating
FDC-B cell interactions (30,57,69,132). In contrast, FcγRIIB, ICAM-1, and
VCAM-1 levels are low and difficult to detect in FDC-reticula of primary
follicles

(30,132,134).

The

presence

of

these

resting

and

activated

FDCs

prompted the hypothesis that FDCs, like other accessory immune cells, may
express PRRs capable of recognizing PAMPs leading to the acquisition of an
activated phenotype required for optimal FDC accessory activity.
To begin hypothesis testing, we sought to determine if FDCs express
TLR4 and if LPS can activate FDCs via TLR4. Activation was indicated by
increased expression of FDC function-associated molecules FcγRIIB, ICAM-1
and VCAM-1 by flow cytometry. TLR4 expression on FDCs in situ was studied
with immunohistochemistry followed by flow cytometric and RT-PCR analyses
on

purified

investigated

FDCs.
by

The

adoptive

role

of

transfer

FDC-TLR4
of

engagement

wild-type

with

LPS-responsive

LPS

was

C3H/HeN

leukocytes into TLR4-mutated LPS-hyporesponsive C3H/HeJ mice with host
FDCs.

The

TLR4

activation

pathway

involves

NF-κB

activation

and

the

involvement of this pathway was examined by flow cytometric analysis of
intracellular

phospho-IκB-α in FDCs.

Finally, we sought to determine if

activated FDCs have increased accessory activity as indicated by the enhanced
ability to promote specific IgG responses in vitro.
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The results indicated for the first time that FDCs express TLR4 on their
surfaces and that TLR4 engagement mediates activation as indicated by a
marked

increase

of

FDC

function-associated

involves the NF-κB pathway.

molecules

and

that

activation

Moreover, like other accessory cells, activated

FDCs have increased accessory activity as indicated by increased anti-OVA
production in comparison with non-activated FDCs. An important implication of
these studies is that TLR agonists may promote immune responses not only by
stimulating dendritic cells (DCs) and enhancing T cell function but also by
stimulating FDCs and promoting B cell function. An understanding of how TLR
agonists influence FDC activation may give insight into how adjuvants should
be formulated to give optimal humoral immune responses when administering
vaccines.

53

Materials and Methods
Animals
Six to eight weeks old BALB/c mice were obtained from the National Cancer
Institute (Bethesda, MD). The C3H/HeNTac mice were from Taconic Farms
(Hudson, NY), and the C3H/HeJ mice were from the Jackson Laboratory (Bar
Harbor, ME). All mice were housed in standard plastic shoebox cages with filter
tops and maintained under specific pathogen-free conditions in accordance with
guidelines

established

by

Virginia

Commonwealth

University

Institutional

Animal Care and Use Committee.
Antibodies and other reagents
Sigma (L-7895) cell culture tested, gel-filtration purified, γ-irradiated
LPS from Salmonella typhosa was used in this study with more than 99% purity.
FITC conjugated rat anti-mouse CD106 (mVCAM-1, catalog # 553332), CD54
(mICAM-1, catalog # 553252), CD16/CD32 (FcγRII/III, catalog # 553144), Fc
blocker (2.4G2, catalog # 553142), rat anti-mouse FDC-M1 (catalog # 551320),
biotinylated anti-rat κ light chain (catalog # 553871), rat IgG2bκ (catalog #
553988), Rat IgG2aκ (catalog # 554688), hamster IgG1κ (catalog # 553971)
isotype controls, streptavidin-HRP (catalog # 550946) and the DAB substrate kit
(catalog

#

550880)

were

from BD

PharMingen

(San

Diego,

CA).

FITC

conjugated rat anti mouse TLR4 was from Imgenex (San Diego, CA, catalog #
IMG-428C).

Anti-biotin

microbeads,

CD45R

(B220)

MicroBeads

(130-049-

501), and MACS LS columns were purchased from Miltenyi Biotec GmbH
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(Auburn, CA). Rabbit anti-mouse TLR4 (ab47093) and biotinylated goat anti
rabbit IgG (ab6720-1) were purchased from Abcam (Cambridge, MA). Biotin
labeled goat anti-rat IgG was from Southern Biotech (Birmingham, AL, catalog
# 3050-08) and the Universal Block was from KPL (Gaithersburg, MD, catalog
# 71-00-61). Antibodies used in flow cytometry were used at a concentration of
1 μg/106 cells while antibodies used in immunohistochemistry were used at a
concentration of 5 μg/ml.
Immunohistochemical labeling of TLR4, FDC-M1, and GL-7 in situ
Popliteal LNs were collected from normal BALB/c mice and frozen in
CryoForm embedding medium (IEC, Needham Heights, MA). Frozen sections
of 10 μm thickness were cut on a Leica (Jung Frigocut 2800E) cryostat and airdried. Following absolute acetone fixation, the sections were dehydrated and the
endogenous peroxidase activity was quenched with the Universal Block. The
sections were washed and saturated with 10% BSA. Serial sections were
incubated with unlabeled rabbit anti-mouse TLR4 or rat anti-mouse FDC-M1.
Sections were washed and then incubated with biotin-conjugated goat anti-rabbit
or anti-rat IgG followed by streptavidin-HRP. The sections were developed
using a DAB substrate kit. For germinal center B cell labeling, 10 μm cryostat
sections of axillary lymph nodes from OVA-immunized BALB/c mice were
labeled with IgM rat anti-mouse T- and B-cell activation antigen (GL-7, Ly-77)
(eBioscience 14-5902-85), followed by biotinylated goat anti-rat IgM (Southern
Biotech 3020-08) and phosphatase-labeled streptavidin (KPL 15-30-00). The
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sections were developed with SIGMAFAST™ BCIP/NBT alkaline phosphatase
substrate (Sigma, B5655). Rabbit polyclonal IgG (Abcam ab27478), rat IgG2c
(BD Biosciences 553982) rat IgM (eBioscience 14-4341) isotype controls were
similarly treated. Images were captured with Optronics digital camera and
analyzed with Bioquant Nova software.
DC, FDC, and B cell isolation
DCs were isolated from splenic leukocytes using the CD11c micro-bead
kit from Miltenyi Biotec GmbH (Auburn, CA). FDCs were isolated by positive
selection from LNs (axillary, lateral axillary, inguinal, popliteal, and mesenteric)
of irradiated adult mice as previously described (130). One day before isolation
mice were irradiated with 1000 rad to eliminate most lymphocytes, then mice
were killed, LNs were collected, opened and treated with 1.5 ml collagenase D
(22 mg/mL,

C-1088882;

Roche),

0.5 mL

of

DNase I

(5000 U/mL,

D-4527;

Sigma), and 2 mL DMEM with 20 mM HEPES. After 45 min at 37°C in a CO2
incubator, released cells were washed in 5 mL DMEM with 10% FCS. Cells
were then sequentially incubated with FDC-specific Ab (FDC-M1) for 45 min,
1 µg of biotinylated anti-rat κ light chain for 45 min, and with 20 µl anti-biotin
microbeads (Miltenyi Biotec GmbH (Auburn, CA) for 15-20 min on ice. The
cells were layered on a MACS LS column and washed with 10 ml ice-cold
MACS buffer. The column was removed from the VarioMACS and the bound
FDCs were released with 5 ml MACS buffer. B220+ B cells were isolated from
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BALB/c lymph nodes using CD45R (B220) MicroBeads from Miltenyi Biotec
GmbH (Auburn, CA).
Labeling of purified FDCs and B220+ B cells with anti-TLR4
FDCs and B220+ B cells isolated from BALB/c mice were incubated
with mouse Fc-Block (BD PharMingen) for 15 min on ice, followed by FITC
conjugated rat anti mouse TLR4 or isotype control for 60 min in the dark at 4°C.
After washing, the cells were analyzed using an FC500 flow cytometer and
Cytomics RXP analysis software. Histograms were gated for FDCs based on
their forward and side scatter properties established with FDC phenotypic
markers including FDC-M1, CD21/35, and CD32 (130). The figures were
plotted using WinMDI software (Scripps Research Institute).
Detection of TLR4 mRNA in purified FDCs by RT-PCR
Total cellular RNA was extracted from 2x106 FDCs purified from lymph
nodes or spleens as well as control splenic dendritic cells of BALB/c mice using
TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) according to the
manufacturer's instructions, and a 100 ng was reverse transcribed into cDNA
using GeneAmp Gold RNA PCR Core Kit. One tenth of cDNA was primed with
TLR4

specific

primers

5'-GCTTTCACCTCTGCCTTCAC-3'

CGAGGCTTTTCCATCCAATA-5' and amplified by PCR.

and

3'-

PCR products were

electrophoresed in 1.5 % agarose, stained with ethidium bromide, and visualized
by UV trans-illuminator.
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Analysis of FcγRIIB, VCAM-1, and ICAM-1 on LPS-treated FDCs in vivo
and in vitro
FDCs were positively selected with FDC-M1 from the draining lymph
nodes of irradiated BALB/c mice three days after injecting 25 μg of LPS in the
four limbs. Control FDCs were isolated from saline injected mice. In addition, 1
x 106 purified FDCs were treated in vitro with 10 μg LPS in 1 ml media for
three days and the surface expression of FcγRIIB, VCAM-1, and ICAM-1 was
compared with 1 x 106 control FDCs cultured in media without LPS. Analysis
was done by incubating FDCs with mouse Fc-Block (BD PharMingen) for
15 min on ice, followed by FITC conjugated rat antibodies against FcγRIIB,
ICAM-1, and VCAM-1 or isotype control for 60 min in the dark at 4°C. After
washing, the cells were analyzed by flow cytometry.
Adoptive transfer
C3H/HeJ and C3H/HeN recipients were exposed to 600 rad of irradiation
and one day later they were reconstituted with 2 x 107 LPS-responsive C3H/HeN
total splenic leukocytes injected behind the neck. The mice were challenged
with LPS in the legs and the FDCs were isolated after 3 days.
Analysis of FcγRIIB, VCAM-1, and ICAM-1 on LPS-treated C3H/HeN and
C3H/HeJ FDCs
FDCs were positively selected from the lymph nodes of C3H/HeN or
C3H/HeJ mice three days after injecting 25 μg of LPS in each limb and control
FDCs were isolated from saline injected mice. FDCs were first incubated with
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mouse Fc-Block for 15 min on ice, followed by FITC conjugated rat antibodies
against FcγRIIB, ICAM-1, and VCAM-1 or isotype control for 60 min in the
dark at 4°C. After washing, the cells were analyzed by flow cytometry.
Intracellular labeling of phospho-IκB−α in Purified FDCs treated with LPS
in vitro
Purified FDCs were serum-starved for 24 hours then treated with 10
μg/ml LPS overnight in DMEM with 10% FCS. Control groups of unstimulated
FDCs as well as macrophage cell line J774 were similarly treated. Cells were
washed then fixed and permeabilized using Fix & Perm cell permeabilization kit
(Caltag, Burlingame, CA). Intracellular phospho-IκB-α was labeled with rabbit
anti-phospho-IκB-α (Cell Signaling Technology, Danvers, MA) followed by PE
conjugated goat anti-rabbit IgG and cells were analyzed with flow cytometry.
Cell culture and ELISA assessment of OVA specific IgG
Lymph nodes cells from OVA-immunized BALB/c mice were cultured,
in the presence of 100 ng/ml OVA-anti-OVA ICs, with FDCs isolated from
LPS-treated mice and compared with control FDCs at ratios of 64, 128 and 256
lymphocytes per FDC. The media was changed after one week and OVA
specific IgG was assessed by ELISA 7 days later as previously described (29).
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Results
Immunohistochemical labeling of TLR4 on FDCs but not on GC B cells in
situ
As shown in panel A of Fig. 1, adjacent sections of lymph nodes were
labeled with FDC specific marker FDC-M1 (Fig. 1A-a) and anti-TLR4 (Fig. 1Ac). TLR4 co-localized with the FDC-M1 as indicated by the labeling in the area
between the arrows. The characteristic labeled FDC-network or reticulum made
up by interactive dendrites of FDCs can be seen. Germinal center B cells
intermingle with FDCs and we sought to determine if they label with anti-TLR4
and contribute to the labeling in Fig. 1A-c. Germinal center B cells are activated
and labeled with anti-mouse T- and B-cell activation antigen GL-7 (Fig. 1B-a),
but in contrast with FDCs, they did not label with TLR4 in adjacent lymph node
sections (Fig. 1B-c).

Thus TLR4 labeling in GCs appeared to be attributable to

FDCs and not B cells.

Isotype controls (Fig. 1A-b, A-d, B-b, B-d) were included

and shown to the right of the corresponding labeled sections.
TLR4 labeling of purified FDCs
To

confirm

expression

of

TLR4,

FDCs

were

purified

by

positive

selection using the monoclonal Ab FDC-M1, and labeled with anti-TLR4-FITC.
As illustrated in panel C of Fig. 1, flow cytometric analysis revealed that
virtually the entire FDC population shifted to the right when labeled with antiTLR4 with more than a two fold increase in mean fluorescent intensity (MFI)
over the background control. Analysis was restricted to viable cells indicating
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that TLR4 is expressed on the surface of FDC membranes. B cells positively
selected with B220, an antigen expressed on B lineage cells throughout their
development but not on plasma cells, also appeared to shift to the right as a
consequence of anti-TLR4 labeling (Fig. 1D). However, in contrast with FDCs
where the MFI more than doubled upon labeling with anti-TLR4, the increased
MFI for the B cells was only 0.2 above the isotype control. In short, murine B
cells may express some TLR4 but it is unlikely that they are making a
significant contribution to the strong TLR4 labeling in GC areas where the FDCreticulum identified by FDC-M1 is present.
TLR4 mRNA in purified FDCs
RNA extracted from purified FDCs from murine lymph nodes (Fig. 2A)
and spleen (Fig. 2B) was reverse transcribed into cDNA. TLR4 specific primers
were used to amplify the relevant DNA and the results were compared with
similarly treated purified splenic dendritic cells (DCs) as a positive control (Fig.
2C). Gel electrophoresis of amplified PCR products revealed a single 361 bp
band shared between dendritic and follicular dendritic cells indicating TLR4
expression by FDCs.
LPS-mediated upregulation of FDC-FcγRIIB, -ICAM-1, and -VCAM-1
Injecting LPS increased the levels of FcγRIIB, ICAM-1, and VCAM-1
on FDCs from the draining lymph nodes (Fig. 3A-a, b, c) where virtually the
entire FDC population shifted to the right when labeled with antibodies reactive
with these markers and the MFI approximately doubled in each case. Similarly,
61

Figure 1: Labeling of FDCs with anti-TLR4. A, Illustrates TLR4 labeling on FDCs in
situ using immunohistochemistry. Adjacent sections from popliteal LNs were labeled for
TLR4 and the FDC-specific marker FDC-M1. As indicated by arrowheads, FDC-M1
labeling (Aa) colocalized with TLR4 expression (Ac), and the characteristic labeling of
FDC network or reticulum made up by interactive FDC dendrites can be seen. B, Lack of
TLR4 labeling on GC B cells. Adjacent sections from axillary LNs of OVA-immune
animals were labeled with GL-7, anti-mouse T and B cell activation Ag (Ba), and antiTLR4 (Bc). As shown between arrowheads, GL-7+ B cells did not label with anti-TLR4.
Isotype controls (Ab, Ad, Bb, and Bd) are shown to the right of the appropriate adjacent
section. C, Flow cytometry was used to assess TLR4 labeling of purified FDCs in vitro.
Purified FDC preparations were labeled with anti-TLR4-FITC and compared with an
isotype control. The MFI of TLR4-FITC-labeled FDCs was double the isotype control. D,
TLR4 labeling of purified B220+ B cells. Purified B220+ B cell preparations were labeled
with anti-TLR4-FITC and compared with an isotype control. B220+ B cells were hardly
labeled with TLR4-FITC, and the MFI of TLR4-FITC-labeled B cells was 0.2 above the
MFI of the isotype control. These data are representative of three separate experiments of
this type.
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Figure 2: RT-PCR analysis of TLR4 mRNA in purified FDCs. Total RNA extracted
from purified FDCs of mouse LNs (A) and spleen (B) were primed with TLR4-specific
primers and compared with purified DCs isolated from mouse spleen (C). A single 361bp band shared between DCs and FDCs is seen, providing evidence for TLR4 expression
in FDCs.

64

65

Figure 3: Up-regulation of FcγRIIB, ICAM-1, and VCAM-1 on LPS-treated FDCs in
vivo (A) and in vitro (B). FDCs were purified from the LNs of LPS-treated BALB/c mice
and compared with control FDCs isolated from saline-injected mice (A). Likewise,
purified FDC preparations treated in vitro with LPS for 3 days were compared with
control FDCs cultured in medium without LPS (B). FDCs were labeled with FITCconjugated rat Abs against FcγRIIB (a), ICAM-1 (b), and VCAM-1 (c) or isotype control.
The MFI of FITC-labeled FDCs were almost double the corresponding isotype controls
in vivo and in vitro, although the intensity of VCAM-1 up-regulation on FDCs stimulated
in vitro was comparatively less. These data are representative of three separate
experiments of this type.
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treating purified FDCs in vitro (Fig. 3B-a, b, c) with LPS for three days increased the
levels of FcγRIIB, ICAM-1, and VCAM-1 expression on FDCs although the intensity of
VCAM-1 upregulation was comparatively less.
FDCs purified from TLR4-mutated C3H/HeJ mice did not respond to LPS
even when reconstituted with leukocytes from TLR4 wild-type mice
FDCs from wild-type LPS-responsive C3H/HeN mice upregulated FDCFcγRIIB, ICAM-1, and VCAM-1 when injected with LPS (Fig. 4A) much like
the BALB/c mice shown in Fig. 3. Moreover this response persisted after
irradiation

and

reconstitution

with

LPS-responsive

C3H/HeN

total

splenic

leukocytes (Fig. 4B). In marked contrast, FDCs from TLR4-mutated C3H/HeJ
mice failed to upregulate FDC-FcγRIIB, -ICAM-1, and -VCAM-1 after LPS
injection

(Fig.

4C)

even

after

reconstitution

with

wild-type

TLR4

LPS-

responsive C3H/HeN leukocytes (Fig. 4D). This suggests that LPS engagement
of TLR4 on the FDC is important, and that FDC activation is not simply a
response to cytokines being produced by other TLR4 responsive leukocytes.
LPS

mediated

upregulation

of

intracellular

phospho-IκB-α

in

FDCs

indicative of NF-κB activation
Signaling

through

TLR4

typically

involves

the

NF-κB

pathway

prompting the hypothesis that stimulation of FDCs with LPS would upregulate
intracellular phospho-IκB-α in FDCs.

Purified FDCs were incubated with 10

μg/ml LPS overnight. Control groups included unstimulated FDCs and murine
macrophage cell line J774 that were similarly treated. Flow cytometric analysis
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revealed that the MFI of intracellular phospho-IκB-α in the control macrophage
cell line about doubled after exposure to LPS (Fig. 5A). The FDC response to
LPS was very similar and the increase in MFI was even higher (Fig. 5B).
Similar results were obtained with 0.1 and 1μg of LPS but the results were most
apparent with the 10 μg dose illustrated in Fig. 5.
LPS activated FDCs exhibited enhanced accessory activity in promoting recall
responses in vitro.
FDCs

from

normal

mice

are

known

to

enhance

recall

responses

optimally at ratios between 1 FDC to 4 - 16 lymphocytes although detectable
accessory activity may be apparent with more lymphocytes (159). We reasoned
that LPS activated FDCs would have enhanced accessory activity and that might
be most apparent in IgG recall responses at low FDC to lymphocyte ratios.
When cultured at a ratio of 1 FDC to 64 lymphocytes, the IgG anti-OVA
produced in cultures containing activated FDCs was about 4 times higher than
the production with FDCs from normal mice which in turn produced anti-OVA
IgG comparable to 1 activated FDC to 256 lymphocytes (Fig. 6). In marked
contrast, FDCs from normal mice were without detectable activity at 1 FDC to
256 or even 128 lymphocytes (Fig. 6).
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Figure 4: Lack of up-regulation of FcγRIIB, ICAM-1, and VCAM-1 on FDCs purified
from TLR4-mutated C3H/HeJ mice even when reconstituted with leukocytes from
TLR4 wild-type mice. The levels of expression of FcγRIIB, ICAM-1, and VCAM-1 in
TLR4-intact LPS-responsive C3H/HeN were assessed using flow cytometry 3 days after
LPS injection (A) or after irradiation, reconstitution with C3H/HeN leukocytes, and LPS
injection (B). Similarly, FcγRIIB, ICAM-1, and VCAM-1 in TLR4-mutated C3H/HeJ
mice were analyzed 3 days after LPS injection (C) or after irradiation, reconstitution with
C3H/HeN leukocytes, and LPS injection (D). FDCs from TLR4-intact LPS-responsive
C3H/HeN mice demonstrated up-regulation of FcγRIIB, ICAM-1, and VCAM-1 when
injected with LPS, and that persisted after irradiation and reconstitution. On the contrary,
FDCs purified from TLR4-mutated C3H/HeJ mice failed to up-regulate their FcγRIIB,
ICAM-1, and VCAM-1 upon encountering LPS, and that persisted even after
reconstitution with TLR4-intact LPS-responsive C3H/HeN leukocytes. These data are
representative of three separate experiments of this type.
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Figure 5: Up-regulation of intracellular phospho-IκB-α in purified FDCs treated with
LPS in vitro. Purified FDC preparations were treated with 10 µg/ml LPS overnight, and
control groups of unstimulated FDCs as well as macrophage cell line J774 were included.
FDC intracellular phospho-IκB-α rose after LPS treatment to levels comparable to those
seen in the control macrophage cell line. These data are representative of three separate
experiments of this type.
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Figure 6: Activated FDCs have enhanced accessory cell activity in OVA-specific recall
responses. OVA-specific lymphocytes were cultured, in the presence of OVA-anti-OVA
ICs, with FDCs isolated from LPS-treated mice and compared with control FDCs at
ratios of 64, 128, and 256 lymphocytes to 1 FDC. Two weeks later, OVA-specific IgG
was assessed by ELISA. At all tested ratios, cultures containing activated FDCs promoted
significantly higher anti-OVA IgG levels than cultures with control FDCs, (p < 0.01;
Student’s t test). Averages were calculated using data from three cultures, and results
illustrate the means ± SEM.
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Discussion
Engagement of TLRs on DCs leads to physiological and phenotypic
changes

that

(145,160,161).

dramatically

alters

their

ability

to

present

Ag

to

T

cells

DC alterations include changes in: survival, chemokine receptor

expression, chemokine secretion, migration, cell shape and endocytic activity
(162).

LPS and other TLR agonists promote DCs maturation and accessory

activity in priming naïve T cells, promoting clonal expansion, and stimulating
differentiation of T cells into effectors (163). We reasoned that for the immune
system to respond to microbial invasion as an integrated unit, microbial patterns
encountered early in immune responses should activate not only the DC-T cell
axis but also the FDC-B cell axis. The data reported here indicated that FDCs
express surface TLR4 and that engagement of this receptor in vivo and in vitro
altered their physiology and phenotype leading to FDC activation.

Moreover,

activated FDCs were far more effective in enhancing the production of specific
IgG than FDCs from normal mice. Immune complex bearing FDCs reside in
germinal

centers

where

B

cells:

proliferate,

isotype

switch,

somatically

hypermutate, become memory cells, and transition from B cells into antibody
forming cells (reviewed in (46,125)). Considerable data indicate that FDCs
influence these B cell functions (reviewed in (44,46)). An understanding of FDC
activation could facilitate our ability to manipulate the immune system such that
the appropriate adjuvants could be selected to activate FDCs and optimize
humoral immune responses when vaccines are administered.
76

Analysis of mRNA by RT-PCR in the present study suggested that TLR4
expression in DCs and FDCs is comparable. The fact that FDCs are barely
endocytic and retain Ag in immune complexes on their surfaces (164) allows the
surface expressed FDC-TLR4, as shown by flow cytometry, to engage LPS in an
environment spatially associated with other FDCs accessory functions, including
IC trapping and receptor mediated B cell-FDC clustering and interactions. The
presence of TLR4 molecules inside the FDCs has not been excluded, but clearly
anti-TLR4 labels FDC membranes intensely. Cytokines help activate many cell
types and we reasoned that cytokines induced by LPS may play an important
role in FDC activation.

However, no support for this idea was found in the

present study. When normal splenic leukocytes, that are fully capable of
secreting cytokines upon TLR4 engagement, were injected into irradiated TLR4
mutated C3H/HeJ mice and challenged with LPS, the FDCs with mutated TLR4
still failed to activate (Fig. 4D). These results argue that functional TLR4 on
FDCs is important. Moreover, when purified wild-type FDCs were treated with
LPS in vitro, they responded well suggesting that FDC-TLR4 is sufficient (Fig.
3B).
FDC-associated

germinal

center

B

cells

failed

to

label

immunohistochemically in situ with anti-TLR4, and purified B cell preparations
positively selected with the pan-B cell marker CD45R (B220) were barely
labeled with anti-TLR4 by flow cytometry. These data are consistent with
similar results reported by Akashi et al where cell surface TLR4-MD-2 was
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hardly detectable on CD19-positive B cells and intracellular staining by the
saponin detergent did not make a difference (165).
FcγRIIB plays an important role in FDC-B cell interactions. Both FDC
and B cells express FcγRIIB (57,58), but B cell activation may be inhibited by
immunoreceptor tyrosine-based inhibition motif (ITIM) signaling mediated by
IC coligating the B cell receptor for Ag (BCR) and B cell-FcγRIIB (122,123).
Engagement of BCR in the absence of such coligation induces rapid activation
of tyrosine kinases, generation of inositol phosphates, elevation of cytoplasmic
Ca2+

concentrations,

and

activation

of

mitogen-activated

protein

kinases

(reviewed in (122,123)). These events promote B cell activation and lead to
proliferation,

differentiation,

and

Ab

secretion

(124).

In

marked

contrast,

coligation of BCR and FcγRIIB by ICs leads to inhibition of the extracellular
Ca2+ influx, reduction of cell proliferation, blockage of blastogenesis, and
inhibition of Ig synthesis (122-124). Nevertheless, ICs on FDCs provide potent
activation signals for B cells that result in induction of germinal center dark
zones where B cells rapidly proliferate and differentiate (reviewed in (125)).
However, FDCs lacking FcγRIIB or expressing only low levels of FcγRIIB are
unable to convert poorly immunogenic IC into a highly immunogenic form for B
cells, although they can trap IC using CRs (complement receptors) (30). In
active GC, FDCs express high levels of FcR relative to B cells, and these FDCFc receptors bind Fc portions of Ab in ICs and appear to minimize their binding
to FcR on B cells (30,44,57). Accordingly, cross-linking of BCR and FcγRIIB
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via IC is minimized, ITIM signaling is reduced, and B cell proliferation and
differentiation is promoted. Thus, activating FDCs and increasing FDC-FcγRIIB
levels would be expected to enhance accessory activity.
FDCs and B cells form large clusters in culture and B cells proliferate
adjacent to FDCs much like they do in the dark zone of GCs in vivo (69). FDCICAM-1 and -VCAM-1 are important adhesion molecules and blocking these
molecules inhibits clustering of FDCs and B cells and the ability of B cells to
proliferate in GC reactions in vitro (69). Upregulating these adhesion molecules
should promote FDC-B cell interactions, facilitate clustering and presentation of
FDC-Ag to B cells, and enhance the GC reaction. The signaling pathway known
to up-regulate FDC-ICAM-1 and -VCAM-1 is mediated via the NF-κB (128)
and up-regulation of FDC-ICAM-1 and -VCAM-1 may be initiated by ICs
engaging FDC-FcγRIIB (70). Similarly, the NF-κB pathway appeared to be
activated

when

FDC-ICAM-1

and

-VCAM-1

were

upregulated

by

LPS

engaging FDC-TLR4 in the present study.
The initial exposure to appropriate immunogen primes T cells and
stimulates specific B cells to begin making Abs. Specific Abs bind the
immunogen and form ICs, ICs are trapped by FDCs, B cells are stimulated by
the Ag in FDC-ICs, and GC reactions are initiated. The data presented here
suggest that FDCs can be activated by TLR4 agonists and such agonists can be
delivered by the pathogen or with the immunogen. Thus, FDCs could be
activated and ready to trap ICs and optimally stimulate B cells as soon as the
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first ICs are made. The ICs themselves can activate FDCs but that requires 24 to
48 hours after encountering adequate amounts of ICs (70). The present study
indicated that FDCs were activated via TLR4 engagement in 3 days, and that
would precede Ab production and IC formation.

Thus, ICs could be trapped by

activated FDCs and that would speed up and enhance GC events including B
cell

proliferation,

isotype

switching,

somatic

hypermutation,

memory

cell

formation, transition from B cells to antibody forming cells, selection, and
affinity maturation. In addition to TLR4, preliminary studies using RT-PCR
indicated that FDCs express TLR-2, TLR-3 and TLR-9. By use of flow
cytometry with purified FDCs we were able to confirm expression of TLR-2 and
TLR-3. Stimulation of FDCs with the TLR-3 ligand poly (I:C) resulted in
upregulation of CR1/2, FcγRIIB and VCAM-1. However, the data suggest that
TLRs may differ in their impact on FDC phenotype & function and further
studies in this area are in progress. Nevertheless, an understanding of how FDCs
can be optimally activated via TLR engagment could provide information
needed to control and enhance the development of protective humoral immune
responses.
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CHAPTER 3
FOLLICULAR DENDRITIC CELLS STIMULATED BY
COLLAGEN TYPE I DEVELOP DENDRITES AND
NETWORKS IN VITRO
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Introduction
Follicular dendritic cells (FDCs) are located in the light zone of germinal
centers (GCs), where their dendritic processes interdigitate and form threedimensional

networks

or

FDC-reticula

(42,46,157,166).

Functions

of

FDCs

include the production of chemokines that help organize lymphoid follicles (67),
capture and retention of immune complexes (ICs) (30), presentation of ICs to B
cells

under

conditions

that

minimize

activation

of

the

immuno

tyrosine

inhibitory motif in B cells (44), promotion of B cell survival (111-114,114),
promotion of Ig class switching, production of high affinity Abs, B cell selection
associated with affinity maturation and production of B memory cells with high
affinity receptors (39,116,167).
Although description of antigen localization in lymphoid follicles dates
back to 1950 (168), the nature of the antigen retaining cells remained obscure
until described at the ultrastructural level in rodent spleen or lymph node
sections by Szakal and Hanna (21) and Nossal et al (166) in 1968. These authors
reported radiolabeled antigen associated with highly convoluted infoldings of
the plasma membrane of FDCs, and antigen was associated with electron dense
material found in the extracellular spaces adjacent to FDC processes (21,22).
Subsequent studies indicated that these antigen retaining cells are not free to
circulate and Ag remained localized to FDCs in the draining lymphatics for
months to years (51). Consequently, antibody induced by the retained Ag is
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restricted to draining lymph nodes and this pattern was followed for as long as
one year (51).
Several

cells

in

lymphoid

tissues

have

dendritic

processes

that

distinguish them from lymphocytes and typical macrophages; however, the
ability of FDCs to trap and retain ICs for long periods makes them unique.
Different names have been used for FDCs, e.g. antigen retaining reticular cells,
follicular immune complex retaining cells, follicular antigen-binding dendritic
cells, follicular reticular cells, follicular dendritic reticulum cells, and dendritic
macrophages until 1982 when the name: follicular dendritic cell was accepted
(23).
Morphologically,

FDC

are

characterized

by

their

irregularly

shaped

euchromatic nuclei surrounded by a narrow rim of cytoplasm from which long
slender highly convoluted dendrites emanate (42). Although FDCs represent
only 1–2% of GC cells, their numerous long slender dendrites intertwine and
create an extensive network or reticulum that makes them a prominent GC
component (42). The extensive network enables FDCs to be in intimate contact
with neighboring B cells (90% of GC cells) and T cells (5–10% of GC cells)
(11,42,169). FDCs use complement (119,120) and FcγRs (30,170) to capture
and retain ICs and they deliver the Ag in the form of IC-coated bodies
(iccosomes) to neighboring B cells for subsequent presentation to GC T cells to
obtain T cell help (38).

83

Our understanding of FDC biology has been promoted by use of
enriched FDCs in vitro. Twenty-one years ago we isolated and characterized
FDCs from murine lymph nodes. These FDCs were identified by the ICs they
retained, and descriptions were based on light microscopy using Nomarski
optics,

scanning

electron

microscopy,

and

transmission

electron

microscopy.

These freshly isolated FDCs had numerous long filliform or beaded dendrites
and lacked the ability to adhere to glass or plastic (42). Subsequent enrichment
procedures included whole body irradiation to remove the irradiation sensitive
lymphocytes, Percoll replaced BSA in the gradients, and more recently positive
selection with FDC-M1 antibodies on magnetic columns (69,130). Increased
handling resulted in individual FDCs that appeared almost spherical under light
microscopy and short to medium length dendritic processes were only readily
apparent

under

electron

microscopy

(130).

Clearly,

the

FDC-reticulum,

so

characteristic of cells in vivo, had been destroyed and the longer FDCs were
cultured the less dendritic they appeared.
Structure typically promotes function and numerous attempts were made
to increase dendrite formation and reestablish FDC-reticula in vitro without
success. Given that FDC purification requires use of collagenase and that FDCs
may be found at the edges of the GCs attached to the supporting reticular fibers
(171), we reasoned that isolated FDCs might reattach to collagen and form
processes and reticula. To test this, positively selected FDCs were incubated on
dried collagen and collagen related molecules. The results presented here
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indicate that FDCs bind these molecules and that interaction with collagen type I
promotes dendrite formation and the production of FDC-reticula in vitro. In
short,

FDCs

placed

on

collagen-coated

plates,

attached

to

the

matrix,

regenerated processes, and formed immobile networks with numerous features
in common with networks in vivo.
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Materials and Methods
Animals
Normal 6- to 8-wk-old BALB/c mice were purchased from the National
Cancer Institute. The mice were housed in standard plastic shoebox cages with
filter tops and maintained under specific pathogen-free conditions in accordance
with guidelines established by Virginia Commonwealth University Institutional
Animal Care and Use Committee.
Antibodies and other reagents
Rat-tail collagen type I was purchased from Roche Diagnostic GmbH
(Indianapolis, IN). Hyaluronic acid, Biglycan and Laminin were from Sigma (St
Louis, MO). Rabbit anti-collagen Type I and biotin-conjugated goat anti-rabbit
IgG

were

from

Abcam

(Cambridge,

MA).

FDC-M1,

biotin-labeled

anti-rat

kappa, Streptavidin-HRP and DAB substrate kit were from BD PharMingen
(San Diego, CA). Anti-Biotin MicroBeads, and MACS LS columns were
purchased from Miltenyi Biotec GmbH (Auburn, CA).
FDC Isolation
FDCs were isolated by positive selection from axillary, lateral axillary,
inguinal, popliteal, and mesenteric lymph nodes of adult mice as recently
described (130). In brief, one day before isolation four mice were irradiated with
1000 rads to eliminate most lymphocytes. On the day of isolation, mice were
killed, lymph nodes were pooled, and the capsules were opened using two 26gauge

needles.

The

nodes

were

incubated
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with

1.5ml

of

collagenase

D

(22mg/ml, C-1088882, Roche), 0.5ml of DNase I (5000 units/ml, D-4527,
Sigma), and 2 ml DMEM with 20 mM HEPES. After 45 min at 37oC in a CO2
incubator, the released cells were washed in 5ml DMEM with 10 % FCS. Cells
were then sequentially incubated with FDC specific Ab (FDC-M1) for 45 min,
1μg of biotinylated anti-rat-κ light chain for 45 min, and with 20μl anti-biotin
MicroBeads (Miltenyi Biotec) for 15-20 min on ice. The cells were layered on
MACS LS column and washed with 10ml of ice-cold MACS buffer. The
column was removed from the VarioMACS and the bound cells were released
with 5ml of MACS buffer. Approximately 85 to 95% of these cells were FDCM1+, CD40+, CR1/2+, and FcγRIIB+.
FDCs adhesion assessment
One million freshly purified FDCs were layered on collagen type I,
laminin, biglycan or hyaluronic acid layers. Twelve hours later, cells were
washed off the matrices and the released cells were counted. The percentage of
attached cells was calculated. Control lymphocytes and FDCs on plastic were
compared.
Collagen coating of plates
Ten mg sterile lyophilized rat tail collagen type I was dissolved in 5 ml
sterile 0.2% acetic acid (v/v) to give a final concentration of 2 mg/ml, pH was
adjusted to 7.4 ± 0.2 by 0.1 M NaOH and 0.1M HCl. Twenty-four-well culture
plates were coated with collagen type I at a concentration of 5 μg/cm2. Collagen
was air dried on the plates for 2 hours at 250C in a laminar flow hood.
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Light microscopy and FDC labeling
FDCs, 1x106, were cultured in DMEM supplemented with 10% FCS on
collagen type I for up to 30 days. Cultures were directly examined using a Nikon
Bio-inverted microscope equipped with Nomarski optics and digital images
were acquired. Thirty days old FDC cultures were labeled for FDC-M1 and ICs.
Cultures were washed with PBS and incubated with FDC specific marker M-1
or

OVA-rabbit-anti-OVA

ICs

for

2

hours.

Cells

were

fixed

in

0.9%

glutraldehyde + 1% paraformaldehyde for 10 min and washed. Cells were then
incubated for 45 mins with biotinylated mouse anti-rat-kappa light chain (MRK1) followed by streptavidin-HRP, for FDC-M1 labeling, or HRP-conjugated
goat anti-rabbit IgG, for IC labeling. Rat IgG isotype control for FDC-M1 and
non-specific rabbit serum control for IC labeling were similarly treated. HRP
was developed with DAB substrate and images were captured.
Scanning Electron Microscopy
Thirty days old FDC cultures on collagen type I were washed with PBS
and fixed in 0.9% glutraldehyde + 1% paraformaldehyde (24). Small culture
chips were prepared and examined with JSM-820 JEOL scanning electron
microscope.
Immunohistochemical labeling of collagen type I and FDC-M1 in vivo
Popliteal LNs were collected 5 and 48 hours after footpad injection of 10
μg OVA in BALB/c mice passively immunized with rabbit anti-OVA IgG and
frozen in CryoForm embedding medium (IEC, Needham Heights, MA). Frozen
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sections of 10-μm thickness were cut on a Leica (Jung Frigocut 2800E) cryostat
and air-dried. Following absolute acetone fixation, the sections were dehydrated
and the endogenous peroxidase activity was quenched with PBS containing
0.1% phenylhydrazine-HCl (Sigma, St Louis, MO). The sections were washed
and saturated with 10% BSA. Serial sections were incubated with unlabeled
rabbit-anti-type I collagen or FDC specific marker M-1. Sections were washed
and then incubated with biotin-conjugated goat anti-rabbit or biotinylated mouse
anti-rat-kappa light chain (MRK-1) followed by streptavidin-HRP. The sections
were developed with a DAB substrate kit (BD Pharmingen, CA) and images
were captured using Optronics digital camera and Bioquant Nova software.
Flow Cytometry
Positively selected FDCs were incubated with purified mouse Fc-block
(2.4G2) for 15 mins on ice followed by 30 mins incubation with FITCconjugated mAb against CD29 (β1), CD49b (α2), CD49a (α1), CD44 and isotype
matched controls. Cells were washed thoroughly and analyzed by Beckman
Coulter FC500 flow cytometer and Cytomics software.
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Results
Assessment of FDC adhesion to extracellular matrices (ECM) components
After overnight incubation, 80 to 90% of FDCs on plastic and lymphocytes on
collagen type I, laminin, biglycan or hyaluronic acid could be removed by
washing indicating a lack of adherence (Data not shown) In marked contrast,
80% of cells in FDC preparations bound these extracellular matrices and
remained fixed (Fig. 1).
Light microscopy of FDCs cultured on collagen type I
Many FDCs cultured on collagen type I started to spread out and
acquired small processes within a week. Cell processes were visible within 14
days (Fig. 2a) forming occasional chains or interconnections between cells (Fig.
2b). By day 30, the cell bodies were spread out and most cells had very fine
filiform processes that appeared to form networks through interdigitation of cell
processes with neighboring cells (Fig. 2c).
Scanning electron microscopy of FDCs on collagen type I
To

determine

the

nature

of

the

FDC

processes,

scanning

electron

microscopy (SEM), was used to study thirty-day-old FDC cultures on collagen
type I where numerous convolutions and branching of fine filiform dendrites
were apparent (Fig. 3a, 3b, 3c). The dendrites often emanated from one pole of
the cell body that was approximately 10-12 μm in diameter. Smaller dendrites
appeared to help anchor the cell body to the collagen extended from the
opposing parts of the cell body (Fig. 3c). Higher magnification showed dendrites
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Figure 1: Adhesion of FDCs to extracellular substrates. Positively selected FDCs that
expressed FDC-M1+, CD40+, CR1/2+, and FcγRIIB+ were incubated on plastic, collagen
type I, laminin, biglycan, or hyaluronic acid. After 12 h, approximately 85% of FDCs on
plastic could be removed by washing, whereas 85% of the FDCs bound to substrates
remained attached
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Figure 2: Light microscopy of FDCs cultured on collagen type I. Purified FDC
preparations were incubated on collagen type I for 30 days. Within the first 14 days,
although many cells remained rounded, FDCs cultured on collagen type I started to
spread out and acquire small processes (a) with occasional chains or interconnections (b).
By day 30, most cells had extended long thin processes that formed networks by
interdigitation with the processes from neighboring cells; the cell bodies had spread out
(c)
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Figure 3: Scanning electron microscopy (SEM) of FDCs on collagen type I showing
dendritic regeneration. FDCs in 30-day-old cultures on collagen type I showed
numerous convolutions and branchings of fine filliform dendrites (a–c). Cell processes
emanated primarily from one pole of cell body (diameter of 10–12 μm) with some
smaller dendrites helping to anchor the cell body to the collagen (c)
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emanating from one pole of an FDC and crossing over another cell body (Fig.
4a, 4b). Groups of 4-6 FDCs were seen forming networks much like those seen
in situ (Fig. 5a, 5b, 5c).
Immunohistochemical labeling of FDC reticula for FDC-M1 and ICs
Functionally, active FDCs are characterized by the presence of FDC-M1
and the ability to trap ICs (130). Cultures of 30 day FDCs, with well developed
dendrites and networks, labeled with the FDC-specific monoclonal Ab FDC-M1
(Fig. 6a) and were able to trap and retain OVA-anti-OVA ICs (Fig. 6c). Isotype
controls for FDC-M1 (Fig. 6b) and ICs (Fig. 6d) lacked labeling.
Immunohistochemical labeling of collagen type I and FDC-M1 in vivo
The presence of reticular fibers interspersed between FDC dendrites was
reported at the ultrastructural level at the periphery of the light zone (37). This
prompted an examination of the localization of collagen type I in lymphoid
follicles as related to germinal center FDCs. Five hours after footpad challenge
with OVA in BALB/c mice passively immunized with rabbit anti OVA IgG,
collagen type I abundantly co-localized with the specific FDC monoclonal
antibody

FDC-M1.

However,

two

days

later,

collagen

type

I

exhibited

characteristic marginal distribution around the FDC-M1+ area (Fig. 7).
Expression of CD29 and CD44 on FDCs
The rapid binding of FDCs to collagen prompted us to look for collagen
binding

receptors

on

FDCs.

Flow

cytometric

analysis

showed

that

approximately 85% of FDCs expressed CD29; the β1 integrin subunit shared by
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collagen (α1,

2, 3, 9, 10, 11β1),

laminin (α6β1) and fibronectin (α4β1) receptors as

well as the hyaluronic acid receptor CD44 (Fig. 8). CD29 and CD44 may, in
part, mediate the interaction between FDCs and collagen type I and its
associated

molecules.

However,

FDCs

treated

with

mAbs

against

these

molecules still bound collagen type I without difficulty (Data not shown).
Expression

of

α1/CD49a

and

α2/CD49b

integrins

significant amounts on freshly isolated FDCs (Fig. 8).
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were

not

detectable

in

Figure 4: Origin of dendrites at higher magnification; SEM. The developed dendrites
clearly emanate from one pole of the FDC (b). Some dendrites cross over other cell
bodies (a)
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Figure 5: Groups of 4–6 FDCs on collagen type I showing the formation of networks
(or reticula); SEM (a–c)
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Figure 6: Immunohistochemical labeling of FDC reticula with FDC-M1 and ICs. The
FDCs in cultures maintained for 30 days on collagen type I were heavily labeled with the
FDC-specific mAb FDC-M1 (a) and retained rabbit OVA-anti-OVA ICs as indicated by
labeling with goat-anti-rabbit IgG (c); HRP/development with DAB. No labeling was
observed in isotype controls for FDC-M1 (b) and ICs (d); Nomarski optics
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Figure 7: Immunohistochemical labeling for collagen type I and FDC-M1. Adjacent
frozen sections from popliteal lymph nodes were labeled for collagen type I (a, c) and
FDC-M1 (b, d) 5 h (a, b) and 2 days (c, d) after challenge with OVA in OVA immune
BALB/c. Sections were incubated with unlabeled rabbit anti type I collagen or FDC-M1.
Biotinylated goat anti-rabbit or biotin-mouse anti-rat-κ was applied followed by
streptavidin-HRP. The sections were developed with DAB substrate. Fibers labeled with
anti-collagen type I were seen co-localizing with FDC-M1 at 5 h (arrows). After 2 days,
the distribution of collagen type I was restricted to the periphery of the follicle labeled for
FDC-M1 (arrows)
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Figure 8: Expression of CD29 and CD44 on FDCs. Purified FDCs preparations were
incubated with FITC-conjugated mAb against CD29 (β1; a), CD44 (b), CD49a (α1; c),
CD49b (α2; d), and isotype-matched controls (gray lines unlabeled FDCs, dotted lines
isotype controls). Flow cytometric analysis showed that approximately 85% of FDCs
expressed CD29 (the β1 integrin subunit) and the hyaluronic acid receptor, CD44
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Discussion
The move from in vivo to in vitro assessment of FDC biology is
important given that cells in vitro are more readily amenable to manipulation.
However, dendrites represent a cardinal morphological feature of FDCs and this
morphology and the associated networks are largely lost when FDCs are isolated
(42). Moreover, the more in vitro manipulations are introduced, the less the
dendritic morphology is apparent (130). Nevertheless, isolated FDCs did have
accessory activity in vitro and dendritic morphology is identifiable at the
electron microscopy level but it has been impossible to regenerate the extensive
processes and networks to study the importance of these structures in vitro. The
fact that FDCs are fixed in GCs supported by reticular fibers and that enzymatic
digestion with collagenase was required to release them from their in vivo
environment prompted the hypothesis that modeling a supporting substrate in
vitro might stimulate reattachment of isolated FDCs and promote regeneration
of dendritic processes and networks. We report here that FDCs have a
remarkable ability to bind to collagen type I and reestablish extensive dendrites
and networks. Structure typically promotes function and the ability to regenerate
extensive

dendrites

and

FDC-networks

on

collagen

type

I

offers

a

new

opportunity to study how FDC structures relate to function.
We reasoned that if FDCs were influenced by collagen or collagenassociated molecules, then an attachment step would be necessary. To test this,
positively selected FDCs were incubated on purified collagen type I, laminin,
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biglycan or hyaluronic acid and left for twelve hours. The vast majority of viable
FDCs adhered to these matrices. The ability to firmly bind all these matrices
may help explain why these cells are fixed and do not migrate in vivo.
Comparison of FDCs incubated on different substrates indicated that collagen
type I exerted the most influence on FDC morphology. Accordingly, we
incubated FDCs on type I collagen for 30 days and cultures were examined to
verify formation of dendrites and reticula. FDCs survived throughout the culture
period without signs of apoptosis or proliferation which is consistent with the
reports of long term culture of murine FDCs up to 8 weeks (115) and human
FDCs up to 150 days (172). In the first week cells started to spread out and
begin to acquire processes with occasional interconnections. However, by day
30, most cells had fine processes that formed networks through interdigitation of
cell processes with neighboring cells. In vivo FDCs trap ICs and form
interconnecting networks or reticula. Studies with labeled Ag indicate that Agbearing ICs remain localized to FDC-networks in lymph nodes draining the site
of Ag injection. For example, Donaldson et al (173) reported that antigen
retaining networks remained localized to lymph nodes draining the injection site
one year after Ag challenge. Similarly, FDCs in vitro resisted washing off the
supporting matrices and on collagen type 1 they formed networks that could
only be mobilized by collagenase treatment.
FDC-M1 is a marker for FDCs and IC trapping and retention is
characteristic of FDCs (69,130). To confirm the identity of the cells, 30-day
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cultures were labeled with FDC-M1 or ICs. Both, FDC-M1 and ICs, intensely
labeled FDC processes and IC binding and surface retention established this
FDC function.
We reasoned that a receptor-mediated mechanism was likely involved in
attaching FDCs to collagen and in signaling formation of dendrites and reticula.
Flow cytometric analysis indicated that FDCs express CD29; the β1 integrin
subunit shared by collagen (α1,

2, 3, 9, 10, 11β1),

laminin (α6β1) and fibronectin

(α4β1) receptors as well as the hyaluronic acid receptor CD44. However,
blocking these molecules did not prevent FDCs from binding collagen type I
suggesting there are additional receptors involved.
Scanning Electron Microscopy was used to study the ultrasturcture of
dendrites and to make sure the processes emanated from cells and were not
fibers formed in the collagen. SEM revealed FDCs organized in groups, ranging
between 4 to 6, forming reticular structures with interconnecting dendrites.
Dendrites emanated from the cell bodies and some were seen extending from
one pole of an FDC over the cell body of another FDC. Characteristically, FDC
dendrites exhibit numerous branches and convolutions, often there is polarity
regarding the cell body, and processes in vivo may be found attached to collagen
fibers (37,42). All of these features were apparent with FDCs on collagen type I.
Besides their structural role, collagens, especially type I collagen which
is the most abundant collagen type, help define functional properties of tissues
(174). Hyaluronic acid binds cells via CD44 and is widely distributed in the
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body.

FDC-CD44

regeneration

and

may

play

network

a

role

formation

in

seen

mechanisms
here

since

leading

to

dendrite

proteoglycan-associated

hyaluronic acid is seen in rat tail collagen (175). The receptor CD44 has been
implicated

in

a

number

of

cellular

functions

such

as

adhesion, growth,

differentiation, and apoptosis (176). Recently, it has been demonstrated that both
8D6 and CD44 expressed on FDCs mediate their antiapoptotic activity that
helps maintain lymphomas in vivo (65).
Collagen type I has been found to enhance activation and dendrite
formation in other cells. The ability of collagen type I to provoke phenotypic
changes associated with activation has been described in DCs including GMCSF-propagated liver DCs (177) and monocyte-derived DCs (178). In addition,
network formation and angiogenic stimulation has been described in endothelial
cells when cultured on type I collagen (179). Moreover, neurons seeded on
collagen gels regenerated neurites that appear to correspond to axons and
dendrites (180).
The characteristic dislocation of collagen type I fibers to the periphery of
active

follicles

two

days

after

antigenic

challenge

agrees

with

a

similar

observation in reactive human tonsils (181). However, neither the paucity of
collagen type I associated with FDCs two days after antigenic challenge in vivo,
nor the ultrastructure of FDC dendrites and networks on the collagenous matrix
in vitro, support the concept that FDCs produce type I collagen in their
processes favoring a fibroblastic origin (182). In short, the data presented here
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indicate that purified FDCs express CD29 and CD44 and are able to regenerate
their dendritic networks in vitro when cultured on collagen type I. We are
looking forward to functional studies comparing the activity of free-floating
FDCs with FDCs in networks with interest.
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CHAPTER 4
IL-6 produced by immune complex-activated follicular dendritic
cells promotes germinal center reactions, IgG responses, and
somatic hypermutation
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Introduction
Follicular dendritic cells (FDCs) are prominent in GCs because their
numerous long slender dendrites intertwine and create extensive FDC-networks
or -reticula. These FDC-networks are fixed in the follicles while T and B cells
are

free

to

circulate.

Nevertheless,

FDCs

release

chemokines

that

attract

recirculating lymphocytes that help organize the follicle and participate in the
GC reaction (66,183). FDCs, bearing specific Ag in the form of ICs, are
requisite for full development of GCs (38,46,69) and interaction of FDCs with
ICs leads to activation and the expression of high levels of FDC-FcγRIIB, ICAM-1 and -VCAM-1 (70). FDC-ICs also deliver a late antigenic signal that
promotes SHM (35). Important events include: 1) induction of specific Ab that
binds immunogen and forms ICs, 2) IC trapping by FDCs, 3) GC B cell
stimulation by Ag in these FDC-ICs, and 4) promotion of SHM by this late
second Ag signal delivered by IC-bearing FDCs (35). However, FDCs provide
signals, beyond specific Ag, that promote B cell maturation and we sought to
determine if FDC-IL-6 promotes SHM.
Interleukin-6, known in the early literature as B-cell stimulatory factor
(BSF-2), is recognized for its role in regulating terminal B cell differentiation
(Reviewed in (184)). Somatic hypermutation (SHM) is a major events in
terminal B cell differentiation that occurs in germinal centers (GCs) in the
second wk after primary immunization (Reviewed in (185-188)). It has also
been reported that murine FDCs are the source of IL-6 in GCs (68) and that ICs
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activate FDCs (70). This prompted the hypothesis that IC-activated FDCs
produce elevated levels of IL-6 and that FDC-derived IL-6 is important not only
for optimal Ab responses but also for GC reactions and SHM. We postulated
that elevated production of IL-6 by IC activated FDCs, one to two wks after
primary

immunization,

would

correlate

with

enhanced

GC

reactions,

IgG

responses, and SHM.
While there are numerous reports supporting the hypothesis that FDCs
produce IL-6 (189-192), there are also studies reporting the inability to detect
IL-6 in FDCs (193-195). To further test the hypothesis that FDCs produce IL-6
and that IC-activated FDCs produce elevated levels of IL-6, ICs were added to
purified FDCs and 2 to 6 days later IL-6 production had clearly increased.
Specific Ab is induced 4-7 days after primary immunization and IC formation
would follow soon thereafter. Thus, 6 to 13 days after immunization a burst in
FDC-IL-6 production would be expected in developing GCs. To test the
postulate that IL-6 promotes GC reactions, specific IgG responses, and SHM;
these responses were studied in IL-6 KO mice and in GC reactions in vitro
where IL-6 was specifically inhibited by anti-IL-6. The present study, including
both in vivo and in vitro experiments, confirms earlier results indicating, that
optimal GC reactions and IgG anti-NIP responses require IL-6 and that FDCs
are the only cells in GC reactions making IL-6 (68). In addition, we found that
IL-6 was not detectable in in vitro GC reactions with IL-6 KO FDCs with T & B
cells from WT mice. In contrast, IL-6 production was normal in GC reactions
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with WT FDCs with T and B cells from IL-6 KO mice. The absence of IL-6 in
cultures lacking WT FDCs resulted in marked reduction in the rate of SHM that
coincided with the reduction in specific anti-NIP. Moreover, GCs were abundant
in irradiated WT mice reconstituted with spleen cells from IL-6 KO mice while
GCs were virtually undetectable in irradiated IL-6 KO mice reconstituted with
normal spleen cells. These data provide strong support for the physiological
relevance of FDC-IL-6 in GC reactions in vitro and in vivo and report for the
first time that FDC-IL-6 is inducible by ICs and is involved not only in
influencing the amount but also the mutations that are known to enhance the
affinity of specific IgG produced.
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Material and Methods
Mice, Ag and immunization
Six to 8 wk old C57BL/6 mice were purchased from the National Cancer
Institute and female IL-6 KO mice (B6.129S2-116tm1Kopf/J) of the same age
were obtained from the Jackson Laboratory. The mice were housed in standard
shoebox cages and given food and water ad libitum. Animals were handled in
compliance with Virginia Commonwealth University Institutional Animal Care
and Use Committee guidelines. Mice were immunized by injecting 0.25 or 25
μg of alum precipitated (NP)36-CGG with ~1.5 x 107 heat killed Bordetella
pertussis s.c. in each front leg and hind foot in a 50 μl volume to give a total of 1
μg or 100 μg of (NP)36-CGG /animal. Fourteen days later these mice were bled,
serum collected, and draining lymph nodes from each group were pooled to
isolate λ+ B cells for extracting RNA. The serum was used to determine NIPspecific Ab levels and the RNA was used to determine mutations per 1000 bases
in the VH186.2 gene segment. In vitro GC reactions were set up using memory
T cells specific for CGG [T(CGG) cells] isolated from mice one month after
immunization with 100 μg CGG as described above. To get NP specific λ B
cells, WT or IL-6 KO mice were immunized with 100 μg (NP)36-CGG plus heat
killed Bordetella Pertusis as explained above and the λ B cells were isolated 6
days later.
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Establishment

of

IL-6

KO

/

WT

chimeras,

immunization,

and

immunohistochemistry
Two

days

after

irradiation

with

600

rads,

IL-6

KO

(B6.129S2-

116tm1Kopf/J) mice were reconstituted with 108 WT or IL-6 KO splenocytes
injected SC behind the neck. Similarly, WT C57B/6 mice were reconstituted
with 108 IL-6 KO or WT splenocytes and 48 hrs later, mice were immunized
with 1 μg (NP)36-CGG /animal. Fourteen days later these mice were bled,
sacrificed, and the spleens were frozen in OCT medium. Sera were used for
determination of the anti-NIP levels, and 10 μm cryostat spleen sections were
prepared and fixed in absolute acetone. The midsaggital spleen sections were
labeled for GC B cells with FITC-conjugated anti-B cell activation marker GL7, and for the FDC-ICs with Rhodamine-Red-X anti-mouse IgG. Resting B cells
were labeled with PerCP-Cy5.5 anti mouse B220 and the number of GL-7+ GCs
were counted in the midsaggital spleen sections.
Antibodies and Reagents
Functional

grade,

Azide

free,

sterile-filtered,

purified

anti-mouse

Interleukin-6 (Cat# 16-7061, Clone MP5-20F3) and rat IgG isotype control Ab
were obtained from eBioscience.

Rat anti-mouse FDC (FDC-M1), biotin mouse

anti-rat kappa (MRK-1), anti-mouse CD21/CD35 (Clone 7G6) and anti mouse
CD32/CD16 (Clone 2.4G2) were purchased from Pharmingen (San Diego, CA).
Mouse CD45R (B220) MicroBeads, mouse CD90 (Thy1.2) MicroBeads, antiBiotin MicroBeads, and MACS LS columns were purchased from Miltenyi
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Biotec GmbH (Auburn, CA). Biotin labeled rat anti-mouse kappa was purchased
from Zymed (San Francisco, CA).

Alkaline phosphatase labeled goat anti-

mouse IgG (H+L) and P-Nitrophenylphosphate substrate were obtained from
Kirkegaard & Perry Laboratories (Gaithersburg, MD). NIP-OVA (4-hydroxy-3ioda-5-nitrophenylacetyl

conjugated

to

ovalbumin)

and

(NP)36-CGG

were

obtained from Biosearch Technologies (Novata, CA). Anti-CGG was obtained
from hyperimmunized mice with serum anti-CGG IgG levels in excess of 1
mg/ml.
FDCs

isolation,

activation

with

ICs

in

vitro,

and

assessment

of

IL-6

production
FDCs were isolated as described previously (130). Briefly, lymph nodes
from lethally irradiated mice were gently digested and the cell suspension
incubated with rat anti-mouse FDC-M1, biotin-mouse anti-rat kappa (Clone
MRK-1) and anti-biotin magnetic microbeads sequentially. Finally the FDCs
were positively selected using a magnetic column (MACS). Approximately 85
+

+

to 95% of these cells expressed the FDC phenotype, FDC-M1 , CD32 ,
+
CD21/35 ,

+

CD40

and

ICAM

+

(130).

Purified

FDCs

were

activated

by

incubating 1x106 cells with 100 ng/ml OVA-ICs made of OVA/rabbit-anti-OVA
at a ratio of 1:6. Four independent experiments with triplicates of IC-stimulated
FDCs were set up and culture supernatant fluids were sampled after 2, 4, and 6
days. In some experiments, culture supernatant fluids were collected after 3, 6,
and 10 days. Controls of B220 purified B cells, Thy1.2 purified T cells, IL-6 KO
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FDCs, WT B and T cells, WT B and T cells with IL-6 KO FDCs with or without
ICs, WT FDCs incubated with IL-6 KO B and T cells with or without ICs, WT
FDCs incubated with soluble 100 ng/ml OVA, WT FDCs pretreated with 10
μg/ml azide-free FcγR or CR blockers (mAb 2.4G2, and 7G6 respectively) or
their isotype controls prior to IC loading and low Tox complement were
included. IL-6 levels in the fluids were assessed using a Bio-Plex Mouse IL-6
assay (Bio-Rad, Hercules, CA, 171-G10738), data were collected on a Bio-Plex
array

reader

(#

LX10004042104),

and

analyzed

using

Bio-Plex

Manager

Software 4.1.
Isolation of lambda light chain positive B cells (λ+ B cells) and memory T(CGG)
cells
Single cell suspensions were prepared from draining lymph nodes after priming
with (NP)36-CGG or CGG as explained above. After depleting kappa light chain
positive B cells with biotin-anti-κ and anti-biotin microbeads with a MACS
+

column, the persisting λ B cells were isolated with anti-B220 microbeads using
a MACS column. The isolated λ

+

B cells were more than 98% pure. Memory

T(CGG) cells from CGG primed mice were incubated with 40μl of anti-CD90.2
microbeads and the T cells were positively selected using a MACS column.
In vitro GC reactions and the anti-NIP Ab Response
GC reactions were initiated in vitro by culturing 1 x 106 unmutated but 6
day primed λ B cells, 0.5 x 106 T cells, and 0.5 x 106 FDCs in the presence of
100ng of (NP)36-CGG as free Ag or in ICs. The ICs were made by incubating
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NP-CGG with anti-CGG at a ratio of 6 ngs/ml anti-CGG to 1 ng of NP-CGG for
two h and then adding IC containing 100 ng NP-CGG to appropriate wells in 24well culture plates. Supernatant fluids were harvested 7 days later and were
assayed for NIP-specific IgG Ab by ELISA using NIP-OVA to coat the plate.
Analysis of mutations in the V region
Anti-NP Igs predominantly use the VH186.2 gene (14,196) and it was
analyzed in this study. Cells were collected on Day 7 of culture and RNA was
isolated using Trizol (Invitrogen, Carlsbad, CA). The RNA was then reverse
transcribed to cDNA with GeneAmp gold RNA PCR Core kit (PE Biosystems,
Foster city, CA) using oligo dt. The VH186.2 gene followed by D and J regions
and a proximal segment of the C gamma gene segment was amplified by two
rounds of nested PCR with high fidelity Pfu-Ultra DNA polymerase (Stratagene,
La Jolla, CA). The forward and reverse primers for the first round PCR, were 5’catgctcttcttggcagcaacagc-3’

and

5’-gtgcacaccgctggacagggatcc-3’,

for

round PCR, 5’- caggtccaactgcagccag-3’ and 5’-agtttgggcagcaga-3.

second
The PCR

reaction was carried out as follows: 95°C 1 min, 56°C 1 min, 72°C 1 min for 30
cycles followed by 72°C for 10 min. The expected 400bp PCR product was then
electrophoresed on 1.2% agarose gel, purified by gel extraction using QIAQuick
kit (Qiagen, Valencia, CA) and cloned using Zero Blunt® TOPO PCR Cloning
Kit

(Invitrogen, Carlsbad, CA). The plasmids were transformed into one shot

TOP10 chemically competent cells (Invitrogen, Carlsbad, CA) and plated onto
LB

media

containing

50μg/ml

ampicillin.
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Multiple

discrete

colonies

were

picked the following day and grown for 24 hours in LB broth containing
50μg/ml ampicilin in a 37°C shaker. The plasmids were isolated using a
QIAprep

Spin

miniprep

kit

(Qiagen,

Valencia,

CA)

and

the

insert

was

sequenced using an ABI sequencer. The sequences were analyzed using GCG
Wisconsin

Package

(Accelrys,

San

Diego,

CA),

clustalW

BioEDIT

(http://www.mbio.ncsu.edu/BioEdit/bioedit.html)

(197,198)

software

and

packages.

Redundant sequences were excluded from our calculation of mutations per 1000
bases to avoid multiplying the effect of a single mutation. To avoid including N
terminal additions, changes within 5 bases of the V-D junction were also
excluded from our calculations of mutations per 1000 bases.
Immunofluorescence and confocal microscopy
Draining lymph nodes (popliteal brachial and axillary) were harvested
from WT or IL-6 KO mice 14 days after immunizing with 1 ug of (NP)36-CGG
and

frozen

on

dry

ice

in

Optimum

Temperature

Compound

(Tissue-Tec,

Torrance, CA). Serial 10μ thin sections were cut from the frozen blocks using a
Jung Frigocut 2800E Cryostat, fixed in absolute acetone, and air-dried. The
sections were blocked with 10% BSA in PBS and then washed and incubated for
1 h with 2 μg/ml FITC-conjugated anti-GL7 and Cy5.5-conjugated anti-B220
(BD Pharmingen, San Diego, CA). Sections were washed, mounted with antifade mounting medium, Vectashield, cover-slipped, and examined with a Leica
TCS-SP2 AOBS confocal laser scanning microscope fitted with an oil planApochromat 40X objective. Two lasers were used, Argon (488 nm) for FITC,
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and HeNe (633nm) for Cy5.5 (shown as pseudo-color magenta). Parameters
were adjusted to scan at 512 X 512 pixel density and 8-bit pixel depth.
Emissions were recorded in 2 separate channels. Digital images were captured,
overlaid

and

BIOQUANT

processed
NOVA

with

Leica

Confocal

and

LCS

Advanced

Image

Analysis

software

Lite

(R&M

softwares.
Biometrics,

Nashville, TN) was used to analyze the immunohistochemistry as described
previously (58). After setting an arbitrary threshold, the system allowed us to
determine number, position, area, and density of labeling that best defined FDCreticula. This predefined threshold was used throughout to enable reliable
comparisons.
Statistical Analysis
The number of mutations per sequence was compared using a Poisson
regression analysis (SAS Proc Genmod version 9.1, SAS Institute Inc.) An
offset of log(306) was used to normalize the fitted group means to the number of
nucleotides. Significant chi-square values for SHM data were determined at p
<0.05. Analysis of IL-6 production, GC numbers, area, and IgG production were
done using a two tailed Student’s T test and significance was accepted at p
<0.05.
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Results
FDC derived IL-6 and activation via IC-FcR interaction enhanced FDC-IL-6
To begin testing the hypothesis that FDCs produce IL-6 and that IC-activated
FDCs produce elevated levels of IL-6, ICs were added to purified FDCs or to purified
FDCs with T and B cells. As shown in figure 1, all cultures containing WT FDCs
produced IL-6 at all time points, 3, 6, and 10 days. Moreover, IL-6 production was
enhanced by IC-mediated FDC activation. In marked contrast, cultures of WT B cells and
T cells, separately or in combination with IL-6 KO FDCs, did not produce detectable
levels of IL-6 even when ICs were added. FDCs isolated from normal mice with FDCM1 have detectable levels of ICs on their surfaces but are capable of trapping more IC
(130) and of being further activated in vitro via engagement of FcγRIIB (71). To further
examine the need for ICs and FcγRs, FDCs were isolated from normal animals, ICs were
added as an in vitro activation signal, and supernatant fluids were collected on days 2, 4,
and 6 (Figure 2). IL-6 was apparent in the control lacking added ICs and it continued to
accumulate over the 6-day period. FDCs may constitutively express IL-6 or this
background IL-6 response may occur as a consequence of FDCs encountering ICs in vivo.
In any case, addition of ICs enhanced FDC-IL-6 production within 48 hrs (p<0.0001) and
IL-6 production continued to increase over the 6 day period. Inhibition of IC trapping via
FcγR with the FcR blocker (mAb clone 2.4G2) significantly inhibited FDC-IL-6
production whereas the isotype control had no inhibitory effect. Moreover, addition of
soluble Ag (OVA) to the FDCs, rather than OVA in ICs did not stimulate IL-6 production
above background. We did not see enhancement of FDC-IL-6 production by the
125

Figure 1: FDCs but not B or T cells produce IL-6 and its production is enhanced by
ICs. WT FDCs incubated with IL-6 KO B and T cells with or without ICs together with
controls of WT B cells, T cells, IL-6 KO FDCs, WT B and T cells, WT B and T cells
with IL-6 KO FDCs with or without ICs were set up and culture supernatant fluids were
sampled after 3, 6, and 10 days. IL-6 levels were assessed with Bioplex. All cultures
containing WT FDCs produced IL-6 at all time points, 3, 6, and 10 days, and IL-6
production was enhanced by activating FDCs with ICs. In marked contrast, cultures of
WT B cells and T cells, separately or in addition to IL-6 KO FDCs, in the presence or
absence of ICs did not produce detectable levels of IL-6 at any time point. Data are
representative of the mean of one of four independent experiments with triplicates + SD.
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Figure 2: ICs induce FDC-IL-6 production by engaging FDC-FcγRs. Purified WT
FDCs were activated by incubating 1x106 FDCs with 100 ng/ml OVA-ICs made of
OVA/rabbit-anti- OVA at a ratio of 1:6. Controls of WT FDCs incubated with soluble
100 ng/ml OVA, and WT FDCs pretreated with 10 μg/ml azide-free FcγR (mAb 2.4G2)
or its isotype control prior to IC loading were included. IL-6 levels in the fluids were
assessed using a Bio-Plex Mouse IL-6 assay after 2, 4, and 6 days. As shown, ICs
enhanced FDC-IL-6 production within 48 hrs (p<0.0001). The IL-6 surge apparent at day
6 after IC loading, precedes the late phases of the GC reaction (starting day 9-10 after
primary challenge) when the presence of IL-6 appears to promote somatic hypermutation.
Inhibiting IC trapping via FcγRs with the FcR blocker (mAb clone 2.4G2) significantly
inhibited FDC-IL-6 production whereas the isotype control had no inhibitory effect.
Moreover, addition of soluble Ag (OVA) to the FDCs did not stimulate IL-6 production
above background. We did not see enhanced FDC-IL-6 production by the addition of low
Tox complement and complement receptors do not activate FDCs whereas engagement
of FcγRIIB does (6). Data represent the mean of triplicate cultures + SD and the results
are representative of four independent experiments of this type
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including low Tox complement and complement receptors do not activate FDCs whereas
engagement of FDC-FcγRIIB does (70).
Anti-IL-6 inhibited specific Ab production in vitro
Germinal center reactions were set up using purified FDCs, CGG-primed memory
T cells, and lambda light chain positive B cells (λ+ B cells) isolated from WT mice. The
λ+ B cells were obtained 6 days after immunization with 100 ug of NP-CGG per mouse.
The 6 days allowed NP specific λ+ B cells to begin clonal expansion and begin producing
IgG anti-NIP in vivo. However, as previously shown (196,199,200) and confirmed in our
studies (35), λ+ B cells taken 6 days after primary immunization have begun class
switching, IgG production is increasing rapidly, but SHM has not occurred. The amount
of NIP specific Ab in the supernatant fluids after 7 days of culture was consistent with
previous results with cells from WT mice (Fig. 3) (35). Without FDCs the anti-NIP IgG
levels were low (Fig. 3 columns 1 & 2). B cells do not survive well in the absence of
FDCs and without FDCs only about 20% of our B cells survive for a wk compared with
80 - 90% in the presence of FDCs (115). Low Ab levels in cultures lacking FDCs are, at
least in part, a reflection of a loss in B cells. Addition of FDCs to the B & T cells resulted
in a dramatic increase in anti-NIP production (Fig. 3 column 3). To test the importance of
IL-6 in promoting this IgG response, neutralizing anti–IL-6 (10 ug/ml) or isotype control
were added to the B cell, T cells and FDC cultures where optimal anti-NIP responses are
obtained (35). Column 4 of Fig. 3 illustrates that anti-IL-6 reduced the anti-NIP response
by nearly 80%. To determine if the IL-6 served as a survival signal, trypan blue exclusion
data indicated that 91.7+3 % of the cells at the start of the culture were recovered from
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cultures containing FDCs and isotype control after 7 days (1.8+0.06 x 106 viable cells
recovered). Flow cytometry after double labeling with B220-FITC and propidium iodide
(PI), revealed that 45.7+1.6 % of these cells were B220+/PI-. In cultures containing FDCs
and anti-IL-6 there were 1.7+0.06 x 106 total viable cells persisting or 88.3+3 % of the
cells at the start of the culture. Flow cytometry of these cultures revealed that 45.0+1 %
of these cells were B220+/PI- (p >0.05). These results suggest that IL-6 is promoting B
cell maturation rather than survival.
Specific Ab responses and GC development impaired in IL-6 KO mice
To establish the impact of IL-6 on specific Ab and GC development, WT
and IL-6 KO mice were immunized with NP-CGG.

At 100 ug of NP-CGG

/mouse, the IgG anti-NIP levels were not significantly depressed in IL-6 KO
mice 14 days after immunization (Data not shown). However, when immunogen
was limited to 1 ug NP-CGG/mouse, the IgG anti-NIP response 14 days after
primary immunization was clearly suppressed in IL-6 KO mice (Fig. 4A).

We

reasoned that ICs would not form as rapidly in IL-6 KO animals with reduced
specific Ab levels and that FDC trapping and activation be delayed and reduced.
Consequently, B cells would not respond as vigorously resulting in fewer and
less robust GCs in IL-6 KO mice. To test this, the number and sizes of GCs were
determined 14 days after primary immunization with 1 ug of NP-CGG. As
illustrated in Fig.

4B & C, GCs were apparent in both WT and IL-6 KO mice.

However, GCs in IL-6 KO mice appeared to be scattered and smaller and this
was confirmed using morphometric analysis which indicated that the number
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and size of GCs in IL-6 KO mice were about half the WT level (Fig. 4D & E).
Thus, the reduced anti-NP response correlated with a reduced GC response in
IL-6 KO mice (Fig. 4A). In addition, the total splenic leukocytes in the IL-6 KO
mice were about half the number of spleen leukocytes in the WT (94.6 x106 +
11.5 Vs 61.7 x 106 + 12.6 p<0.01), and the GL-7+ cells represented 3 + 0.2 %
and 0.6 + 0.3 % of the splenic leukocytes in the WT and the IL-6 KO groups
respectively (p <0.003).
Irradiated wild type mice reconstituted with IL-6 KO splenocytes but not IL-6
KO mice reconstituted with WT splenocytes developed GCs and anti-NIP IgG
in response to 1 ug NP-CGG.
FDCs are irradiation resistant and to determine if FDC derived IL-6 is
important under physiological conditions in vivo, we set up irradiation chimeras
reasoning that WT FDCs would provide IL-6 and induce GCs and IgG responses
with IL-6 KO splenocytes. As illustrated in figure 5A, anti-NIP levels were
significantly lower in the IL-6 KO mice (p < 0.02) as compared to the WT mice
regardless of the source of donor splenocytes. GCs in the WT mice reconstituted
with IL-6 KO splenocytes were readily apparent and labeled intensely with GL7 (Fig. 5B) and, as expected, these GCs developed in association with the ICretaining FDC-network (Fig 5.B2). In marked contrast, GC in IL-6 KO mice
were poorly developed and very difficult to find even with WT splenocytes
which could serve as a source of IL-6 (Data Not shown). Moreover, the number
of GCs per midsaggital splenic section from IL-6 KO mice reconstituted with
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Figure 3. Anti-IL-6 mediated inhibition of anti-NIP IgG production in GC reactions in
vitro. GC reactions were set up using cells isolated from WT mice. Culture contents are
indicated beneath each column (BTAg: B cells, T cells, & Ag; BTIC: B cells, T cells, &
ICs; BTFDCIC ISO: B cells, T cells, FDCs, & isotype control Ab; BTFDCIC α-IL-6: B
cells, T cells, FDCs, & anti-IL-6). After 7 days of culture, supernatant fluids were
collected and assayed for NIP-specific IgG by ELISA. The values represent the mean ±
SEM from triplicate independent experiments. Either isotype control or anti-IL-6 Ab (at
10 ug /ml) were added to B, T and FDC cultures and the difference between isotype
control and anti-IL-6 was statistically significant (p<0.05).
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Figure 4: Reduced NIP specific serum IgG and a similar reduction in GCs in draining
axillary lymph nodes from IL-6 KO mice 14 days after primary immunization. Panel A,
Wild type (WT) or IL-6 KO mice were injected s.c. with 1 ug of alum precipitated
(NP)36–CGG using heat–inactivated Bordetella pertussis as adjuvant. Two wk after
primary immunization, serum was collected and assayed for IgG anti NIP. The data are
representative of two independent experiments with 6 mice in each group. Panel B,
Illustrates labeling with FITCconjugated anti-GL7 (B1) that labels GC B cells and
defines a GC within the cortex of a lymph node from a WT mouse. B2 illustrates labeling
of the same follicle with Cy5.5-conjugated anti- B220 that labels all B cells. B3 is an
overlay of panels B1 and B2 indicating the extent of GC B cells relative to B cells
generally. Panels C1, C2, & C3 are the same reagents with an IL-6 KO mouse. Panel D,
illustrate the number and panel E, size of GL7+ GCs per midsagittal axillary lymph node
section.
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Figure 5: WT mice reconstituted with IL-6 KO splenocytes, but not IL-6 KO mice
reconstituted with WT splenocytes, developed GCs and anti-NIP IgG. Chimeras were
generated by reconstituting irradiated WT C57B/6 mice with 108 IL-6 KO splenocytes
and vice versa. One day later, these mice with irradiation resistant FDCs and splenocytes
were challenged with 1 μg NP-CGG and the NIP-specific IgG was assessed after 14 days
when the mice were sacrificed. Cryosections were prepared from each spleden, and GCs
in the midsaggital sections were labeled with GL-7 and counted. As shown in figure 5,
the anti-NIP levels were significantly lower in the IL-6 KO mice (p < 0.02) as compared
to the WT mice. Germinal center development in the irradiated IL-6 KO mice was
markedly impaired (averaged less than 2 as compared with 16 GL-7+ GCs counted in the
reconstituted WT mice) and GC development was not rescued by reconstitution with WT
splenocytes capable of producing IL-6.
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WT splenocytes averaged less than 2 as compared with 16 GL-7+ GCs/section in
WT mice reconstituted with IL-6 KO splenocytes (p<0.0005).
SHM impaired in IL-6 KO mice
IL-6 helps regulate late events in B cell differentiation and we reasoned that IL6 may influence SHM, which occurs after the initial induction of IgG anti-NIP
late in the first wk after primary immunization (35). The antibody response to
the hapten 4-hydroxy-3-nitrophenylacetyl (NP) coupled to the T cell-dependent
carrier CGG is dominated in C57BL/6 mice by lambda light chain bearing
antibodies (201-204) expressing the VH186.2 gene (205).

This response has

been well characterized and consequently was adopted in the current study. To
examine SHM, the draining lymph nodes from the mice immunized with 1 ug of
NP-CGG and studied in Fig. 4 were collected at day 14, the λ+ B cells were
harvested and SHM was determined. Consistent with the IgG response and GC
reaction data in Fig. 4, mutations were also apparent but reduced in the IL-6 KO
mice. The rate of mutation in the VH186.2 gene segment switched to Ig-gamma
decreased from 18 to 8.9 mutations/1000bp (P <0.001) in WT vs IL-6 KO mice.
The mutations are illustrated in Table 1 which shows the DNA sequence
alignment of the

VH186.2

gene.

The

corresponding

amino

acid

sequence

alignments were done and as expected, most mutations were in the CDR1& 2
regions (Table 2).
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Anti-IL-6 inhibited SHM in GC reactions in vitro
Provided that FDCs bearing the appropriate ICs are present (35), SHM
can be studied in GC reactions in vitro. This prompted experiments to determine
if anti-IL-6 will inhibit SHM under controlled conditions in culture to confirm
the results in vivo. Germinal center reactions were set up in vitro using purified
FDCs, CGG-primed memory T cells, and λ+ B cells isolated from WT mice. The
λ+ B cells were obtained 6 days after immunization with 100 ug of NP-CGG per
mouse. The 6 days allowed NP specific λ+ B cells to clonally expand and begin
producing IgG anti-NIP in vivo. However, as previously shown (196,199,200)
and confirmed in our studies (35), λ+ B cells taken 6 days after primary
immunization are not mutated. However, SHM would be one of the next events
in a GC reaction. These 6 day B cells were cultured for 7 additional days in vitro
and the production of specific anti-NIP Ab and mutations in the VH186.2 gene
segment were determined. The anti-NIP response of these mice is illustrated in
Fig. 3 where anti-IL-6 reduced the IgG response by nearly 80%.

Similarly, the

mutation rate in these anti-IL-6 treated cultures was reduced (3.50 vs 0.65
mutations per 1000 bases in control vs anti-IL-6 treated cultures; P< 0.02). The
data in Table 3 illustrate the DNA sequence alignment of VH186.2 gene
obtained in cultures with the isotype control and cultures treated with anti-IL-6.
Note that most sequences from cultures treated with the isotype control
contained mutations whereas only two sequences from the anti-IL-6 treated
cultures contained mutations. Of the 12 sequences analyzed from isotype control
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cultures there were a total of 13 mutations. Eight of these were replacement
mutations and five were silent. Six of the eight replacement mutations were in
the CDR2 region. These data from cultures with the isotype control are
compatible with the much larger published data sets (35) where mutations in
vitro with IC loaded FDCs ranged from 3 to 12 mutations/1000 bases with over
60% of these mutations in CDR1 or CDR2. Results from the anti-IL-6 treated
cultures were similar in that two of the three mutations were replacement
mutations.
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Table 1: Vh186.2 sequence alignments from 1μg (NP)36-CGG immunized
WT vs IL6 KO

Footnote: The sequences shown in table 1 are for lambda B cells obtained from
WT or IL-6 KO mice whose anti-NIP levels are shown in figure 4 part A. The
anti-NIP levels as well as sequence analysis were performed 14 days after
challenge of these mice with 1 μg of NP-CGG.
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Table
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sequence
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translation
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Table 3: Comparison of Vh186.2 sequence alignments from isotype and anti-IL6 treated cultures

Anti-IL-6
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Discussion
The contribution of IL-6 to terminal B cell differentiation has long been
recognized (184). However, the physiological relevance of FDC-IL-6 to GC B
cell differentiation is unclear given that IL-6 can be produced by many cells and
IL-6 production by FDCs has not been consistently found (193-195). In the
present study, we confirmed that murine FDCs produce IL-6 and provide strong
support for the physiological relevance of FDC-IL-6 in GC reactions. IL-6 was
not detectable in in vitro GC reactions with IL-6 KO FDCs even with T & B
cells from WT mice that could serve as a source of IL-6. In contrast, IL-6
production was normal in GC reactions with WT FDCs with T and B cells from
IL-6 KO mice. Moreover, FDCs are irradiation resistant and GC reactions were
abundant in irradiated WT mice reconstituted with spleen cells from IL-6 KO
mice while GCs were virtually undetectable in irradiated IL-6 KO mice
reconstituted with normal spleen cells. Moreover, like ICAM-1, VCAM-1 and
FcγRIIB (70), activating FDCs with ICs upregulated FDC-IL-6 production.
Immune complexes would be generated in vivo ~3-7 days after primary
immunization suggesting that a burst in FDC-IL-6 production would occur in
the follicles ~5 days after immunization and continue for a week or more.
Although, class switching and low affinity Ab production may occur before a
GC reaction (19,206), the IgG response is amplified as GCs develop over the
next week. Moreover, SHM is a late event apparent in GCs after the first wk
(35,196,199,200). Thus, SHM would coincide with optimal production of IL-6
145

by IC-activated FDCs. Both in vivo and in vitro data indicated that anti-NIP
responses and SHM can take place in the absence of IL-6, but IL-6 clearly
promoted both responses. The novel findings reported here are that FDC-IL-6
levels are upregulated by ICs and that FDC-IL-6 is high in the second week after
immunization concurrent with SHM, and that IL-6 is required for optimal SHM.
Thus, FDC-IL-6 appears to influence not only GC development and the level of
IgG produced, but also the mutations that promote enhanced IgG affinity.
Results presented here confirm and extend the report of Kopf, et al. (68)
who first demonstrated that IL-6 mRNA is produced by cells within murine GC
clusters and determined it was the FDC-enriched populations (> 80 % pure)
rather

than

the

Immunohistochemistry

lymphocytes
performed

that
by

these

produced
authors

the
on

IL-6
cryosections

mRNA.
from

immune WT mice further supported their results revealing that cells with
dendritic morphology within FDC-network produced the IL-6. This production
was limited to active GCs and not detected in primary follicles, which may help
explain why some studies have failed to detect IL-6 in FDCs. By use of an IL-6
bioassay, Kopf et al found that IL-6 was present only in cultures containing
either FDC-lymphocyte clusters or the FDC irradiated population but not in the
sorted T or B lymphocytes. However, IL-6 was not quantified and our data
extend this report by quantification of IL-6 production in highly purified FDCs
in vitro and demonstrated IC mediated induction.
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The extent of in vivo suppression of the immune response in the IL-6 KO
mice in the present study appears to be less than that observed by Kopf and
colleagues (68).

Our use of Bordetella pertussis as adjuvant may have helped

compensate for the lack of IL-6 in vivo. Alternatively, CGG may be more
stimulatory in the absence of IL-6 than the OVA they used.
A previous study of GC reactions in vitro indicated that FDCs promote
IgG production by B cells taken 6 days after primary immunization. However, in
the absence of a second late exposure to Ag, SHM was not detected (35). This
model was used in the present study which suggests that optimal SHM also
requires

IL-6.

Typically

SHM

occurs

in

the

second

wk

after

primary

immunization, however, if memory T cells are given along with immunogen in
the form of IgG-ICs, extensive GC development and high levels of SHM can be
obtained in the first wk in vivo (35). The importance of ICs is indicated by the
observation that replacing ICs with Ag, which will not load on FDCs, does not
induce SHM in the first wk even though memory T cells are present (35).
Moreover, it is important for the ICs be made with IgG to promote SHM (207)
and IgG-ICs are arranged on FDCs with a periodicity known to optimally
engage BCRs and stimulate B cells (34,35).

In short, the combined data provide

support for the concept that the unique ability of FDCs to trap and retain IgGICs for months provides them with the Ag necessary to deliver late specific and
non-specific signals like IL-6 needed to promote SHM. Moreover, FDCs bearing
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the appropriate ICs promote activation-induced cytidine deaminase production,
and affinity maturation by NP specific B cells (39).
In the present study, the in vivo reductions in specific Ab and SHM in IL-6 KO mice
were most apparent at low Ag dose. At our usual immunization dose of 100 ug of NPCGG /mouse, neither the reductions in IgG anti-NIP levels nor SHM were statistically
significant 14 days after immunization (Data not shown). However, defects in Ab
production and SHM were readily apparent when the dose was reduced to 1 ug of NPCGG/mouse. A similar Ag dose-effect relationship has been reported in lymphotoxin
alpha KO mice.

Mature FDC-reticula and GCs do not develop in these mice,

nevertheless, if the Ag dose is high enough, SHM is apparent in these FDC-reticula
defective animals (208). Most infections start with only a few organisms, and if specific
Ab is significant in immunity, it is important that immunity develops before the infection
gets widespread. The results reported here indicate that under low immunogen dose
conditions FDC-IL-6 is likely to be important in generating rapid production of high
affinity specific IgG. We look forward to studies testing the relationship between FDCIL-6, selection of high affinity clones with SHM, and affinity maturation both in vivo and
in vitro.
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CHAPTER 5
T-Independent Antibody Responses to T-dependent Antigens: A
Novel Follicular Dendritic Cell-Dependent Activity
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Introduction
Antigens are classified as T cell dependent (TD)4 or T cell independent
(TI) depending on whether T cell help is needed to induce an Ab response. TI
Ags are further classified into TI type 1 and 2. The TI-1 Ags, such as LPS, are B
cell mitogens, which function by non-specifically or polyclonally activating
most B cells (209). The TI-2 Ags, such as polysaccharides, are large molecules
with repeating epitopes that are typically able to activate complement, but lack
the ability to induce MHC-dependent T cell help (95). In ideal form, TI-2 Ags
are

flexible,

non-degradable,

and

hydrophilic

molecules

capable

of

simultaneously engaging multiple B cell receptors (BCRs) (98). The molecular
structure

of

classical

TI-2

Ags

consists

of

a

non-immunogenic

backbone

exhibiting recurring immunogenic epitopes 95-675 Å apart. This periodicity
appears to be optimal for simultaneously engaging and cross-linking multiple
BCRs and rapidly inducing IgM responses (within 48 hrs) (98,210).
Follicular dendritic cells (FDCs) reside in the light zones of germinal
centers (GC) and retain Ags in the form of immune complexes (ICs). FDC-ICs
resist degradation and persist for months to years on numerous intertwining
dendrites. The non-mobile FDCs remain in the GCs where their intertwining
dendrites create extensive Ag retaining reticula (ARR) intimately in contact with
numerous mobile B cells (37,42). In GCs, which are typically involved in
refining humoral immunity to TD Ags, FDCs promote: B cell survival, Ig class
switching, somatic hypermutation, selection of somatically mutated B cells with
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high affinity receptors, affinity maturation, B memory production, and induction
of secondary IgG and IgE responses (29,35,38,46,69,112,114,185,186,211,212).
FDCs trap Ag in the form of ICs via Fc and C receptors although FcRs
are adequate to periodically arrange the ICs (34,44,70). In addition to Ag, FDCs
provide costimulatory signals to B cells. Both C3 (C3b) and C4 (C4b) engage
C4 binding protein (C4BP) which co-localizes with ICs on FDCs (59). C4BP in
ICs trapped on FDCs has been shown to signal B cells via CD40 independent of
T-cell derived CD40L (CD154) (59). Notably, injection of mice with FDC-M2,
which

recognizes

an

epitope

on

C4

bound

within

ICs,

inhibits

TI

GC

development (59). Moreover, C3- and C4-deficient mice showed impaired TI
Ab responses consistent with the concept that ICs on FDCs provide Ag-specific,
complement-derived, and CD40-mediated signals to B cells in TI GCs (59). In
addition, FDCs produce BAFF (B-cell activation factor of the TNF family) (6062) that also promotes TI B cell activation (213,214). The functional outcome of
BAFF

signaling

is

multifaceted

and

different

receptors

mediate

different

functions. Peripheral B cell survival, plasma cell survival, MZ B cell integrity,
GC maintenance, CD21 & CD23 expression, TI B cell responses and Ig class
switching all appear to be influenced by BAFF (64).
The Ags trapped in ICs on FDCs are typically TD and these Ags are
arranged periodically with characteristic 200-500 Å spacing on the cell surface
(24,34). The periodicity of ICs on FDCs was reported initially with ICs trapped
in vivo (24) followed by similar results in vitro (34). This periodicity of TD Ags
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in ICs on the surfaces of flexible FDC dendrites with 200-500 Å spacing
corresponds with recurring immunogenic epitopes 95-675 Å apart on a flexible
backbone of ideal TI-2 Ags (98,210). We reasoned that the periodically arranged
FDC-ICs would promote extensive BCR cross-linking and would induce rapid
TI IgM production when delivered in conjunction with cosignals mediated by
FDC-C4BP and/or FDC-BAFF.
To test the above hypothesis, ICs were used to load FDCs and B cells
were stimulated in vivo and in vitro in the absence of T cells or T cell factors.
Our data indicated that OVA-IC challenged nude mice produced OVA-specific
IgM within 48 hrs after IC challenge and the response was maintained for
weeks. In marked contrast, OVA in adjuvant induced no OVA specific IgM at
any time. The draining lymph nodes of these IC challenged mice exhibited well
developed

GL-7+

GCs

associated

with

FDC-

ARR and B lymphocyte-induced maturation protein-1+ (Blimp-1+) plasmablasts
within 48 hrs of IC administration and the GCs persisted for at least 7 days.
Moreover, purified FDCs loaded with OVA-IC induced purified human and
murine B cells to produce OVA-specific IgM in vitro in 48 hrs. We also tested
the postulate that anti-IgD mAb, which can not signal alone, will signal the vast
majority of B cells as a consequence of engaging multiple BCRs when loaded
on FDCs in the form of ICs. Evidences of in vitro B cell activation included
increased levels and redistribution of intracellular phosphotyrosine, expression
of the B cell activation marker GL-7, Blimp-1+ plasmablast differentiation, B
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cell proliferation and polyclonal IgM production within 48 hrs. This TI but
FDC-dependent IgM response was inhibited when FDC-FcγRIIB was blocked to
interfere with the ability to periodically arrange ICs. Similarly, neutralizing
FDC-C4BP or BAFF also inhibited this TI response.

In short, this study is the

first to report the ability of FDCs to convert TD Ags into TI Ags capable of
inducing B cell activation and Ig production in the absence of T cells or T cell
factors.
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Materials and Methods
Mice
Homozygous athymic NCr-nu/nu and heterozygous NCr-nu/+ mice were
purchased

from

The

National

Cancer

Institute

at

Frederick,

MD

(NCI-

Frederick). FDC networks develop in the presence of B cells but much faster in
normal mice with both T and B cells (215). Accordingly, the nu/nu mice used
were 9 months of age to be sure the time was adequate for FDC-networks to
fully develop. Mice were housed in standard plastic shoebox cages with filter
tops and maintained under specific pathogen-free conditions in accordance with
guidelines

established

by

Virginia

Commonwealth

University

Institutional

Animal Care and Use Committee.
Immunization
Homozygous nude (nu/nu) and heterozygous (nu/+) mice were injected
with 20 μg OVA, in each limb, in the form of (1) alum precipitated OVA
(Sigma-Aldrich, St. Louis, MO, A5503) with Bordetella pertussis, or (2) OVA
immune

complexes

(ICs)

made

of

NIP

(4-Hydroxy-3-iodo-5-

nitrophenylacetyl)-OVA (Biosearch Technologies, Novato, CA, N-5041-10)
+ goat polyclonal anti-tri-nitro-phenol Abs (Anti-TNP, Biomeda corp., Foster
City, CA, J05) or (3) OVA ICs made of alum precipitated NIP-OVA with
Bordetella pertussis + anti-TNP. Anti-TNP Abs effectively binds NIP forming
ICs with the NIP-OVA. Fifty μg azide-free functional grade purified anti-mouse
CD90 (Thy-1, eBioscience, 16-0901) were given IP per nude mouse 12 hrs
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before Ag challenge to inhibit residual T cell activity, especially γδ T cells, that
may be present in these animals. Animals were bled 48 hrs, 1 week and 2 weeks
after Ag challenge. Homozygous nu/nu mice were also bled after 7 weeks.
OVA-specific IgM and IgG were assessed in the collected sera and levels were
recorded after subtracting the pre-immunization background levels.
Confocal microscopy for GCs, FDC-reticula, and plasmablasts
Confocal

microscopy

was

used

to

assess

GC

development

and

plasmablast differentiation in association with FDC-ARR at 48 hrs and 7 days
after IC administration. To this end, groups of nu/nu mice were challenged with:
a) OVA-specific rabbit serum (Meridian Life Science Inc, Cincinnati, OH,
W59413R) + alum-precipitated OVA and B. pertussis or b) normal (nonspecific) rabbit serum (Gibco, Grand Islands, NY) + alum-precipitated OVA and
B. pertussis. Two and 7 days later, axillary lymph nodes (LNs) were collected
and frozen in CryoForm embedding medium (IEC). Frozen sections of 10-μm
thickness were cut on a Leica (Jung Frigocut 2800E) cryostat then air dried.
Following fixation in absolute acetone, the sections were blocked with 10%
horse serum and washed in phosphate buffered saline. Mid-saggital sections
were triple labeled with GL-7-FITC (BD Pharmingen, San Jose, CA, 553666)
(for GC B cells), B220-Cy5.5 (Pharmingen, San Jose, CA, 552771) (general B
cell marker), and Rhodamine Red-X-affinipure goat anti-rabbit IgG (Jackson
ImmunoResearch

Laboratories,

West

Grove,

PA,

111-295-144)

multiple

adsorbed to minimize any cross reactivity with mouse, rat and human serum
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proteins (to label the OVA ICs retained in the FDC reticulum). To label GCassociated plasmablasts, the Rhodamine Red-X-affinipure goat anti-rabbit IgG
was replaced with Blimp-1-PE (Santa Cruz Biotechnology Inc, Santa Cruz, CA.
sc-13203

PE).

Vectashield

Sections

(Vectashield,

were
Vector

mounted

with

anti-fade

Laboratories,

mounting

Burlingame,

medium,

Calif.),

cover-

slipped, and examined with a Leica TCS-SP2 AOBS confocal laser scanning
microscope fitted with an oil plan-apochromat 40X objective. Three lasers were
used, Argon (488 nm) for FITC, HeNe (543 nm) for Rhodamine-Red X or PE,
and HeNe (633nm) for Cy5.5 (shown as pseudo-color magenta). Parameters
were adjusted to scan at 512X512 pixel density and 8-bit pixel depth. Emissions
were recorded in 3 separate channels and digital images were captured and
processed with Leica Confocal and LCS Lite softwares.
In vitro stimulation of purified B cells with purified IC-bearing FDCs
Naïve “untouched” human B cells were purified by negative selection on
LS MACS separation columns using The Naive B Cell Isolation Kit II (Miltenyi
Biotec, Auburn, CA, 130-091-150). Murine B cells were purified by positive
selection using CD45R (B220) on LS MACS separation columns MicroBeads
(Miltenyi Biotec, Auburn, CA, 130-049-501).
FDCs were isolated by positive selection from LNs (axillary, lateral
axillary,

inguinal,

popliteal,

and

mesenteric)

of

irradiated

adult

mice,

as

previously described (130). In brief, one day before isolation, mice were
irradiated with 1000 rad to eliminate most lymphocytes, then sacrificed, and
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LNs were collected, opened, and treated with 1.5 ml of collagenase D (22
mg/ml, C-1088882; Roche), 0.5 ml of DNase I (5000 U/ml, D-4527; SigmaAldrich), and 2 ml of DMEM with 20 mM HEPES. After 45 min at 37°C in a
CO2 incubator, released cells were washed in 5 ml of DMEM with 10% FCS.
Cells were then sequentially incubated with FDC-specific Ab (FDC-M1) (BD
Pharmingen, San Jose, CA, 551320) for 45 min, 1 μg of biotinylated anti-rat κL
chain (BD Pharmingen, San Jose, CA, 553871), for 45 min, and 20 μl of antibiotin microbeads (Miltenyi Biotec, Auburn, CA, 130-090-485) for 15–20 min
on ice. The cells were layered on a MACS LS column and washed with 10 ml of
ice-cold MACS buffer. The column was removed from the VarioMACS, and the
bound FDCs were released with 5 ml of MACS buffer.
Purified

FDCs

were

loaded

with

100

ng/ml

OVA

ICs

made

of

OVA/rabbit anti-OVA at a ratio of 1:6. IC-loaded FDCs were used to stimulate
20x106 purified B cells at a ratio of 1FDC:2B cells. Cells were cultures in 10 ml
culture medium and OVA-specific Abs were assessed after 48 hrs.
The

rat

anti-mouse

IgD

mAb

clone

11-26

(SouthernBiotech,

Birmingham, Alabama, 1120-14) was selected because this mAb per se does not
induce proliferation of mature B cells in vitro, nor does it activate B cells in vivo
(216). Consequently, any ability of this mAb to activate B cells would be
attributable to the influence of FDCs. To load this mAb on FDCs it was
complexed

with

Fc-specific

rabbit

anti-rat

IgG

(Jackson

ImmunoResearch

Laboratories, West Grove, PA, 312-005-046) at a ratio of 1:4 and the ICs were
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incubated with purified FDCs. Anti-IgD ICs at doses of 0.1, 1.0, and 10 μg/ml
were used to load FDCs and used to stimulate 104, 105, and 106 purified murine
B cells in 1 ml cDMEM. Controls included B cells in the absence of FDCs with
free and complexed anti-IgD in the presence or absence of 10% Low Tox
Complement

(Cedarlane

Laboratories

Ltd.

Ontario,

Canada)

to

provide

complement-mediated co-stimulation as well as conditions where the B cell
FcγRIIB was blocked with azide-free anti-CD16/CD32 (mAb clone 2.4G2,
553140, BD Pharmingen, San Jose, CA) to minimize ITIM signaling. To assess
the role of FDC-FcγRIIB in IgM production by FDC-IC-stimulated B cells,
0.5x105 FDCs were treated with 1 μg/ml azide-free anti-CD16/CD32, prior to
loading with anti-IgD ICs. ICs were trapped with the complement receptors and
105 B cells were cultured with the IC-bearing FDCs. Culture supernatant fluids
were assessed after 48 hrs for polyclonal mouse IgM production by ELISA.
ELISA
Total

and

OVA-specific

IgM

were

assessed

in

sera

and

culture

supernatant fluids 48 hrs after stimulation of B cells with OVA or anti-IgD-ICbearing FDCs in vivo and in vitro. Samples were loaded on ninety-six well
plates coated with 100 μg/ml OVA (for OVA-specific Abs) or goat anti-mouse
IgM (for total IgM). Samples were left overnight, washed, and captured mouse
IgM

was

detected

streptavidin-alkaline

with

biotinylated

phosphatase.

goat

Alkaline
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anti-mouse

phosphatase

IgM
was

followed

developed

by
with

pNPP alkaline phosphatase substrate system (KPL, Gaithersburg, Maryland, 5080-00) and read on ELISA reader at 405 nm.
Assessment of FDC-BAFF production and the effect of neutralizing BAFF
and C4BP on IgM production by IC-stimulated B cells
One million purified FDCs were cultured in vitro for 48 hrs alone or with 100
ng/ml soluble OVA, OVA-ICs, or OVA-ICs, in the presence of 10 μg/ml FcR
blocker (2.4G2), or rat IgG2b isotype control. Culture supernatant fluids were
collected and BAFF production was assessed by ELISA using Quantikine
Mouse

BAFF/BLyS/TNFSF13B

Immunoassay

(R&D

Systems,

Inc.,

Minneapolis, MN, MBLYS0). To assess the effect of FDC-BAFF blockade on
IgM production by IC-stimulated B cells, B220 purified B cells were cultured
with anti-IgD IC-bearing FDCs at a ratio of 1 FDC:2 B cells in the presence of 1
μg/ml

decoy

recombinant

mouse

BAFF

R/TNFRSF13C/Fc

chimera,

(R&D

Systems, Inc., Minneapolis, MN, 1357-BR). Control conditions included B cells
alone, B cells + anti-IgD mAb, B cells + anti-IgD ICs, and B cells + anti-IgD
mAb + FDCs. FDC-M2 is a rat anti-mouse mAb that detects an epitope of C4
localized to the ICs trapped on FDCs (59,217). This anti-C4 appears to block
C4-bBP which is capable of interacting with CD40 on B cells (59). In mice
immunized with TNP-Ficoll, a TI-2 Ag, injection of FDC-M2 blocks the FDCIC-mediated CD40-dependent activation of follicular B cells and reduces TI GC
development by 90% (59). To test the effect of FDC-M2 on IgM production by
FDC-IC-stimulated B cells, 0.5x106 B220 purified B cells were stimulated with
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0.25x106 anti-IgD IC-bearing FDCs in the presence or absence of 1 μg/ml
C4BP-blocking FDC-M2 (from hybridoma cell line generously provided by Dr.
M. Kosco-Vilbois, NovImmune SA, Switzerland). Forty-eight hrs later culture
supernatants

were

Visualization

and

collected

and

assessed

quantification

of

for

mouse

intracellular

IgM

with

ELISA.

phosphotyrosine

in

stimulated B cells using confocal microscopy and flow cytometry
Purified B cells were stimulated with anti-IgD-IC-bearing FDCs for 45
minutes. Cells were washed, fixed, and permibilized using Fix & Perm cell
permeabilization

kit

detected

FITC-conjugated

with

(Caltag

Laboratories).

Intracellular

anti-phosphotyrosine,

phosphotyrosine

clone

4G10,

was

(Upstate

Biotechnology, Lake Placid, NY, 16045). Cells were washed and analyzed with
flow cytometry or deposited onto polylysine-coated glass slides for visualization
with confocal microscopy using argon beam emitting 488 nm laser.
Flow cytometric analysis of GL-7, Blimp-1, and CFSE labeling of B cells
stimulated with anti-IgD IC-bearing FDCs in vitro
Purified B cells were stimulated with anti-IgD IC-bearing FDCs for 48
hrs then assessed for GL-7 and Blimp-1 expression as well as B cell
proliferation

using

carboxyfluorescein

diacetate,

succinimidyl

ester

(CFSE)

dilution assay. To assess GL-7 expression, cells were washed, blocked with Fcblocker to reduce non-specific binding of GL-7 to the Fcγ receptors, labeled
with FITC-conjugated anti-B-cell activation antigen (GL-7), or isotype control
rat IgM-FITC (BD Pharmingen, San Jose, CA, 553942). An unstimulated B cell
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control was similarly treated and GL-7 expression was assessed by flow
cytometry. For intracellular Blimp-1 assessment, purified B cells stimulated
with anti-IgD-IC-bearing FDCs for 48 hrs, were washed, fixed, and permibilized
using Fix & Perm cell permeabilization kit (Caltag Laboratories). Intracellular
Blimp-1

was

labeled

with

PE-conjugated

anti-Blimp-1(Santa

Cruz

Biotechnology Inc, Santa Cruz, CA. sc-13203 PE) then cells were washed and
analyzed with flow cytometry. B cell proliferation was assessed by The
CellTrace™ CFSE Cell Proliferation Kit (C34554, Invitrogen) following the
protocol of the manufacturer. The working range of CFSE is 0.5-25 μM/ml,
however, 1 μM CFSE/106 cells/ml was satisfactory and avoided toxicity that
occasionally occurs with high concentrations of DMSO that was used as a CFSE
solvent. After labeling, data were collected using FC500 Flow Cytometer
Beckman Coulter, analyzed using Cytomics RXP analysis software, and plotted
using WinMDI software (Scripps Research Institute).
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Results
Nude mice challenged with OVA-ICs but not OVA mounted OVA-specific IgM
responses
If periodically arranged FDC-ICs can induce specific IgM in the absence
of T cells, then nude mice should rapidly produce specific IgM when challenged
with a TD Ag in the form of ICs but not with free Ag. This hypothesis was
tested in nu/nu mice given 50 μg of α-Thy-1, to block any residual T cell
activity, and challenged with OVA in adjuvant or OVA in ICs with or without
adjuvant. As expected, anti-OVA was not detectible in animals immunized with
OVA over a 7 week period even with adjuvant (Fig. 1-A). In marked contrast,
OVA-specific IgM was present in the sera of all ICs injected animals with or
without adjuvant in just 48 hrs. The highest OVA-IgM levels were induced
using OVA-ICs in adjuvant and these IgM levels were maintained over a 7 week
assessment period. The adjuvant effect was expected, given that LPS activates
FDCs

and

promote

their

accessory

activity

(71).

Phenotypically

normal

heterozygous nu/+ mice also responded to ICs by producing OVA-specific IgM
within 48 hrs (Fig. 1-B), although, these IgM levels declined as the isotype
switched from OVA specific IgM to IgG, in the presence of T cell help (Fig. 1C).
GCs in nude mice are associated with well-developed ARR and plasmablasts
Rapid

induction

of

OVA-specific

IgM

responses

in

nu/nu

mice

challenged with OVA-ICs prompted study of GC development and plasmablast
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differentiation in their draining lymph nodes. As expected for a TD protein Ag,
GCs were not detected at day 2 or at day 7 in nu/nu mice challenged with OVA
+ adjuvant in the presence of non-specific rabbit serum where ICs would not
form (Fig. 2-A). The B cell follicles labeled with B220 (magenta) but not with
the GC B cell marker GL-7 (green). In marked contrast, the follicles in nu/nu
mice challenged with OVA-ICs developed large GCs within 48 hrs and these
persisted for at least one week (Fig. 2-B). The overlay of B220 and GL-7
illustrated a GL-7 bright GC B cell zone surrounded by a zone of resting B220
bright B cells. Note the activation marker GL-7 corresponds with an area of dim
B220 labeling since activated B cells tend to down regulate B220 upon
acquisition of the GL-7+ phenotype (218). In Fig. 2-C, labeling with anti-rabbit
IgG (binds rabbit IgG in OVA + rabbit-anti-OVA IgG ICs) revealed welldeveloped crescent-shaped FDC-ARR at day 2 and day 7. A funnel-shaped Ag
transport site extending from the sub-capsular sinus into the lymph node cortex
was seen in association with the ARR illustrated at day 7 (37). As shown in the
overlay, the green GC is capped with the ARR in red and this overlapping
orange-yellow interface represents the GC light zone.
The vigorous OVA specific IgM responses in nu/nu mice suggested that
challenge with OVA ICs would induce plasmablasts and plasma cells, which
label with Blimp-1. As shown in Fig. 2-D, Blimp-1 positive cells were found at
the paracortical borders of multiple GCs (red) with a group migrated toward the
medullary cords deeper in the node. These cells were also GL-7+ and the overlay
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of Blimp-1 (red) and GL-7 (green) resulted in orange-colored cells suggesting
that these cells are plamablasts. We reason that these cells are migrating toward
the medullary cords and bone marrow where they would be expected to mature
into plasma cells that would no longer label with GL-7.
Purified OVA IC-bearing FDCs induced OVA-specific IgM production by
purified B cells within 48 hrs in the absence of T cells and T cell factors
If periodically arranged FDC-ICs can induce specific IgM in the absence of T
cells or T cell factors; then purified FDCs should rapidly stimulate specific IgM
by purified naïve B cells in vitro if they bear Ag in ICs but not with free TD Ag.
FDC-B cell interactions are not MHC or species restricted and murine FDCs can
stimulate human B cells effectively (56). Purified murine (Fig. 3-A) or human
(Fig. 3-B) B cells in cultures lacking T cells and T cell factors produced OVAspecific IgM in 48 hrs when stimulated with FDCs bearing OVA ICs. Both the
kinetics of the response and the IgM production are consistent with a Tindependent response. Control conditions, that failed to produce a detectable
response, included FDCs with B cells stimulated with free OVA that would have
unfettered access to BCR.
Purified B cells were signaled by FDCs bearing anti-IgD-ICs as indicated by
intracellular

phosphotyrosine

distribution,

expression

of

activation

marker

GL-7, plasmablast differentiation, and B cell proliferation
If Ags in FDC-ICs promote simultaneous binding and cross-linking of
multiple BCRs, as we hypothesize, then anti-IgD loaded on FDCs in the form of
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Figure 1: Nude mice challenged with OVA ICs, but not with OVA, mounted OVAspecific immune responses in 48 h. A, Groups of nu/nu mice, pretreated with 50 µg of
anti-Thy-1 to block residual T cell activity, were challenged with alum-precipitated OVA
with B. pertussis, OVA-ICs, or OVA-ICs with B. pertussis. Serum anti-OVA IgM levels
were determined 48 h, 1 wk, and 2 wk later, and results were recorded after subtracting
background levels using preimmunization sera. As expected, anti-OVA was not
detectible in animals immunized with OVA in adjuvant (baseline tracking). In marked
contrast, OVA-specific IgM was present in the sera of all IC-injected animals with or
without adjuvant in just 48 h and was maintained over a 7-wk assessment period. B,
Phenotypically normal heterozygous nu/+ mice with competent T cell compartment also
responded to ICs by producing OVA-specific IgM within 48 h, although these IgM levels
declined over time. C, The phenotypically normal nu/+ also produced IgG, and the
increase in this isotype correlated with a decrease in IgM. Note that neither class
switching nor OVA-specific IgG was detectable in nu/nu mice lacking T cell help
(baseline tracking). Data are represented as mean ± SD.
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Figure 2: Robust GC and plasmablast responses were induced in nude mice by OVAICs in 48 h and sustained for at least 1 wk in association with IC-retaining FDCreticula. Groups of nu/nu mice were challenged with OVA-specific rabbit serum or
normal (nonspecific) rabbit serum plus alum-precipitated OVA and B. pertussis. Two and
7 days later, mid-saggittal sections from axillary LNs were triple labeled with GL-7-FITC
(green, GC-B cells), B220-Cy5.5 (magenta, pan-B cell marker), and Rhodamine Red Xgoat anti-rabbit IgG (red, OVA-ICs in FDC-reticulum). GC-associated plasmablasts were
labeled with anti-Blimp-1-PE (red). A, GCs were not detected in athymic nu/nu mice
challenged with OVA and adjuvant at days 2 or 7. The B cell follicles labeled well with
B220 (magenta) but not with the GC B cell marker GL-7 (green); thus, the overlay
(B220/GL-7) was magenta. B, As early as 48 h, nu/nu mice challenged with OVA-ICs
exhibited large GCs that were maintained at least for 1 wk. The GL-7bright B cells (green)
correspond with an area of B220dim labeling (magenta). The overlay (B220/GL-7)
illustrates GL-7bright GC B cells surrounded by a zone of resting B220bright B cells. C,
Labeling with anti-rabbit IgG revealed well-developed, crescent-shaped, ARR (red) both
at days 2 and 7. Funnel-shaped Ag transport site extending from the subcapsular sinus
(indicated in this illustration by a red left bracket in the 7 day data) was seen in
continuation with the ARR. In the overlay of the ARR and the GL-7, the GL-7+ GC B
cells (green) were seen capped with the ARR (red) and the light zone of the GC where
the FDC-ARR (red) overlapped with the GC B cells (green) appeared orange-yellow
(areas between orange arrows). D, Blimp-1+ plasmablasts were found at the paracortical
borders of multiple GCs (red arrowheads) both at days 2 and 7, and some migrated
toward the medullary cords deeper in the node (green arrowheads). These cells were also
GL-7+ (green) giving an orange overlay (yellow arrows).
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Figure 3: Purified OVA-IC-bearing FDCs induced OVA-specific IgM production by
purified B cells within 48 h in the absence of T cells. Purified murine or human B cells
were incubated with purified OVA-IC-loaded FDCs at a ratio of 1FDC:2B cells, and
OVA-specific Abs were assessed after 48 h. Murine (A) and human (B) B cells stimulated
with FDCs bearing OVA ICs produced OVA-specific IgM in 48 h. Control conditions
that failed to produce a detectable response included FDCs with B cells stimulated with
free OVA that would have had free access to BCRs. Data are represented as mean ± SD
and are representative of two experiments of this type.
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ICs should engage multiple BCRs and induce signaling in the vast majority of B
cells. B cell signaling may be indicated by increases in and redistribution of
intracellular phosphotyrosine in the form of patches (patching) and owing to cell
motility and cell surface fluidity such patches can aggregate to one pole of the
cell in the form of caps (capping) (219,220). The anti-IgD mAb (rat anti-mouse
IgD clone 11-26) was selected for study because, among a number of rat antimouse IgD mAbs tested, clone 11-26 does not induce B cell activation (216).
This mAb was complexed with Fc-specific rabbit anti-rat IgG (leaving the Fabs
free to engage BCRs) and loaded on the surface of FDCs. As shown in Fig. 4-A,
phosphotyrosine

labeling

in

unstimulated

B

cells

was

low

and

evenly

distributed. In marked contrast, B cells stimulated with FDCs bearing anti-IgD
ICs (Fig. 4-B) labeled more intensely and the phosphotyrosine was capped
(fluorescence localized at one pole of the cell surface), or patched on the
membrane

indicating

a

marked

redistribution.

Most

B

cells

exhibited

the

patched or capped intracellular phosphotyrosine pattern consistent with being
signaled (Fig. 4-C). Moreover, flow cytometric analysis (Fig. 4-D) confirmed
that

the

B

cells

exhibited

higher

levels

of

intracellular

phosphotyrosine

(increased MFI) and the entire B cell population had clearly shifted to the right
suggesting that virtually the entire B cell population had been signaled by antiIgD

bearing

FDCs.

High

magnification

imaging

revealed

that

the

phosphotyrosine labeling (green) was intense at areas of contact between the B
cell membrane and the AMCA-labeled IC-bearing FDCs (blue) (Fig. 4-E). In
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addition, the activation marker GL-7 was induced when B cells were stimulated
with anti-IgD IC-bearing FDCs in vitro (Fig. 4-F). Note the shift to the right,
indicating increased GL-7 expression, when B cells were stimulated with antiIgD IC-bearing FDCs. The MFI on the highest 33% of FDC-IC-stimulated B
cells was almost 4 times that of the unstimulated B cell control. Blimp-1
expression was also induced by IC-bearing FDCs in vitro within 48 hrs. About
0.6% of B cells expressed Blimp-1 in control cultures lacking anti-IgD ICbearing FDCs (Fig. 4-G), however, the addition of anti-IgD IC-bearing FDCs,
(Fig. 4-H), induced a 4-fold increase (2.4%) and many cells showed high Blimp1 levels. Moreover, B cell proliferation was induced by IC-bearing FDCs in
vitro within 48 hrs. The response was IC-dependent since purified B cells
cultured with FDCs alone (Fig. 4-I) or FDCs in addition to the mAb rat anti-mIgD (Fig. 4-J) did not divide. In contrast, 30% of B cells stimulated with antiIgD IC-bearing FDCs showed up to two rounds of division within 48 hrs in the
absence of T cell and T cell factors (Fig. 4-K).
Purified B cells stimulated with anti-IgD-IC-bearing FDCs produced IgM
within 48 hrs
Given that B cells are signaled by anti-IgD ICs on FDCs, we reasoned
that the simultaneous engagement of multiple B cell receptors should signal, at
least some B cells adequately, to rapidly produce IgM. Moreover, this should be
possible in the absence of T cells or T cell factors as was seen in Fig. 3 with
OVA ICs. As illustrated in Fig. 5-A, free anti-IgD, or anti-IgD-ICs alone, or in
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the presence of complement-mediated accessory signals did not stimulate IgM
production. Blockade of B cell-FcγRIIB to minimize ITIM signaling did not
alter the lack of responsiveness. In marked contrast, anti-IgD-ICs loaded on
FDCs stimulated polyclonal B cell IgM production within 48 hrs. This response
was B cell number dependent (1x104 - 1x106) as shown in Fig. 5-B but
increasing doses of anti-IgD-ICs (0.1-10 μg/ml) did not improve IgM responses,
indicating that 100 ng anti-IgD-ICs was an adequate agonist level.
Blockade of FDC-FcγRIIB, -C4BP, and –BAFF significantly inhibited IgM
production by FDC-IC-stimulated B cells
We reasoned that the mechanism underpinning the TI FDC-dependent
Ab response would require that FDCs deliver both primary and secondary
signals to B cells.

Periodically arranged Ag is thought to provide the first signal

and FDC-FcγRIIB appears to be important in periodically arranging ICs such
that extensive cross-linking of multiple BCRs can occur (34).

As shown in Fig.

6, blockade of FDC-FcγRIIB with 2.4G2 and loading anti-IgD ICs on FDCs via
complement receptors resulted in a significant inhibition of IgM production by
FDC-IC-stimulated B cells (Fig. 6-A). Secondary signals in the form of FDCC4BP and -BAFF are believed to promote B cell activation, proliferation and
IgM secretion. Blockade of FDC-C4BP with FDC-M2 (Fig. 6-B) resulted in
~75% reduction in the IgM response suggesting that engagement of B cell CD40
is a critical part of the induction mechanism.

Furthermore, FDCs produce BAFF

and the level of FDC-BAFF produced was enhanced by the addition of OVA
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ICs (Fig. 6-C), and this enhancement was abrogated by the FcR blocker 2.4G2
as previously reported for FDC-ICAM and VCAM (70). Addition of the decoyBAFF-R-Fc (Fig 6-D) resulted in 20% inhibition of IgM production [from 633 +
17 to 503 + 58 with p value <0.02] by the FDC-IC-stimulated B cells indicating
that FDC-BAFF, together with FDC-FcγRIIB and –C4BP, play important roles
in the mechanism involved in the FDC-dependent induction of TI Ab responses
to T-dependent Ags.
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Figure 4: B cell signaling induced by FDC-anti-IgD-ICs in vitro was indicated by
intracellular phosphotyrosine distribution, expression of activation marker GL-7,
plasmablast differentiation, and B cell proliferation. Purified B cells were stimulated
with anti-IgD-IC-bearing FDCs for 45 min, and the distribution of phosphotyrosine was
analyzed. A, Phosphotyrosine labeling in unstimulated B cells was low and evenly
distributed when visualization with confocal microscopy. B, FDC-ICs led to B cell
signaling, as indicated by increases in and redistribution of intracellular phosphotyrosine
in the form of patches (magenta arrowhead) and caps (yellow arrowhead). C, Most B
cells exhibited the patched or capped intracellular phosphotyrosine pattern, consistent
with being signaled. D, Flow cytometric analysis indicated that the entire B cell
population had shifted to the right, suggesting that virtually all B cells had been signaled
by anti-IgD-bearing FDCs, resulting in increased intracellular levels of phosphotyrosine.
E, High magnification imaging revealed that the phosphotyrosine labeling (green) was
intense at areas of contact (white arrowheads) between the B cell membrane and the 7amino-4-methylcoumarin-3-acetic acid-labeled ICs on FDCs (blue). F, Purified B cells
were stimulated with anti-IgD IC-bearing FDCs for 48 h and labeled with anti-GL-7 or
isotype control, and GL-7 expression was assessed by flow cytometry. Compared with
the isotype control (red, MFI = 2) and the unstimulated B cell control (black, MFI = 2.5),
B cells stimulated with anti-IgD IC-bearing FDCs (green) shifted to the right indicating
increased GL-7 expression and an MFI of 9.0 on the highest 33% of activated B cells. G
and H, Purified B cells were incubated for 48 h alone or with anti-IgD IC-bearing FDCs
and labeled with PE-conjugated anti-Blimp-1. Approximately 0.6% of the isolated B cells
expressed Blimp-1 (G). However, the addition of anti-IgD IC-bearing FDCs (H) induced
a 4-fold increase (2.4%), and many cells in H were in the second and third decades of the
Blimp-1-PE (y)-axis, indicating high Blimp-1 expression. I–K, Purified B cells cultured
with FDCs alone (I) or FDCs in addition to the mAb rat anti-m-IgD (J) did not divide,
whereas 30% of B cells stimulated with anti-IgD IC-bearing FDCs showed up to two
rounds of division within 48 h in the absence of T cell and T cell factors (K). All results
are representative of at least three separate experiments.
175

176

Figure 5: Purified FDCs bearing anti-IgD-ICs on their surfaces induced IgM
production by purified B cells within 48 h in a B cell number-dependent manner. The
rat anti-mouse IgD mAb clone 11–26, which does not per se induce proliferation of
mature B cells in vitro nor activate B cells in vivo, was complexed with Fc-specific rabbit
anti-rat IgG. A, Purified B cells (105) were cultured under different conditions, and IgM
production was assessed by ELISA 48 h later. As expected, free anti-IgD mAb (1 µg), or
anti-IgD-ICs alone, or in the presence of complement-mediated accessory signals did not
stimulate IgM production, and blockade of B cell-FcγRIIB to minimize ITIM signaling
did not alter the lack of responsiveness. However, anti-IgD-ICs loaded on FDCs
stimulated polyclonal B cell IgM production within 48 h. B shows that the IgM response
was B cell number dependent and that 100 ng of anti-IgD loaded as ICs on FDCs was an
adequate stimulus. Data are represented as mean ± SD and are representative of three
experiments of this type.
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Figure 6: Blockade of FDC-FcγRIIB, -C4BP, and -BAFF significantly inhibited IgM
production by FDC-IC-stimulated B cells. A, FDC-FcγRIIB was blocked with 2.4G2,
and anti-IgD ICs, incubated in 10% Low Tox Complement, were trapped using
complement receptors. Anti-IgD ICs did not stimulate B cells in the absence of FDCs,
and IgM production by FDC-IC-stimulated B cells was significantly inhibited by
blockade of FDC-FcγRIIB, which is involved in the periodicity of ICs. B, Half million
B220-purified B cells were stimulated with 0.25 x 106 anti-IgD IC-bearing FDCs in the
presence or absence of 1 µg/ml C4BP-blocking FDC-M2 for 48 h, then IgM production
was assessed by ELISA. The addition of FDC-M2 resulted in ~75% reduction in IgM
production. Control conditions of B cells alone, and B cells plus anti-IgD ICs, did not
stimulate IgM production by purified B cells. C, One million FDCs were cultured for 48
h, and BAFF production was assessed. Addition of 100 ng/ml soluble OVA (OVA Ag)
did not significantly increase BAFF production over levels produced by FDCs alone.
Addition of OVA in the form of ICs significantly increased BAFF production by FDCs (p
< 0.001). This enhancement was minimized by the addition 10 µg/ml FcR blocker 2.4G2
(p < 0.005 for FDCs + OVA-ICs vs FDCs + 2.4G2 + OVA-ICs). Replacement of 2.4G2
with its isotype control rat IgG2b restored the enhancement (p = 0.2 for FDCs + OVAICs vs FDCs + isotype Ctrl + OVA-ICs, and p < 0.01 for FDCs + 2.4G2 + OVA-ICs vs
FDCs + isotype Ctrl + OVA-ICs). D, One million B220-purified B cells were stimulated
with 0.5 x 106 anti-IgD IC-bearing FDCs in the presence or absence of 1 µg/ml decoy
BAFF-R-Fc for 48 h; then, IgM production was assessed by ELISA. Addition of the
decoy-BAFF-R-Fc resulted in 20% inhibition of IgM production (from 633 ± 17 to 503 ±
58 with p < 0.02). Control conditions of B cells alone, B cells plus anti-IgD mAb, B cells
plus anti-IgD ICs, and B cells plus anti-IgD mAb plus FDCs did not result in B cell
stimulation and IgM production, indicating the importance of FDC-ICs in the IgM
response. Data are represented as mean ± SD and are representative of three experiments
of this type.
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Discussion
The data presented here support the novel concept that FDCs can convert
TD Ags into TI Ags capable of inducing specific IgM responses in 48 hrs or
less. We were prompted to test this concept after: 1) observing TD-Ags in ICs
on FDCs periodically spaced 200-500 Å apart (24,34), which is consistent with
recurring epitopes 95-675 Å apart on the flexible backbone of an ideal TI-2 Ag
(98,210); 2) noting the ability of FDCs to provide BAFF and C4BP which are
known to support TI B cell activation (59-62,213,214). These relationships are
illustrated in the model shown in Fig. 7, and more details are provided in the
figure legend. We report here that nude mice, pre-treated with anti-Thy-1 to
minimize any residual T cell activity, responded to ICs by producing specific
IgM in 48 hrs while free Ag in adjuvant did not induce IgM in nude mice even
after many weeks. In contrast, normal mice challenged with Ag in adjuvant
induced detectible IgM in 4 days followed by IgG (Data not shown), and
phenotypically normal nu/+ mice injected with ICs exhibited the rapid IgM
response followed by a switch to IgG, which we attribute to T cell help that is
lacking in the nu/nu mice (Fig. 1). Moreover, the draining lymph nodes of ICchallenged nude mice exhibited well developed GL-7+ GCs associated with
ARR and Blimp-1+ plasmablasts within 48 hrs that persisted for at least one
week, further supporting the concept that B cells in the follicles are stimulated
by the ICs on FDCs. In contrast, GCs and plasmablasts were lacking in Ag
immunized nude controls where the B cells remained in the resting state
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consistent with the lack of T cell help. TI-2 Ags have been used to load FDCs
and induce GCs in animals lacking cognate T & B cell interactions. When mice
with mutations that inactivate the TCR Cβ and Cδ genes were immunized with
4-hydroxy-3-nitrophenylacetyl

(NP)-Ficoll,

GCs

with

peanut

agglutinin-binding

B cells were observed in the splenic follicles. These GCs contained mature ICbearing FDCs and although they were rapidly induced, their duration was short
(104). We reason that engagement of FDC-FcγRIIB by IgG-TD Ag ICs induces
FDC activation and production of FDC-BAFF and other trophic factors that
maintain GCs. These in vivo studies were supported by in vitro experiments
where highly purified IC-bearing FDCs and naïve B cells from humans or mice
were co-cultured in the absence of T cells or T cell factors. B cells stimulated
with IC-bearing FDCs in these cultures produced specific IgM in 48 hrs while
no response was observed when ICs were replaced with free Ag. Both the
kinetics of the response and the IgM production are consistent with TI
responses. Furthermore, rat anti-mouse IgD mAb clone 11-26, which by itself
does not activate B cells (216), became a potent B cell activator when loaded on
FDCs in the form of ICs capable of simultaneously binding and cross-linking
multiple BCRs. Within 48 hrs, activation was indicated by increased tyrosine
phosphorylation in virtually all B cells along with patching and capping together
with expression of the B cell activation marker GL-7, Blimp-1+ plasmablast
differentiation, and B cell proliferation assessed by the CFSE dilution assay.
Moreover, this signaling appeared to be productive in that FDCs bearing those
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Figure 7: Model illustrating FDC-dependent, T-independent B cell activation and Ig
production. A, Monomeric proteins generally express only a single copy of each
antigenic determinant, making them unable to cross-link multiple BCRs and activate B
cells in the absence of T cell help. B, TI-2 Ags contain numerous periodically arranged
epitopes (green protrusions) attached to a flexible backbone (red curve). This
arrangement allows extensive simultaneous cross-linking of BCRs (Y-shaped green). The
multiple BCR cross-linking delivers a signal leading to B cell activation and Ig
production. C, FDCs express high levels of FcγRIIB (red) and CRs (blue), which trap ICs
containing TD Ags (multicolor clusters). ICs loaded via FcγRIIB alone exhibited
periodicity of 200–500 Å apart (18 ), and we reasoned that this spatial arrangement
would allow cross-linking of multiple BCRs specific for a single epitope, leading to B
cell activation and Ig production as in B. D, Transmission electron micrograph showing
HRP (a TD Ag) retained on the FDC surface in IC clusters 200–500 Å apart. This
facilitates BCR cross-linking and B cell activation as explained in B and C. E, FDCs
accessory activity includes secondary signals or cosignals that promote B cell activation
and Ig production. Specifically, FDC-derived BAFF (22 44 ) ligates BAFF receptors on
B cells, and FDC-derived C4BP (21 ) ligates B cell-CD40, which is a classical cosignal
in B cell activation. F, B cells stimulated with IC-bearing FDCs, FDC-BAFF, and FDCC4BP rapidly differentiate into plasma cells and secrete Ag-specific IgM.
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ICs induced polyclonal IgM in 48 hrs consistent with a TI response. Thus, we
conclude that TD Ags in the form of ICs can induce specific IgM responses in
an FDC-dependent but T cell independent fashion.
The concept that TD proteins can trigger B cells when appropriately
arranged is supported by a number of reports in the literature. Studies on the
requirements for generation of Ab responses to repetitive determinants on
polymers, polysaccharides and higher order structures such as viral capsid
proteins indicated that high molecular weight arrays of Ag are efficient in
eliciting an Ab response independent of T-cell help, whereas their less ordered
counterparts are less immunogenic and require T-cell help (97,221,221,222).
Certain

bacteria,

viruses,

mammalian

cells,

some

polymeric

proteins

like

collagen, and hapten-protein complexes have repeating antigenic determinants.
The multivalent presentation of antigenic determinants extensively cross-links
BCRs and leads to B cell activation, proliferation, and Ig secretion that is
characteristic of TI-2 responses. For example, multimerization of monomeric
proteins by aggregation facilitates presentation of their Ag determinants in a
highly arrayed structure fit for cross-linking BCRs and inducing Ab responses in
the absence of T cell help (222).
In addition, FDCs deliver secondary or co-stimulatory signals to B cells
and the data presented here provide support for the involvement of FDC-C4BP
that signals via B cell CD40, and FDC-BAFF that engages the B cell BAFF
receptor. A role for other FDC molecules involved in signaling has not been
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ruled out. For example, CD21L on FDCs engages CD21 in the B cell coreceptor complex and CD21L-CD21 interactions not only promote Ag specific
recall responses but also polyclonal responses induced by LPS (29,223). In
addition, FDC-8D6 as well as BAFF inhibit B cell apoptosis (60,63,65,114,115);
FDCs block IC mediated ITIM signaling in B cells via FcγRIIB and minimize
this inhibitory pathway (30,57,58), and FDCs provide IL-6 for terminal B cell
differentiation (68).
Classic TI-2 Ags induce robust responses in splenic marginal zones
(MZs) while lymph nodes are not heavily involved (224). In this respect, the
reported FDC-dependent T-independent response appears to differ from classic
TI-2 Ags. ICs are loaded on FDCs within minutes after Ag challenge (37) and
follicular B cells appear to be heavily involved (Fig. 2). Lymph node responses
are robust with GCs and plasmablasts apparent within 48 hrs. However, a role
for other B cell subsets that can interact with the ICs in the FDC-ARR has not
been ruled out. The anatomical proximity of the MZ to the splenic B cell
follicles, where FDCs reside in the spleen, make it likely that a dynamic
interaction between both compartments exists. An elegant commentary recently
published on the follicular dimension of MZ B cells concluded with the a
question whether MZ-B cells can be triggered to respond to Ags on FDCs when
they visit the splenic follicles or not (225) and we plan to extend this work and
test this possibility.
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Responses to classical TI antigens appear to be more robust when T cells
are present (97). The reported FDC-dependent TI response appears to be similar
in that the 48 hr IgM responses in nu/+ mice were higher than in nu/nu mice
(Fig. 1). Moreover, IgM production induced by FDC-ICs in vitro was also
significantly enhanced at 48 hrs in the presence of normal T cells (Data not
shown). The enhanced IgM response that occurs within 48 hrs is not likely
attributable to MHC class II-restricted T-cell help as a period of ~48 hrs is
needed before primed T cells are able to provide cognate T cell help.

However,

cytokines and other T cell derived trophic factors may be present. For example,
activated FDCs produce BAFF, IL-6, and IL-15 and these cytokines can rapidly
induce cytokine production by conventional T cells (226-230). Moreover, NK T
cells and γδT cells that mediate non-MHC class II-restricted non-cognate help
may be a source of B cell activation factors within 48 hrs. We were impressed
by the decline in IgM titers in nu/+ mice and we suspect that this will continue
and this contrasts with the nu/nu mice that maintained their IgM for 7 weeks.
The short time required to induce FDC-dependent TI IgM responses may
have practical application. IgM is the first class of antibodies produced during a
primary Ab response and it plays important roles in host protection [reviewed in
(231)].

Moreover,

its

multimeric

structure

makes

it

a

strong

complement

activator; a single bound IgM pentamer can trigger the classical pathway of
complement activation and can lyse a red blood cell, while approximately a
thousand IgG molecules are required to accomplish the same (232). In synergy
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with complement, IgM offers immediate protection to systemic bacterial and
viral infections (3) and patients with normal IgG levels but selective IgM
deficiency

suffer

from

morbid

recurrent

upper

respiratory

tract

infections,

asthma, celiac disease, and meningitis (233,234). Other potential applications
include countering the negative effect of regulatory T cells and the nonresponder state as a consequence of a limited MHC-II repertoire that may be
unable to load certain peptides. We reason that individuals who fail to respond
to a vaccine, as a consequence of problems with Ag presenting cells or the effect
of

T

regulatory

cells,

should

mount

rapid

specific

IgM

responses

when

immunized with appropriate ICs. The ICs should load on FDCs and bypass
limitations imposed by MHC and T cells. Similarly, specific IgM responses
should be inducible in animals or people with congenital and/or acquired T cell
insufficiencies (235,236) including HIV infected (237), aged (238), diabetic
(239), uremic (240) and neonates (241,242). We look forward to experiments
designed to test these postulates.
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CHAPTER 6
In vitro Induction of Human Primary Antibody Responses: A
Novel Model for Rapid Vaccine Assessment
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Introduction
In vivo studies of human immune responses to therapies and vaccines are
limited by technical and ethical considerations. Studies with closely related nonhuman primates are confronted by problems such as the high cost, limited
availability,

paucity

of

genetic

models

for

human

diseases,

and

lack

of

genetically inbred strains suitable for stem cell or tissue transplantation. Studies
in mice have been helpful in demonstrating the feasibility of stem cell
transplantation and some other therapies; but, rodents are not humans, and
human-related studies carried out solely in mice might not accurately predict the
real outcome in humans.
Inspite of progress that has been achieved since the inception of these
models, major limitations prevent them from being fully representative of the
human immune system. For example, the mouse thymus lacks the expression of
HLA class I and II, which is required for the selection of T cells after human
stem cell (HSC) engraftment. And inspite of the recent approach of transgenic
expression of human HLA molecules in mice engrafted with HSCs, the limited
diversity in the human major and minor histocompatibility alleles that can be
expressed in a mouse, renders these optimized models inadequate to fully
represent the human system (243).
The initiation of an adaptive immune response in vivo is dependent not
only on an efficient cross talk between the major players of the immune system,
but also on a highly compatible and competent interaction between the immune
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system cells and other molecules and non-immune cells, such as the stromal
cells in primary and secondary lymphoid tissues. Despite the recent reports by
the

Garcia

group,

where

humanized

mice

intrarectally

infected

with

HIV

showed depletion of T cells similar to humans, there was a significant difference
in the phenotype of T cells in the humanized mice guts if compared to human
gut CD4+T cells. T cells in the humanized mice guts showed low levels of
CXCR4, compared to the co-expression of CCR5 and CXCR4 by human gut
CD4+ T cells (244,245).
Several attempts have been made to further manipulate the humanized
mouse model to render it physiologically close enough to fully represent the
human systems. One approach was the addition of human endothelium, growth
factors, and chemokines, which might help promote the appropriate trafficking
and expansion of human cells. Another approach was to engraft artificial lymph
nodes consisting of biocompatible scaffolds containing human stromal cells in
the humanized mouse models (243).
However, even the optimized humanized mouse model does not solve
the problem of the variation in the individual human immune responses to
certain vaccines. Each person’s immune cells would be needed in a separate
mouse model to faithfully predict specifically his/her response to a tested
vaccine. The inpracticality of this approach and the increased desire for the
reduction of the number of animals used to test vaccines, the animal suffering,
and finding replacement methods for the biological quality control testing of the
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human vaccines argues for the development of an efficient human in vitro
immune system response-testing model.
Unfortunately,

induction

of

specific

primary

human

antibody

(Ab)

responses in vitro has been challenging (246-252). This is attributable, at least in
part, to the natural scarcity of antigen (Ag)-specific T and B cells in nonimmune individuals as well as the complexity of circuits controlling lymphocyte
activation and proliferation (253)..
The functional element of a human lymph node or spleen is the follicle,
which

develops

a

germinal

center

(GC)

when

stimulated

by

antigen

(11,106,107,125,187,188,218,254-258). The GC is the "hot spot" in the lymph
node or spleen where critical interactions take place in developing an effective
humoral immune response. Upon antigen stimulation, follicles are replicated and
an

active

human

lymph

node

can

have

dozens

of

active

follicles

with

functioning GCs. Interactions between B cells, T cells, and follicular dendritic
cells (FDCs) take place in GCs.

These interactions result in stimulation of Ab

specific B cells, Ig class switching, somatic hypermutation, and the selection of
high affinity B cells responsible for affinity maturation and the production of
high quality Ab (35,39).
In this study, we sought to design in vitro GCs to examine humoral
responses to vaccines.

Succinctly, while T cells are necessary for B cell

responses to T dependent Ags, they are not sufficient for the development of
fully functional and mature Ab responses that are required to assess most
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vaccines. FDCs provide critical assistance needed for the B cells to achieve their
full potential and accessory functions of FDCs and regulation of these functions
is critical to an understanding of fully functional and mature Ab responses
(35,38,40,44,45,159,259).
Mature

Ab

responses

involve

dendritic

cell

(DC)

maturation,

Ag

processing, MHC-restricted Ag presentation, CD4+ T cell priming, B cell
activation, immune complex (IC) formation, IC trapping by FDCs, FDC-B cell
interactions

leading

to

clonal

selection, somatic hypermutation and affinity

maturation. When responding to T cell dependent Ags in vivo, these processes
reach

maturity

in

GCs.

Accordingly, we sought to generate primary Ab

responses in temporally-controlled GC reactions (GCRs) in vitro by sequential
integration of the activated cellular components (260-264).
Antibody responses are greatly influenced by the form of antigens and T
cell help. Consequently, we started by characterizing the effect of these
variables in well-defined test models prior to their integration in the in vitro
model. Results showed that mature Ag-pulsed DCs are competent in priming
CD4+ T cells in vitro, while antigens trapped in the form of ICs on the surface of
FDCs efficiently stimulated B cells. Moreover, B cell help by cognate Agspecific T cells was an absolute necessity for class switching and affinity
maturation.
To develop our in vitro model, immature monocyte-derived DCs (mDCs)
were pulsed with Ovalbumin (OVA) or recombinant protective antigen of
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Bacillus anthracis (rPA) for processing. Bacterial lipopolysaccharide (LPS) was
used as maturation signals for mDCs. Negatively selected CD4+ T cells were
added for priming and ten days later, naïve B cells and FDCs bearing Ags in the
form of ICs were added. Ag specific IgM and IgG were assessed by ELISA at
different intervals, affinity maturation was assessed by salt dissociation, and
cultures

were

microscopically

examined

for

morphological

alterations

and

cluster formation. Preliminary results show the clustering of CD4+ T cells with
DCs through the 10 days of priming and fusion with FDC-B cell clusters when
GCRs were induced. An initial response dominated by Ag-specific IgM was
observed in the first week followed by class switching to a dominant IgG
response in the second week. In addition, preliminary results suggest an increase
in Ag specific IgG affinity in the second week and imply the increased
efficiency of this in vitro model in predicting the human immune response to
certain antigens like HIV-gp120 than experimental murine models.
In summary, Ag specific affinity matured primary human Ab responses,
with class switching from specific IgM to IgG was generated in GCRs entirely
in vitro thus providing the means for individually and safely assessing emerging
vaccines and therapeutics in a human immune system.
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Materials and Methods
Mice
Normal 8–12 wk old BALB/c mice were purchased from the National
Cancer Institute (Frederick, MD) or The Jackson Laboratory (Bar Harbor, ME).
The mice were housed in standard plastic shoebox cages with filter tops and
maintained under specific pathogen-free conditions in accordance with VCU
Animal Care and Use guidelines. Food and water were supplied ad libitum.
Germinal center reactions in vitro
To induce a human antigen-specific GCR in vitro, the different cellular
components of the GC were prepared as follows:
(1)
heparinized

Peripheral
blood

blood

by

mononuclear

density

cells

centrifugation

(PBL)
using

were

obtained

Lymphocyte

from

Separation

Medium (ICN, Aurora, OH). Cells were centrifuged at 400 x g for 20 minutes,
the cells were collected from the interface and washed three times in RPMI 1640
media (Cellgro, VA).

After washing the cells were suspended in RPMI-1640

supplemented with 10% of fetal calf serum (HyClone, Logan, Utah) and
antibiotics for cell culture.
(2) CD14+ human monocytes were isolated on MACS columns from the
PBLs using CD14 MicroBeads, human, (Miltenyi Biotech, # 130-050-201).
(3) Monocyte-derived dendritic cells (mDCs) were generated by treating
107 CD14+ cells with a mixture of IL-4 (50 ng/ml) and GM-CSF (50 ng/ml).
Two days later the cells were fed with another dose of the cytokines to enhance
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their differentiation. On day 5, LPS was added at 1 μg/ml concentration together
with 1 μg/ml OVA or rPA to provide Ag for processing and LPS for DC
maturation.
(4) After 8 hours, 20 x 106 CD4+ T cells isolated by Naïve CD4+ T Cell
Isolation Kit II, human, (Miltenyi Biotech, #130-094-131) were added and left
for 5 days for DCs to present OVA and prime the CD4+ T cells.
(5) At the end of the 5 days the T cells and remaining DCs were spun
down and 15 x 106 naïve B lymphocytes were isolated and added to them
together with FDCs loaded with 5 μg OVA or rPA in ICs.
(6) Murine FDCs were isolated from lymph nodes (axillary, lateral
axillary, inguinal, popliteal, mesenteric, and paraaortic) of normal young adult
mice as previously described (130).

In brief, One day before isolation, mice

were irradiated with 1000 rad to eliminate most lymphocytes, and one day later
mice were killed, and LNs were collected, opened, and treated with 1.5 ml of
collagenase D (22 mg/ml, C-1088882; Roche), 0.5 ml of DNase I (5000 U/ml,
D-4527;

Sigma-Aldrich), and 2 ml of DMEM with 20 mM HEPES buffer.

After 45 min at 37°C in a CO2 incubator, released cells were washed in 5 ml of
DMEM with 10% FCS. Cells were then sequentially incubated with FDCspecific Ab (FDC-M1) for 45 min, 1 µg of biotinylated anti-rat kL chain for 45
min, and 20 µl of anti-biotin microbeads (Miltenyi Biotec) for 15–20 min on ice.
The cells were layered on a MACS LS column and washed with 10 ml of ice-
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cold MACS buffer. The column was removed from the VarioMACS, and the
bound FDCs were released with 5 ml of MACS buffer.
Cultures

were

assessed

microscopically

and

differentiated

cells

were

tracked with specific mAbs and examined with confocal microscopy. Culture
supernatant fluids were collected one and two weeks later and OVA- and rPAspecific IgG and IgM were assessed by ELISA.
Affinity maturation in vitro
Generation

of

high

affinity

antibodies

is

important

for

efficient

immune

responses. To test for affinity maturation in vitro we used a simple salt
dissociation method for human cultures. In the salt dissociation method, we let
OVA-specific IgG produced in 5 and 10 days old in vitro cultures to bind OVA
coated plates. Two hours later, 1/16M-4M NaCl was used to dissociate the
bound Abs for an hour on a shaker. Plates were washed and the remaining
bound Abs (higher affinities) were detected using alkaline phosphatase labeled
anti-human IgG and the optical densities (ODs) were obtained using an ELISA
reader.
In vitro GCRs versus animal models in predicting human immune responses
Animal models and in vitro models may be equally valid in testing the
human response to antigens that do not directly modify the response of the
immune cells. However, antigens that have species-specific effects may be
tested in animals but the results cannot be extrapolated from one species to the
other. For example, gp120 is a glycoprotein exposed on the surface of the HIV
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that binds human but not murine CD4 on CD4-expressing T cells (265-268). We
reasoned that gp120 would block the T cell help if tested on human cells,
whereas, a normal response would be generated if tested in BALB/c mice. To
test our reasoning and consequently the efficiency of our in vitro human model,
we immunized BALB/c mice with gp120 and tested their sera for mouse antigp120, 7 and 14 days later using ELISA. In parallel, we generated human in
vitro GCRs against gp120 and tested the culture supernatant fluids for human
anti-gp120, 7 and 14 days later and both assessment techniques were compared.
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Results
Germinal center-like in vitro clusters
Preliminary

results

showed

the

clustering

of

mature

antigen-loaded

monocyte-derived dendritic cells with CD4 T cells, and we reason this promted
T cell priming. Preliminary confocal microscopy studies showed well-developed
clusters of antigen-specific CD4 T cells associated with DCs. Additionally, B
cells clustered with FDCs, and formed a B cell zone of FDCs and B cells
segregated from the T cell zone in the GCR. Moreover, B cell proliferation
resulted in the development of a high density and low density compartments
similar to the dark and light zones of GCs in vivo (data not shown).
Induction of primary human immune responses to OVA and rPA in vitro
As shown in Fig. 1, GCRs in vitro were productive only in the presence
of OVA-specific T cells and OVA-IC-loaded FDCs indicating the importance of
specific T and FDC help to the antigen-specific B cells. Responses were typical
of a T cell-dependent response in that, Ag-specific IgM dominated in the first
week and that was followed by class-switching to Ag-specific IgG in the second
week. Preliminary results with rPA showed a specific response similar to that of
Ova (data not shown).
Affinity maturation in vitro
Preliminary studies using a simple salt dissociation method showed that
the human in vitro immune responses exhibited higher affinity of Ag-specific
Abs as they progress from the first week (5 days) to the second week (10 days).
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(data not shown), at all molar concentrations of NaCl, bound Abs that resisted
dissociation by the addition of salt (high affinity Abs) were higher at day 10 as
compared to day 5 (data not shown).
HIV-gp120 failed to induce Ag-specific IgG responses in human in vitro
GRCs despite the generation of normal responses in BALB/c mice
Our preliminary results showed that challenging BALB/c with gp120
induced a normal T cell dependent response dominated by Ag-specific IgM in
the first week that switched to gp120-specific IgG in the second week. In
contrast, gp120 failed to induce class switching even after two weeks of setting
up in vitro human GCRs (data not shown). The gp120 binds human CD4 T cells
specifically, and inhibits T cell priming and we reason that this resulted in a lack
of class switching in these cultures. The fact that FDCs bear ICs in a periodic
arrangement

capable

of

engaging

multiple

BCRs

and

induction

of

T-cell

independent responses can explain production of gp120-specific IgM in the first
week that persisted through the second week (34).
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Figure 1: Induction of primary human immune responses to OVA. Germinal centers
developed in vitro where productive only in the presence of OVA-specific T cells and
OVA IC-loaded FDCs indicating the importance of specific T and FDC help to the
antigen-specific B cells. Responses were typical of a T cell-dependent nature. They were
dominated by OVA-specific IgM (A) in the first week that class-switched to OVAspecific IgG in the second week (B).
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Discussion
The data presented here support the novel concept that Ag specific
primary human Ab responses, including Ig class switching can be generated in
GCRs entirely in vitro. We report here that mature Ag-pulsed mDCs, primed
MHC-matched human naïve CD4 T cells in vitro. Naïve B cells helped by ICbearing FDCs produced Ag-specific Abs dominated by IgM in the first week
followed by class switching to a dominant IgG response in the second week and
an increase in the affinity of Ag specific IgG. Preliminary data suggest the
induction of affinity maturation and compartementalization in these GCRs in
vitro.
Traditionally, new vaccines and therapeutics are tested in animals like
mice, rabbits or, in some cases in higher primates, like monkeys. Animal testing
is time-consuming, expensive, controversial, and carries the risk of being
untranslatable in humans. No matter how well an experimental vaccine works in
animals, the application in humans is riddled with uncertainty and unforeseeable
complications. Here, we report an in vitro model that may sidestep such
devastating setbacks by allowing researchers to test vaccines and possibly
therapeutics in human immune systems constructed in vitro.
Speed and flexibility are two major advantages of the reported model.
The need for speed has come about in response to emerging infectious diseases
like SARS or avian flu. If a disease is spreading quickly and is highly virulent,
time is of the essence and animal testing would take too long to be helpful.
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Flexibility is a landmark of this model. Previous trials to induce human
in vitro antibody responses were restricted to certain antigens for which primed
cells can be isolated from immune human subjects like TT or HBV. In this
model we bypassed this limitation by priming naïve human CD4 T cells in vitro
using mature Ag-pulsed DCs. This allows screening of antigens from different
sources including bacteria, fungi, parasites and viruses. In fact, the use of naïve
cells gives the model flexibility as wide as the diversity of the B cell and T cell
repertoires.
The model can predict issues not apparent in studies conducted in animal
models. For example, in contrast to the expected normal response of the murine
model to HIV-gp120 exhibiting classic T-cell dependent class switching from
Ag-specific IgM to IgG, the human cells in vitro may not switch to IgG, owing
to the inhibitory effect of gp120 on the human but not the murine CD4 T-cell
activity.
The dose-dependent immuno-modulatory effects of certain drugs like
chemotherapeutic agents can be simultaneously tested for toxicity without risk
to human health using this model. Although, humanized SCID mice models
have been traditionally developed for this purpose, their responses are low, they
use a lot more human cells, they take more time (a month or more), they are
expensive, and need special facilities for containment. More importantly, FDCs,
the major B-cell co-stimulators in GCs, take 8 weeks or more to develop in
SCID mice and humanized SCID mice would not be expected to work rapidly
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by means of immune complexes being trapped on FDCs as we demonstrated in
these chimeras.
We are excited by the prospect of reconstructing GCRs in vitro where
the important events for productive humoral immune responses take place and
this is of utmost importance to critically assess vaccines. For example, it is not
uncommon to find non-responders to particular vaccine and these people are put
at risk when given a live vaccine. It may be possible to identify these people by
setting up their immune system in vitro and determining their non-responsive or
poor responsive state before they were challenged with a live vaccine capable of
causing disease. In addition some therapeutic agents and industrial chemicals are
toxic to the immune system and the in vitro immune system could be helpful in
determining immunotoxicity in the context of the human immune system. The
ability to get potent responses in vitro may even be useful in the production of
human monoclonal Abs reactive against toxic agents and pathogens. In short, we
report generation of primary human antibody responses entirely in vitro. The
reported model can be used for the assessment of vaccines and therapeutics in a
fast, flexible, and accurate way.
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Summary and conclusion
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FDC-FcγRIIB levels are up-regulated 1-3 days after challenge of actively
immunized mice with Ag. This kinetics suggested that memory cells are not driving this
response, prompting the hypothesis that IC-FDC interactions lead to FDC activation. To
test this, mice passively immunized with anti-OVA Ab were OVA challenged to produce
ICs. After 3 days, levels of ICs, FcγRIIB, ICAM-1, and VCAM-1 on FDC were analyzed.
FDC were also stimulated with ICs in vitro, and mRNA for FcγRIIB, ICAM-1, and
VCAM-1 was quantified by quantitative RT-PCR. IC labeling in passively immunized
WT and FcγRIIB-/- mice revealed five to six FDC-reticula per LN midsagittal section. In
WT mice, these IC-bearing FDC-reticula corresponded with FDC-reticula labeling for
FcγRIIB, ICAM-1, and VCAM-1. Increases in these molecules on IC-stimulated FDC
were confirmed by flow cytometry. FcγRIIB-/- mice showed normal trapping of ICs on
FDC-reticula; mediated by CR, however, no increase in VCAM-1 or ICAM-1 was seen
either on IC-bearing FDC-reticula or on purified FDCs. Addition of ICs in vitro resulted
in a dramatic increase in mRNA for FcγRIIB, ICAM-1 and VCAM-1 in WT FDC, but
not in FDC from FcγRIIB-/- mice, 2.4G2-pretreated WT FDC, B cells, or macrophages.
Thus, although FDC-FcγRIIB was not essential for IC trapping, engagement of FDCFcγRIIB with ICs initiated an FDC activation pathway.
Microbial molecular patterns engage TLRs and activate dendritic cells and other
accessory cells. FDCs exist in resting and activated states, but are activated in GCs, where
they provide accessory function. We reasoned that FDCs might express TLRs and that
TLR-engagement might activate FDCs leading to the up-regulation of molecules
important for accessory activity. To test this hypothesis, TLR4 expression on FDCs was
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studied in situ with immunohistochemistry, followed by flow cytometry and RT-PCR
analysis. TLR4 was expressed on FDC reticula in situ, and flow cytometry indicated that
TLR4 was expressed on surface membranes and TLR4 message was readily apparent in
FDCs by RT-PCR. Injecting mice or treating purified FDCs with LPS up-regulated
molecules important for accessory activity, including FDC-FcγRIIB, FDC-ICAM-1, and
FDC-VCAM-1. Treatment of purified FDCs with LPS also induced intracellular phosphoIκB-α, indicating NF-κB activation, and that correlated with increased FcγRIIB, ICAM-1,
and VCAM-1. FDCs in C3H/HeJ mice were not activated with LPS even when mice were
reconstituted with C3H/HeN leukocytes, suggesting that engagement of FDC-TLR4 is
necessary for activation. Moreover, activated FDCs exhibited increased accessory activity
in anti-OVA recall responses in vitro, and the FDC number could be reduced 4-fold if
they were activated. In short, we report expression of TLR4 on FDCs for the first time
and that engagement of FDC-TLR4 activated NF-κB, up-regulated expression of
molecules important in FDC accessory function, including FcγRIIB, ICAM-1, and
VCAM-1, as well as FDC accessory activity in promoting recall IgG responses.
FDCs reside in GCs in which their dendrites interdigitate and form non-mobile
networks. FDC purification requires the use of collagenase and selection columns and
leaves FDCs without detectable dendrites; the cardinal morphological feature of FDCs,
when examined by light microscopy. We have reasoned that isolated FDCs might
reattach to a collagen matrix, extend their processes, and form immobile networks in
vitro. As a test for this, cells were plated on collagen type I, laminin, biglycan, and
hyaluronan. After 12 h, 80%–90% of FDCs adhered to all tested matrices but not to
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plastic. Within 2 weeks, FDCs adhering to type I collagen had spread out and had begun
to acquire processes with occasional interconnections. By day 30, most FDCs had fine
processes that formed networks through interdigitation with neighboring cells. FDC
identity was confirmed by FDC-M1 labeling, immune complex trapping, and retention by
FDCs in the networks. Scanning electron microscopy confirmed that groups of FDCs
were in networks composed of convolutions and branching dendrites emanating from
FDC cell bodies. In vivo, collagen type I was co-localized with FDCs, 5 h after challenge
of immune mice with antigen. However, 2 days later, the collagen type I fibers were
largely found at the periphery of the active follicles. Flow cytometry established the
expression of CD29 and CD44 on FDCs; this may have partly mediated FDC-collagen
interactions. Thus, we report, for the first time, that FDCs attach to collagen type I in
vitro and regenerate their processes and networks with features in common with networks
present in vivo
The contribution of IL-6 to terminal B cell differentiation has long been
recognized and reports that FDCs produce IL-6 prompted the hypotheses that ICs induce
FDCs to produce IL-6 and that FDC-IL-6 promotes GCRs, SHM and IgG production.
FDCs were activated in vitro by addition of ICs and FDC-IL-6 production was
determined. WT and IL-6 KO mice, as well as chimeras with WT and IL-6 KO cells,
were immunized with NP-CGG and used to study anti-NIP responses, GC formation, and
SHM in the VH186.2 gene segment in Ig-gamma. FDC-IL-6 increased when FDCs
encountered ICs. At low immunogen dose, 1 µg NP-CGG/mouse, the IgG anti-NIP
response in IL-6 KO mice was low and immunohistochemistry revealed a reduction in
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both the number and size of GCs. The physiological relevance of FDC-IL-6 was apparent
in the chimeric mice where total splenocytes from WT mice were unable to provide the
IL-6 needed for normal IgG and GC responses in IL-6 KO animals with IL-6-defective
FDCs. Moreover, the rate of mutation decreased from 18 to 8.9 mutations/1000 bases (P
<0.001) in WT vs. IL-6 KO mice. Addition of anti-IL-6 to GCRs in vitro reduced Ab
levels and SHM from 3.5 to 0.65 mutations/1000 bases (P<0.02). Thus, the absence of
FDC-IL-6 correlated with a reduction in SHM that coincided with the reduction in GCs
and specific anti-NIP. This is the first study to document that ICs induce FDC-IL-6 and
that FDC-derived IL-6 is physiologically relevant in generating optimal GCRs, SHM, and
IgG levels.
FDCs periodically arrange membrane-bound ICs of T-dependent Ags 200–500Å
apart, and in addition to Ag, they provide B cells with co-stimulatory signals. This
prompted the hypothesis that Ag in FDC-ICs can simultaneously cross-link multiple
BCRs and induce TI B cell activation. TI responses are characterized by rapid IgM
production. OVA-IC-bearing FDCs induced OVA-specific IgM in anti-Thy-1-pretreated
nude mice and by purified murine and human B cells in vitro within just 48 h. Moreover,
nude mice immunized with OVA-ICs exhibited well-developed GL-7+ GCs with ICretaining FDC-reticula and Blimp-1+ plasmablasts within 48 h. In contrast, FDCs with
unbound-OVA, which would have free access to BCRs, induced no GCs, plasmablasts, or
IgM. Engagement of BCRs with rat-anti-mouse IgD (clone 11–26) does not activate B
cells even when cross-linked. However, B cells were activated when anti-IgD-ICs,
formed with Fc-specific rabbit anti-rat IgG, were loaded on FDCs. B cell activation was
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indicated by high phosphotyrosine levels in caps and patches, expression of GL-7 and
Blimp-1, and B cell proliferation within 48 h after stimulation with IC-bearing FDCs.
Moreover, anti-IgD-IC-loaded FDCs induced strong polyclonal IgM responses within 48
h. Blockade of FDC-FcγRIIB inhibited the ability of FDC-ICs to induce T-independent
IgM responses. Similarly, neutralizing FDC-C4BP or -BAFF, to minimize these FDCcostimulatory signals, also inhibited this FDC-dependent IgM response. This is the first
report of FDC-dependent but TI responses to T cell-dependent Ags.
Induction of potent primary human Ab responses entirely in vitro is challenging,
although such in vitro responses could be helpful in assessing vaccines and therapeutics
without jeopardizing human health. Given that DCs prime T cells and that FDCs promote
B cell responses, and that the four players are indispensible for the induction of a primary
Ab response, we hypothesized that a primary Ab response can be induced in temporallycontrolled GCRs in vitro. To test this, human monocyte derived-DCs were given OVA,
anthrax rPA or HIV-gp120 for processing, matured with LPS, and CD4+ T cells were
added for priming. Ten days later, naïve B cells and OVA, rPA or gp120 IC-bearing
FDCs were added and Ab production was subsequently assayed by ELISA. The CD4+ T
cells clustered with DCs through the 10 days of priming and fused with FDC-B cell
clusters when GCRs were induced. IgM dominated the primary human immune response
to OVA and rPA in the first week then declined as class switching to IgG was induced by
the Ag-specific T cells. Moreover, high affinity Abs detectable in the second week
replaced the low affinity Abs of the first week indicating affinity maturation. In contrast,
antibodies against gp120 did not classswitch, which we attribute to the inhibitory activity
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of gp120 on CD4+ T cells (265-268). Consequently, gp120 would be a problematic
vaccine in humans inspite of its effective induction of an effective immune response in
mice. In short, Ag specific primary human Ab responses, including Ig class switching
from specific IgM to IgG and affinity maturation, can be generated in GCRs entirely in
vitro. Thus, potential vaccines can be rapidly and safely assessed using the human
immune system in an accurate and flexible way.
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